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Rho GTPases are a family of proteins known to be involved in cytoskeletal regulation 
and are important for several processes including cell migration, cell polarity, vesicle 
trafficking and cytokinesis. RhoBTB1 is an atypical member of the Rho GTPase family. 
It consists of a non-functional GTP-binding domain followed by a proline-rich region 
and two tandem BTB domains. The only known interacting partner for RhoBTB1 is 
cullin3, a scaffold protein in ubiquitin ligase complexes. So far RhoBTB1 has not been 
shown to affect the cytoskeleton and it has no known cellular function. Most Rho 
GTPases are regulated by GEFs, GAPs, RhoGDIs and post-translational lipid 
modifications at the C-terminus. However, RhoBTB1 is not regulated by any of these 
mechanisms. RhoBTB1 has additional domains that could be involved in protein-
protein interaction, leading to an alternative mechanism for RhoBTB1 regulation. This 
project has shown that RhoBTB1 can interact with RhoA and ROCK1 as well as cullin3. 
The interaction between RhoA and RhoBTB1 was explored since RhoBTB1 has the 
potential to recruit substrates for ubiquitination by cullin3 complexes. The region of 
interaction between RhoA and RhoBTB1 was mapped and RhoBTB1 influenced the 
protein level of RhoA, suggesting that it inhibits RhoA degradation by the proteasome. 
RhoBTB1 was found to localise diffusely in the cytoplasm or to punctate structures. 
Knockdown of RhoBTB1 led to a change in cell morphology in a 3D Matrigel matrix, 
indicating that it influences cell shape in 3D, although it did not alter cell shape on 2D 
substrata. RhoBTB1 can be phosphorylated by ROCK1 in vitro and the region of 
interaction between RhoBTB1 and ROCK1 was mapped using ROCK1 deletion 
mutants. I hypothesize that RhoBTB1 interacts with RhoA to affect its ubiquitination 
and degradation and hence affects cell morphology in a 3D matrix, and that RhoBTB1 






Firstly, I would like to thank my supervisor Professor Anne Ridley for giving me the 
opportunity of conducting my PhD in her laboratory and for her guidance. This 
experience has given me the opportunity to improve my skills as an independent 
researcher. I would like also to thank my second supervisor, Dr Claire Wells, for all the 
suggestions throughout my PhD.  
Of course a big thank you goes to the members of Ridley’s lab. Thank you to Silvia, 
Naren, Christina and Elvira who welcomed me into the lab and helped me in my first 
months. A very special thank you goes to Barbara who came back to the lab and 
shared with me all the challenges of working on a new protein (“Go BTB team!”). Thank 
you for all your support and most of all for your friendship. A big thank you to Magali 
who was my bench and office buddy. Thank you to the current members Sofia, 
Camilla, Vicky, Campbell and Ritu for all the discussions and friendly environment. A 
big special thank you goes to Richard who helped me to go through the endless 
cloning and IP assays; and who has been a good friend. Thank you for teaching me 
about British culture, for correcting my eds and for not taking all my “British” points after 
all my complaints about the weather and British beef. It was a pleasure to meet and 
work with all of you. 
Furthermore, thank you to all the nice people I have met throughout these four years. 
Thank you for the pubs after work, comedy nights and great pizza nights. I would like to 
thank specially Rimple for always making me laugh and being a good friend.  
Finally, I would like to thank my family and friends in Brazil. I am really greatful for all 
your support and friendship. Mãe, Pai, Be e Elo, obrigada pelo amor e suporte de 
vocês. Eu tenho muita sorte de poder contar com uma familia que sempre me apoia 





Table of Contents 
Abstract ........................................................................................................................ 2 
Acknowledgements ....................................................................................................... 3 
Table of Contents ......................................................................................................... 4 
List of Figures ............................................................................................................... 9 
List of Tables .............................................................................................................. 13 
List of supplementary movies...................................................................................... 14 
Abbreviations .............................................................................................................. 15 
1 Introduction .......................................................................................................... 18 
1.1 Rho GTPases ............................................................................................... 18 
1.1.1 Regulation of Rho GTPases .................................................................. 22 
1.1.1.1 GEFs ................................................................................................. 23 
1.1.1.2 GAPs ................................................................................................. 25 
1.1.1.3 GDIs .................................................................................................. 26 
1.1.1.4 Transcriptional and post-transcriptional regulation ............................. 26 
1.1.1.5 Covalent modifications ....................................................................... 28 
1.1.2 Regulation of the actin cytoskeleton ...................................................... 30 
1.1.2.1 Cell migration ..................................................................................... 33 
1.1.3 Other activities of Rho GTPases ............................................................ 37 
1.1.4 Crosstalk between Rho GTPases .......................................................... 39 
1.1.5 Rho GTPases in tumorigenesis ............................................................. 41 
1.1.6 Atypical Rho GTPases ........................................................................... 45 
1.1.7 RhoBTB proteins ................................................................................... 47 
1.2 Ubiquitination and cullin3 .............................................................................. 51 
1.2.1 Ubiquitination process ........................................................................... 51 
1.2.2 Cullin3 ................................................................................................... 54 
1.3 Aims of the project ........................................................................................ 58 





2.1 Materials ....................................................................................................... 59 
2.1.1 Reagents and Kits ................................................................................. 59 
2.1.2 Buffers and solutions ............................................................................. 61 
2.1.3 Antibodies .............................................................................................. 63 
2.1.4 Oligonucleotides .................................................................................... 64 
2.1.5 Plasmids ................................................................................................ 65 
2.1.6 Restriction Enzymes .............................................................................. 66 
2.1.7 Software ................................................................................................ 66 
2.2 Methods: molecular biology .......................................................................... 66 
2.2.1 Transformation of Escherichia coli (E. coli) ............................................ 66 
2.2.2 Extraction of plasmid DNA from bacteria ............................................... 66 
2.2.3 Determination of DNA concentration ...................................................... 67 
2.2.4 DNA amplification using Polymerase Chain Reaction (PCR) ................. 67 
2.2.5 Ethanol precipitation of DNA .................................................................. 68 
2.2.6 Digestion of DNA using restriction enzymes .......................................... 68 
2.2.7 Agarose gel electrophoresis .................................................................. 68 
2.2.8 Extraction of DNA from agarose gels ..................................................... 69 
2.2.9 DNA ligation .......................................................................................... 69 
2.2.10 Site-directed mutation ............................................................................ 70 
2.2.11 Sequencing ........................................................................................... 70 
2.2.12 GFP-RhoBTB1 and GFP-RhoBTB1 S3T2A subcloning ......................... 71 
2.2.13 Cloning of KCTD13 (BACURD1) into N-GFP-CB6 vector ...................... 71 
2.2.14 Construction of RhoBTB1 1-210, RhoBTB1 1-427, RhoBTB1 266-696 
and RhoBTB1 485-696 fragments using N-GFP-CB6 vector ............................... 72 
2.2.15 Extraction of total RNA from mammalian cells ....................................... 73 
2.2.16 qPCR ..................................................................................................... 74 
2.3 Methods: cell biology .................................................................................... 75 
2.3.1 Cell culture ............................................................................................ 75 





2.3.1.2 Growing and passaging cells ............................................................. 76 
2.3.1.3 Synthetic siRNA transfection using OligofectamineTM ......................... 76 
2.3.1.4 DNA transfection using LipofectamineTM2000 .................................... 77 
2.3.1.5 DNA transfection using PEI ................................................................ 77 
2.3.2 Treatment of cells with inhibitors ............................................................ 78 
2.3.3 Morphology assay ................................................................................. 78 
2.3.3.1 3D-Morphology-Based assay ............................................................. 78 
2.3.4 Motility and Transmigration assays ........................................................ 79 
2.3.4.1 Adhesion assay .................................................................................. 79 
2.3.4.2 Intercalation assay – fixed cell imaging .............................................. 79 
2.3.4.3 Intercalation assay – live cell imaging ................................................ 80 
2.3.4.4 Transwell-based 3D invasion assay ................................................... 80 
2.3.4.5 Transwell-based 3D TEM assay......................................................... 81 
2.3.5 Immunofluorescence ............................................................................. 82 
2.3.6 Confocal microscopy ............................................................................. 82 
2.4 Methods: cell biochemistry............................................................................ 83 
2.4.1 Preparation of cell lysates ...................................................................... 83 
2.4.2 SDS-PAGE and western blot ................................................................. 83 
2.4.3 Stripping of western blot ........................................................................ 83 
2.4.4 Preparation of GST-fusion proteins........................................................ 84 
2.4.5 Pull down ............................................................................................... 84 
2.4.6 Immunoprecipitation and co-immunoprecipitation .................................. 85 
2.4.7 Ubiquitination assay in vivo ................................................................... 85 
2.4.8 In vitro kinase assay with radiolabeled ATP ........................................... 86 
2.4.9 Pro-Q ..................................................................................................... 87 
2.4.10 DSS crosslinking ................................................................................... 87 
3 RhoBTB1 and cancer cell interaction with endothelial cells .................................. 88 





3.2 Interaction of MCF-7, Cal51 and HCC1954 breast cancer cells with a matrix of 
collagen I ................................................................................................................. 92 
3.3 Optimization of adhesion, intercalation and transendothelial migration with 
MCF-7, Cal51 and HCC1954 cell lines .................................................................... 94 
3.3.1 MCF-7, Cal51 and HCC1954 breast cancer cells intercalate between 
confluent human umbilical endothelial cells ......................................................... 94 
3.3.2 Breast cancer cell morphology on endothelial cells ................................ 97 
3.3.3 Adhesion timecourse of HCC1954 and Cal51 cells to endothelial cells 103 
3.3.4 Breast cancer cell interaction with endothelial cells on a thick layer of 
collagen 105 
3.4 Effects of RhoBTB1 depletion in Cal51 cells on endothelial interaction ....... 110 
3.4.1 RhoBTB1 effects on β1 integrin and RhoA levels ................................. 112 
3.5 Discussion .................................................................................................. 118 
3.5.1 Characterization of breast cancer cell lines with endothelial cells ........ 118 
3.5.2 Effects of RhoBTB1 depletion in Cal51 cells on endothelial interaction 120 
4 Characterization of RhoBTB1 ............................................................................ 123 
4.1 Introduction ................................................................................................. 123 
4.2 RhoBTB1 homodimerises and heterodimerises .......................................... 125 
4.3 Interaction of RhoBTB1 with cullin3 ............................................................ 130 
4.4 Ubiquitination of RhoBTB1.......................................................................... 133 
4.5 Phosphorylation of RhoBTB1 ...................................................................... 135 
4.6 Localisation of RhoBTB1 ............................................................................ 137 
4.7 Discussion .................................................................................................. 141 
5 Role of RhoBTB1 in RhoA regulation ................................................................. 146 
5.1 Introduction ................................................................................................. 146 
5.1.1 RhoA effectors ..................................................................................... 147 
5.1.2 RhoA in transendothelial migration ...................................................... 149 
5.1.3 Regulation of RhoA ............................................................................. 149 
5.2 Depletion of RhoBTB1 leads to a decrease in RhoA total levels ................. 151 





5.4 Discussion .................................................................................................. 167 
6 Interaction of RhoBTB1 and ROCK1.................................................................. 172 
6.1 Introduction ................................................................................................. 172 
6.1.1 ROCK effectors ................................................................................... 173 
6.1.2 Regulation of ROCKs .......................................................................... 174 
6.1.3 ROCKs in cancer ................................................................................. 176 
6.2 Effects on RhoA downstream effectors after RhoBTB1 depletion in MDA-MB-
231 cells ................................................................................................................ 177 
6.3 Effects of ROCK1 and ROCK2 depletion in MDA-MB-231 cells on endothelial 
interaction ............................................................................................................. 179 
6.4 RhoBTB1 interacts with ROCK1 ................................................................. 180 
6.5 Phosphorylation of RhoBTB1 by ROCK1 .................................................... 188 
6.6 Discussion .................................................................................................. 197 
7 Concluding remarks ........................................................................................... 202 
7.1 RhoBTB1 and potential functions in cancer ................................................ 202 
7.2 RhoBTB1-interacting partners and Rho function ......................................... 203 






List of Figures 
Figure 1.1 - Rho GTPase family .................................................................................. 19 
Figure 1.2 - Rho GTPase effectors ............................................................................. 21 
Figure 1.3 - Regulation of Rho GTPases .................................................................... 22 
Figure 1.4 – Nucleotide-binding site of Rho proteins ................................................... 23 
Figure 1.5 - Interaction between Rho proteins and RhoGEFs ..................................... 24 
Figure 1.6 - Interaction between Rho proteins and RhoGAPs ..................................... 25 
Figure 1.7 - Single cell migration ................................................................................. 33 
Figure 1.8 – Rac1 and RhoA crosstalk ........................................................................ 40 
Figure 1.9 – Members of the RhoBTB subfamily ......................................................... 48 
Figure 1.10 – Rotes of ubiquitin modifications in regulating proteins ........................... 52 
Figure 1.11 - Cullin proteins ........................................................................................ 54 
Figure 1.12 - Dimerization of BTB-protein and dimerisation of cullin3 ......................... 56 
Figure 2.1 - Schematic diagram of RhoBTB1 subcloning into pEGFP-C1 ................... 71 
Figure 2.2 - Schematic diagram of BACURD1 cloning into N-GFP-CB6 ..................... 72 
Figure 2.3 - Schematic diagram of RhoBTB1 cloning into N-GFP-CB6 ....................... 73 
Figure 3.1 - Cancer cell extravasation ......................................................................... 89 
Figure 3.2 – Morphology of breast cancer cell lines .................................................... 91 
Figure 3.3 - Diagram of transwell 3D invasion assay .................................................. 92 
Figure 3.4 - Invasion of breast cancer cell lines into collagen I.................................... 93 
Figure 3.5 - Intercalation assay - live cell imaging ....................................................... 94 
Figure 3.6 - Intercalation of MDA-MB-231 and Cal51 cells into HUVECs .................... 95 
Figure 3.7 - Spreading and intercalation of HCC1954 cells into HUVECs ................... 96 
Figure 3.8 - Spreading and intercalation of HCC1954 cells stained with CFSE into 
HUVECs ..................................................................................................................... 96 
Figure 3.9 - Intercalation of MCF-7 cells into HUVECs................................................ 97 
Figure 3.10 - Interaction of Cal51 cells with HUVECs - transcellular migration ............ 98 
Figure 3.11 - Interaction of Cal51 cells with HUVECs - paracellular migration ............ 99 





Figure 3.13 - Quantification of Cal51 cell paracellular migration versus transcellular 
migration ................................................................................................................... 100 
Figure 3.14 - Interaction of HCC1954 cells with HUVECs ......................................... 101 
Figure 3.15 - Interaction of MCF-7 cells with HUVECs .............................................. 102 
Figure 3.16 - Interaction of EGTA-treated MCF-7 cells with HUVECs ....................... 103 
Figure 3.17 - Diagram of adhesion assay ................................................................. 104 
Figure 3.18 - Adhesion timecourse of HCC1954 and Cal51 cells to HUVECs ........... 104 
Figure 3.19 - Interaction of MDA-MB-231 cells with endothelial cells on a thick collagen 
I layer ........................................................................................................................ 106 
Figure 3.20 - Interaction of Cal51 cells with endothelial cells on a thick collagen I layer
 ................................................................................................................................. 107 
Figure 3.21 - Interaction of HCC1954 cells with endothelial cells on a thick collagen I 
layer.......................................................................................................................... 108 
Figure 3.22 - Interaction of MCF-7 cells with endothelial cells on a thick collagen I layer
 ................................................................................................................................. 109 
Figure 3.23 - RhoBTB1 depletion in MDA-MB-231 and Cal51 cells .......................... 110 
Figure 3.24 - Adhesion and intercalation of Cal51 cells into endothelial cells ............ 111 
Figure 3.25 - Effects of RhoBTB1 depletion in β1 integrin expression and cancer cell 
adhesion to endothelial cells in MDA-MB-231 cells ................................................... 113 
Figure 3.26 - Expression of β1 integrin in breast cancer cell lines ............................. 114 
Figure 3.27 - Expression of β1 integrin in Cal51 cells after RhoBTB1 depletion ........ 115 
Figure 3.28 - Effects of RhoBTB1 depletion in RhoA expression and activity; and 
cancer cell intercalation into endothelial cells in MDA-MB-231 cells ......................... 116 
Figure 3.29 - Expression of RhoA in Cal51 cells after RhoBTB1 depletion ............... 117 
Figure 4.1 - Interaction of GFP-RhoBTB1 with myc-RhoBTB1 .................................. 125 
Figure 4.2 - RhoBTB1 can form homodimers and homotetramers ............................ 126 
Figure 4.3 - Domain structure of GFP-RhoBTB1 and GFP-RhoBTB1 deletion mutants
 ................................................................................................................................. 127 
Figure 4.4 - Interaction of RhoBTB1 with RhoBTB1 deletion mutants ....................... 128 
Figure 4.5 - Interaction of RhoBTB1 with RhoBTB2 .................................................. 129 





Figure 4.7 - Interaction of RhoBTB1 deletion mutants and cullin3 ............................. 131 
Figure 4.8 - Interaction of RhoBTB1 and cullin3 after MLN4924 treatment ............... 132 
Figure 4.9 - Ubiquitination of RhoBTB1 ..................................................................... 134 
Figure 4.10 - Possible phosphorylation sites on RhoBTB1 ........................................ 135 
Figure 4.11 - Phosphorylation of RhoBTB1 ............................................................... 136 
Figure 4.12 - Localisation of RhoBTB1 ..................................................................... 138 
Figure 4.13 - Localisation of RhoBTB1 and RhoBTB1 deletion mutants ................... 140 
Figure 4.14 - Model of interaction between RhoBTB1 homodimer and cullin3 .......... 143 
Figure 5.1 - Expression of RhoA in MDA-MB-231 cells after cullin3 depletion ........... 152 
Figure 5.2 - Inhibition of cullin3 affects RhoA total protein levels in MDA-MB-231 cells
 ................................................................................................................................. 153 
Figure 5.3 - Expression of RhoA in MDA-MB-231 cells after RhoBTB1 depletion ..... 154 
Figure 5.4 - Interaction of RhoBTB1 and RhoA mutants ........................................... 156 
Figure 5.5 - Interaction of RhoBTB1 deletion mutants and RhoA dominant negative 
mutant (RhoA-N19) ................................................................................................... 158 
Figure 5.6 - Interaction of BACURD1 with RhoA-N19 ............................................... 159 
Figure 5.7 - Competition between RhoBTB1 and BACURD1 to interact with RhoA-N19
 ................................................................................................................................. 161 
Figure 5.8 - RhoBTB1 depletion does not affect the actin cytoskeleton of MDA-MB-231 
cells .......................................................................................................................... 163 
Figure 5.9 - Morphology of MDA-MB-231 and PC3 cells in 2D and 3D cultures ........ 164 
Figure 5.10 - Morphology of MDA-MB-231 cells in Matrigel ...................................... 165 
Figure 5.11 - Morphology of PC3 cells in Matrigel ..................................................... 166 
Figure 5.12 - Model of interaction between RhoBTB1, RhoA and cullin3 .................. 169 
Figure 5.13 - Model of competition between RhoBTB1 and BACURD1 .................... 170 
Figure 6.1 - ROCK1 and ROCK2 .............................................................................. 173 
Figure 6.2 - RhoBTB1 depletion does not affect levels of p-LIMK1/2, p-cofilin and p-
MLC2 in MDA-MB-231 cells ...................................................................................... 177 
Figure 6.3 - RhoBTB1 depletion reduces levels of ROCK1 and ROCK2 proteins in 





Figure 6.4 - mRNA levels of ROCK1 and ROCK2 after RhoBTB1 depletion in MDA-MB-
231 cells ................................................................................................................... 179 
Figure 6.5 - Effects of ROCK1/2 knockdown on adhesion and intercalation of MDA-MB-
231 cells into endothelial cells................................................................................... 180 
Figure 6.6 - RhoBTB1 interacts with ROCK1 ............................................................ 181 
Figure 6.7 - RhoBTB1 interaction with ROCK1 deletion mutants .............................. 182 
Figure 6.8 - GST-RhoBTB1 1-301 interaction with ROCK1 deletion mutants ............ 184 
Figure 6.9 - Domain structure of ROCK1 deletion mutants ....................................... 185 
Figure 6.10 - RhoBTB1 interacts with ROCK1 375-727 but not with ROCK1 1-420 .. 186 
Figure 6.11 - Inhibition of cullin3 does not affect ROCK1 total protein levels in MDA-
MB-231 cells ............................................................................................................. 187 
Figure 6.12 - ROCK inhibitor reduces RhoBTB1 phosphorylation ............................. 188 
Figure 6.13 - Phosphorylation of RhoBTB1 by ROCK1 ............................................. 189 
Figure 6.14 - Mutation of possible phosphorylation sites does not prevent 
phosphorylation of RhoBTB1 .................................................................................... 191 
Figure 6.15 - Mutation of serine 69 does not affect RhoBTB1 interaction with RhoA-N19
 ................................................................................................................................. 193 
Figure 6.16 - Mutation of serine 480 or threonine 483 affects RhoBTB1 interaction with 
RhoA-N19 and cullin3 ............................................................................................... 195 
Figure 6.17 - Effect of different RhoBTB1 residues on cullin3 interaction .................. 196 
Figure 6.18 - Potential phosphorylation sites for ROCKS .......................................... 199 
Figure 6.19 - Model of RhoBTB1 inactive conformation ............................................ 200 






List of Tables 
Table 2-1 Reagents and Kits ...................................................................................... 59 
Table 2-2 Buffers and solutions .................................................................................. 61 
Table 2-3 Primary antibodies ...................................................................................... 63 
Table 2-4 Secondary antibodies and reagents ............................................................ 63 
Table 2-5 siRNAs ........................................................................................................ 64 
Table 2-6 qPCR primers ............................................................................................. 64 
Table 2-7 Mutagenesis primers ................................................................................... 64 
Table 2-8 Cloning primers ........................................................................................... 65 
Table 2-9 Sequencing primers .................................................................................... 65 
Table 2-10 Expression plasmids ................................................................................. 65 
Table 2-11 Restriction enzymes .................................................................................. 66 
Table 2-12 Lasers and filters used for confocal microscopy ........................................ 82 
Table 3-1 Molecular classification of breast cancers ................................................... 90 







List of supplementary movies 
Movie 3.1  MDA-MB-231 cell intercalation 
Movie 3.2 Cal51 cell intercalation 
Movie 3.3 HCC1954 cell intercalation 






ABP     actin-binding protein 
ADF      actin-depolymerizing factor 
ADP     adenosine diphosphate 
Akt     Akt serine/threonine kinase/Protein kinase B 
AP-1     activating protein-1 
Arp2/3     actin-related protein 2/3 
ATP     adenosine triphosphate 
BCR      BTB-cullin3-Rbx1 
BSA     bovine serum albumin 
BTB     broad complex, tramtrack, bric à brac 
CAND1    cullin-associated and neddylation-associated 1 
CFSE      carboxyfluorescein succinimidyl ester 
CRL      CULLIN-RING ubiquitin ligase 
CRL3     cullin3-RING ubiquitin ligase 
DAPI     4’,6-diamidino-2-phenylindole 
DH      Dbl-homology 
DHR      Dock Homology Region 
DMEM     Dulbeco’s modified eagle medium 
DMSO     dimethyl sulphoxide 
DNA     deoxyribonucleic acid 
DSS     disuccinimidyl suberate 
DTT     dithiothreitol 
EBM-2     endothelial cell basal medium-2 
ECL     enhanced chemiluminescence 
ECM      extracellular matrix 
EGF(R)    epidermal growth factor (receptor) 
EGTA     ethylene-glycol-tetra-acetic acid 
EMT      epithelial-mesenchymal transition 
Ena/VASP     Enabled/vasodilator-stimulated phosphoprotein 
ER      oestrogen receptor 
ERK     extracellular signal-regulated protein kinase 
F-actin     actin filaments 
FCS     fetal calf serum 
FH      formin homology  





GAP     GTPase-activating protein 
GDI     guanine nucleotide dissociation inhibitor 
GDP     guanosine diphosphate 
GEF     guanine nucleotide exchange factor 
GFP     green fluorescent protein 
GPCR     G protein-coupled receptor 
GST      glutathione S-transferase 
GTP     guanosine triphosphate 
HEPES 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic 
acid 
HER2      human epidermal growth factor receptor 
IPTG      Isopropyl β-D-1-thiogalactopyranoside 
JNK     c-Jun N-terminal kinase 
LB     L-Broth 
LIMK     LIM kinase 
MBS      myosin-binding subunit 
mDia      mammalian homolog of Drosophila diaphanous 
MLC     myosin light chain 
MMP     matrix metalloprotease 
MRCK     actin-myosin regulatory kinase 
MTOC     microtubule-organizing centre 
NADPH oxidase nicotinamide adenine dinucleotide phosphate-
oxidase 
NAE      NEDD8-activating enzyme 
NFκB     nuclear factor kappa B 
NLS      nuclear localization sequence 
NPF      nucleation promoting factor 
N-WASP     neuronal WASP 
PAE      primary aortic endothelial 
PAK     p21-activating kinase 
PBS     phosphate –buffered saline 
PCR     polymerase chain reaction 
PECAM-1    platelet endothelial cell adhesion molecule  
PEI     polyethylenimine 
PFA     paraformaldehyde 
PH      pleckstrin homology 





PI(3,4,5)P3    phosphatidylinositol (3,4,5)-triphosphate 
PIP2      phosphatidylinositol (4,5)-bisphosphate 
PIP5K      phosphatidylinositol-4-phosphate 5-kinase 
PKA     protein kinase A 
PKC     protein kinase C 
PKN     protein kinase N 
PMSF     phenylmethylsulphonyl fluoride 
POZ      Pox virus and Zinc finger 
PR      progesterone receptor 
PRM      proline-rich motif 
RBD      Rho GTPase-binding domain 
REM      Ras exchange motif 
RING     really interesting new gene 
RNA     ribonucleic acid 
ROCK     Rho-associated kinase 
ROS      reactive oxygen species 
RPMI      Roswell Park Memorial Institute 
RT      room temperature 
SAPK     stress-activated protein kinase 
SCAR     suppressor of cyclic AMP repressor 
SCF complex    Skp, Cullin, F-box containing complex 
SDS      sodium dodecyl sulphate 
SH3      Src homology 3 
SRE      serum response element 
SRF      serum response factor 
TAE     Tris-acetate-EDTA 
TBS      Tris-buffered saline 
TEM      transendothelial migration 
VCA      verprolin-homology, central and acidic 
VSVG      vesicular stomatitis virus glycoprotein 
WASP     Wiskott-Aldrich Syndrome protein 
WAVE     WASP-family verprolin-homologous protein 
WH2      WASP-homology-2 
WRC      WAVE regulatory complex 
WT     wild-type 
 






1.1  Rho GTPases 
The Rho family of GTPases is a subfamily of the Ras superfamily. Rho GTPases are 
highly conserved and found in nearly all eukaryotes. The human Rho GTPase family 
consists of 20 proteins that are divided into 8 subfamilies: Rac1, Rac2, Rac3 and RhoG 
subfamily, Cdc42, RhoQ and RhoJ subfamily, RhoA, RhoB and RhoC subfamily, RhoV 
and RhoU subfamily, RhoH subfamily, RhoBTB1 and RhoBTB2 subfamily, Rnd1, Rnd2 
and Rnd3 subfamily, and RhoF and RhoD subfamily (Heasman and Ridley, 2008). 
These subfamilies can be classified as typical or atypical depending on their mode of 
regulation (Figure 1.1). Rac, Rho, Cdc42 and RhoF/RhoD subfamilies are considered 
typical because they act as molecular switches, cycling between an active GTP-bound 
form and an inactive GDP-bound form. The ratio of GTP-bound form/GDP-bound form 
is regulated by guanine nucleotide exchange factors (GEFs), GTPase-activating 
proteins (GAPs) and guanine nucleotide dissociation inhibitors (GDIs). The atypical 
Rho GTPases are mostly constitutively GTP-bound, therefore they are likely to be 
regulated by different mechanisms; and their function might involve their additional 
domains that are not found in classical Rho proteins (Aspenstrom et al., 2007). For 
example, RhoBTB proteins have broad complex, tramtrack, bric à brac (BTB) domains 
that are able to interact with cullin3, a scaffold protein of ubiquitin ligase complexes 
involved in protein ubiquitination (Berthold et al., 2008a). This interaction points to a 
potential role of RhoBTB proteins in protein degradation.  






Figure 1.1 - Rho GTPase family 
The Rho GTPase family consists of 20 proteins that are subdivided into 8 subfamilies. 
These proteins can be classified as typical (orange circle) or atypical (purple circle) 
depending on their mode of regulation (modified from Heasman and Ridley (2008)). 
 
 
Most Rho GTPases undergo post-translational modifications at their C-terminal CAAX 
motif (where C represents cysteine, A is an aliphatic amino acid, and X is a terminal 
amino acid). This motif is post-translationally prenylated, either by a farnesyl or 
geranylgeranyl isoprenoid lipid. These modifications are important for the translocation 
of Rho GTPases to the plasma membrane and/or endomembranes and are required 
for their biological activity (Roberts et al., 2008). Another modification that occurs near 
the C-terminus of several Rho GTPases is palmitoylation. For example, RhoU and 
RhoV do not have a functional CAAX motif, but a C-terminal CFV motif that can be 
palmitoylated and target these proteins to membranes. The only subfamily that does 
not undergo lipid modifications near the C-terminus is the RhoBTB subfamily. These 




Rho GTPases lack a CAAX motif and they are localized mainly in the cytoplasm 
(Aspenstrom et al., 2007). There is no evidence that RhoBTB proteins could be 
palmitoylated.  
Rho GTPases have been implicated in several cellular processes including 
organisation of the actin and microtubule cytoskeletons, regulation of gene expression, 
vesicle trafficking, cell cycle progression, cell morphogenesis, cell polarity and cell 
migration (Etienne-Manneville and Hall, 2002). Furthermore, Rho GTPases also play 
an important role in some pathological processes including cancer progression, 
inflammation and wound repair (Vega and Ridley, 2008).  
After cells are stimulated by extracellular factors such as soluble molecules, adhesive 
interactions or mechanical stresses, Rho GTPases can be activated and initiate 
signalling cascades through a wide range of effectors or targets including kinases and 
scaffold/adaptor-like proteins. The activation of Rho GTPases (GTP-bound form for the 
typical proteins) leads to changes in the conformation of these molecules, increasing 
their ability to bind to effectors (Hall, 2012; Schwartz, 2004). The most well-known 
effectors are those that interact with the best characterized Rho GTPases: RhoA, Rac1 











Figure 1.2 - Rho GTPase effectors 
Regulation of Rho, Rac and Cdc42 by GEFs and GAPs after extracellular stimuli leads 
to the activation of several signalling pathways involved in actin polymerization, 
membrane trafficking, cytokinesis, cell cycle, microtubule stability, myosin 
phosphorylation, AP1-dependent gene expression, cell contractility, focal adhesion, cell 
adhesion, and proliferation (adapted from Schwartz (2004)).  
  




1.1.1 Regulation of Rho GTPases 
Classically, Rho GTPases are known to be regulated by GEFs, GAPs and GDIs. These 
proteins control the cycling between the active GTP-bound form and the inactive GDP-
bound form. However, new ways of regulating Rho GTPases are emerging, which is 
important, especially to understand how the atypical Rho GTPases are regulated 




Figure 1.3 - Regulation of Rho GTPases 
Rho GTPases can be regulated by classic regulators such as GEFs, GAPs and GDIs. 
These proteins control the cycling between the active GTP-bound form and the inactive 
GDP-bound form. RhoGDIs can also regulate the localisation and degradation of Rho 
GTPases. Other modes of regulating Rho GTPases include post-translational 
modification (lipid modification, phosphorylation, ubiquitination and SUMOylation); and 
transcriptional and post-transcriptional (miRNA) regulation.  
  





Guanine nucleotide exchange factors (GEFs) are proteins that accelerate release of 
bound GDP that is replaced with GTP, activating the GTPase. The nucleotide-binding 
site is found between two loops called switch 1 and switch 2. The switch regions 
together with the P-loop (phosphate-binding loop) interact with the phosphates and the 
Mg2+-binding pocket to determine the conformation and the affinity of the binding 




Figure 1.4 – Nucleotide-binding site of Rho proteins 
The switch regions (switch 1 and switch 2) together with the P-loop (phosphate-binding 
loop) interact with the phosphates and the Mg2+-binding pocket to determine the 




In mammals, GEFs that regulate Rho GTPases are divided into two unrelated families: 
Dbl-homology (DH) domain family (at least 70 members) and Dock Homology Region 
(DHR) domain family (11 members). Most GEFs are part of the DH family and they 
consist of a catalytic Dbl-homology (DH) domain followed by a pleckstrin homology 
(PH) domain. The DH domain catalyzes the exchange of GDP for GTP and the PH 
domain is believed to play a role in localising Dbl proteins to plasma membranes, 
and/or to affect the catalytic activity of the DH domain (Bos et al., 2007; Cook et al., 
2014; Schmidt and Hall, 2002). GEFs of the DHR family have two conserved domains 
called DHR-1 and DHR-2. The DHR-2 domain interacts with the nucleotide-free form of 




Rho GTPases and forms an intermediate in the catalytic reaction for exchange of GDP 
to GTP (Gadea and Blangy, 2014; Laurin and Cote, 2014).   
GEFs act by remodelling the switch regions of the Rho GTPases and insert residues 
close to or into the P-loop and Mg2+-binding pocket that inhibit the binding of 
phosphates and Mg2+. This promotes GTPase intermediates that lack nucleotide and 
Mg2+. GTP is then preferentially loaded into Rho GTPases, because GTP is found in 
higher concentrations than GDP inside cells (Bos et al., 2007; Cherfils and Zeghouf, 
2013). Several GEFs insert an acidic residue in the P-loop, creating repulsive 
electrostatic interactions that expel GDP from the binding site. Other GEFs bring a 
hydrophobic residue close to the Mg2+-binding pocket, which lowers its affinity and 
consequently the affinity for GDP. Some GEFs modify the conformation of switch 2 in 
the binding site, bringing the methyl group of a conserved alanine close to the Mg2+-
binding pocket, having a similar effect on GDP affinity (Cherfils and Zeghouf, 2013) 
(Figure 1.5).   
 
Figure 1.5 - Interaction between Rho proteins and RhoGEFs 
GEFs can remodel the switch regions and insert residues close to or into the 
nucleotide-binding site that alter binding of phosphates and Mg2+. Several GEFs insert 
an acidic residue in the P-loop, creating repulsive electrostatic interactions that expel 
GDP from the binding site. Other GEFs bring a hydrophobic residue close to the Mg2+-
binding pocket, which lowers its affinity and consequently the affinity for GDP. Some 
GEFs modify the conformation of switch 2 in the binding site, bringing the methyl group 
of a conserved alanine close to the Mg2+-binding pocket, having a similar effect on 
GDP affinity.   
 





GTPase-activating factors (GAPs) are proteins that promote the hydrolysis of GTP by 
providing an essential catalytic group that accelerates the intrinsic GTPase activity of 
the GTPases. The human genome encodes around 80 GAPs. However, less than half 
of them have been studied so far. RhoGAPs have a GAP domain of about 150 amino 
acids with a highly conserved arginine in a loop structure (arginine “finger”). This 
domain alone can bind to GTP-bound Rho proteins and catalyze their GTPase activity 
(Jacobs and Hall, 2005; Moon and Zheng, 2003). 
The arginine “finger” in the GAP domain is inserted into the phosphate-binding site to 
stabilize negative charges at the γ-phosphate during the transition state of GTP 
hydrolysis. The arginine also interacts with a glutamine from the switch 2 of the 
GTPase that places a water molecule for the nucleophilic attack of the γ-phosphate of 
GTP (Figure 1.6) (Bos et al., 2007; Cherfils and Zeghouf, 2013; Jacobs and Hall, 2005; 




Figure 1.6 - Interaction between Rho proteins and RhoGAPs 
The arginine “finger” in the GAP domain is inserted into the phosphate-binding site to 
stabilize negative charges at the γ-phosphate during the transition state of GTP 
hydrolysis. The arginine also interacts with a glutamine from the switch 2 of the 
GTPase that places a water molecule for the nucleophilic attack of the γ-phosphate of 
GTP. 
 





Guanine nucleotide dissociation inhibitors (GDIs) are proteins known to control the 
cycling of the Rho GTPases between cytosol and membranes; and to regulate the 
activation/inactivation of Rho GTPases.  
There are three RhoGDIs in humans: RhoGDI1-3. RhoGDIs consist of a N-terminal 
domain that interacts with the switch 1 and switch 2 domains of Rho GTPases, 
restricting the flexibility that is important for the GDP/GTP cycling; and a C-terminal 
domain that includes the geranylgeranyl-binding pocket that is important to extract Rho 
GTPases from the membrane (Cherfils and Zeghouf, 2013; Garcia-Mata et al., 2011).  
RhoGDIs have been shown to play three distinctive roles in regulating Rho GTPases. 
They inhibit the release of GDP and hence prevent Rho GTPase activation by GEFs; 
they interact with the GTP-bound form of Rho GTPases and inhibit GTP hydrolysis, 
both intrinsic and GAP-catalysed; and they control the cycling of Rho GTPases 
between cytosol and membrane by forming high-affinity complexes with prenylated 
Rho GTPases in the cytosol (DerMardirossian and Bokoch, 2005; Garcia-Mata et al., 
2011). RhoGDIs have also been shown to protect some Rho GTPases from 
proteasomal degradation (Boulter and Garcia-Mata, 2010).  
1.1.1.4 Transcriptional and post-transcriptional regulation 
Expression of the classical Rho GTPases, RhoA, Rac1 and Cdc42, are relatively 
similar in most tissues. However, some Rho GTPases are restricted to particular 
tissues and in some cases, they need specific stimuli to be expressed (Wennerberg 
and Der, 2004). For example, the RhoB gene is an immediate early gene and it can be 
induced after stimulation with EGF (Jähner and Hunter, 1991) and genotoxic stress 
(Fritz et al., 1995). Atypical Rho GTPases have also been shown to be regulated at a 




transcriptional level. For example, expression of Rnd3 is induced after Raf activation 
(Hansen et al., 2000) and expression of RhoU is increased by Wnt-1 (Tao et al., 2001).  
Rac1 and Cdc42 have been shown to have splice variants. A Rac1 splice variant 
Rac1b has enhanced intrinsic guanine nucleotide exchange (self-activation), impaired 
GTPase reaction and fails to interact with RhoGDIs, leading to accumulation of the 
GTP-bound conformation of Rac1b in cells (Fiegen et al., 2004; Singh et al., 2004). A 
Cdc42 splice variant is a brain-specific isoform that can be palmitoylated (Cdc42-palm) 
instead of or in addition to being prenylated (Cdc42-prenyl). This change in lipid 
modification has an effect on protein localisation and function (Kang et al., 2008; Wirth 
et al., 2013). 
Rho GTPases undergo post-transcriptional regulation. microRNAs (miRNAs) are non-
coding RNA molecules that can control the expression of mRNAs. These short 
sequences silence target genes by either inhibiting translation or degrading mRNA. 
Several Rho GTPases can be regulated by miRNAs. Most of the work on miRNAs has 
been done in cancer models, showing how the regulation of Rho GTPase expression 
by miRNAs can affect cancer progression (Liu et al., 2012). For example, it has been 
shown that RhoA is target of miRNA-155 (Bijkerk et al., 2012; Kong et al., 2008) and 
miRNA-125a-3p (Huang et al., 2013); RhoB is a target of miRNA-21 (Liu et al., 2011b); 
RhoBTB1 is a target of miRNA-31 (Xu et al., 2013); and Cdc42 is a target of miRNA-29 
(Park et al., 2009) and miRNA-137 (Chen et al., 2011). Sometimes the same miRNA 
can target two different Rho GTPases. miRNA-185 has been reported to decrease the 
levels of RhoA and Cdc42, leading to inhibition of proliferation in human colorectal 
cancer cells (Liu et al., 2011a). 
 
 




1.1.1.5  Covalent modifications 
Rho GTPases undergo several covalent modifications in addition to lipids that can 
regulate the proteins in a positive (activation) or negative (inactivation/degradation) 
way. These include ubiquitination and phosphorylation. 
Ubiquitination is the covalent attachment of an ubiquitin to lysine resides in the target 
protein. This modification often leads to protein degradation. However, it can also 
change the localisation of proteins or their activity (Xu and Jaffrey, 2011). Ubiquitination 
of Rho GTPases can be triggered by bacterial toxins and growth factors (Visvikis et al., 
2010), but other factors could be involved as well. Several Rho GTPases have been 
reported to undergo ubiquitination, including RhoA, Rac1, Rac1b, Cdc42, RhoB and 
RhoBTB2 (de la Vega et al., 2011; Nethe and Hordijk, 2010). Ubiquitination has been 
proposed to be a mechanism to control the local activity of Rho GTPases (de la Vega 
et al., 2011; Mettouchi and Lemichez, 2012; Sahai et al., 2007; Tian et al., 2011) and it 
can affect either the GTP-bound form (active) or GDP-bound form (inactive). For 
example, Rac1 is ubiquitinated only when in the active form and bound to the plasma 
membrane (Kovacic et al., 2001; Lynch et al., 2006; Nethe et al., 2010; Visvikis et al., 
2008). However, RhoA can be ubiquitinated in different conformations by different 
mechanisms. Nucleotide free RhoA and GDP-RhoA are substrates of Smurf1 ubiquitin 
ligase (Wang et al., 2003) while only GDP-RhoA is a substrate of the BACURD-cullin3 
complex (Chen et al., 2009). Recently, it has been proposed that GDP-RhoA and GTP-
RhoA are substrates of SCFFBXL19 E3 ubiquitin ligase, facilitated by Erk2-mediated 
phosphorylation of RhoA (Wei et al., 2013). In all cases, the ubiquitination of RhoA 
leads to degradation by the proteasome.  
Phosphorylation is another covalent modification that can regulate Rho GTPases. 
Some protein kinases such as PKA, ROCK1, Src and Akt have been shown to 
phosphorylate RhoA, Rnd3 (RhoE), Cdc42 and Rac1, respectively (Kwon et al., 2000; 




Lang et al., 1996; Riento et al., 2005; Tu et al., 2003). In most cases, phosphorylation 
seems to have a negative effect on the activity of Rho GTPases. RhoA can be 
phosphorylated on serine 188 (Ser188) by PKA and this allows RhoGDIs to bind with 
high-affinity to RhoA, translocating RhoA from membranes to the cytosol. Although 
binding to RhoGDIs inhibits RhoA activity, the interaction can protect RhoA from 
ubiquitin-mediated degradation (Ellerbroek et al., 2003; Lang et al., 1996; Rolli-
Derkinderen et al., 2005). Phosphorylation of Rnd3 by ROCK1 and PKC on 7 serines 
increases protein stability and translocates Rnd3 to the cytosol which reduces its 
activity in inducing stress fibre disruption (Riento et al., 2005; Riou et al., 2013). Rac1 
is phosphorylated on serine 71 (Ser71) by Akt and threonine 108 (Thr108) by ERK. 
Phosphorylation of Ser71 appears to decrease GTP-binding without affecting GTPase 
activity of Rac1 while phosphorylation of Thr108 inhibits interaction of Rac1 with PLCγ1 
and induces translocation of Rac1 to the nucleus (Kwon et al., 2000; Tong et al., 2013).  
  




1.1.2 Regulation of the actin cytoskeleton 
A highly conserved function of Rho GTPases is the control of the actin cytoskeleton. 
Several cellular processes including cell migration, cell division, endocytosis and 
chemotaxis depend on the actin cytoskeleton (Jaffe and Hall, 2005). 
Initial studies using fibroblasts have shown that RhoA induces the assembly of focal 
adhesions and formation of stress fibres while Rac1 stimulates the formation of 
lamellipodia (Ridley and Hall, 1992; Ridley et al., 1992), giving the first clues about the 
role of Rho GTPases in actin cytoskeleton regulation. Later, Cdc42 was shown to 
regulate the formation of filopodia (Nobes and Hall, 1995). 
The actin cytoskeleton consists of actin filaments (F-actin) that are formed by the self-
assembly of monomeric globular actin (G-actin). The filaments are double helical and 
each asymmetric filament has a dynamic barbed end and a less active pointed end. 
The dynamics of assembly and disassembly is dependent on ATP hydrolysis. ATP-
actin associates at the barbed end and ADP-actin dissociates from the pointed end. 
Moreover, this process is under the control of over a hundred actin-binding proteins 
(ABPs). ABPs interact directly with F-actin or G-actin; and control the structure and 
dynamics of the actin cytoskeleton (Goley and Welch, 2006; Pollard and Borisy, 2003). 
ABPs can regulate different steps including filament nucleation, elongation, severing, 
capping, and depolymerization (Lee and Dominguez, 2010). Rho GTPases are known 
to interact with or alter the activity of ABPs and therefore regulate the 
assembly/disassembly of the actin cytoskeleton. Extracellular signals, such as 
cytokines, growth factors and hormones, are sensed by cell surface receptors and 
transmitted to Rho GTPases. Active Rho GTPases then interact with their effector 
proteins, activating signal cascades that will lead to stress fibres, lamellipodia and 
filopodia (Jaffe and Hall, 2005) (Figure 1.2).  




The first step of actin polymerization is known as nucleation, which involves the 
formation of a stable multimer of actin monomers that will function as a template to the 
elongation of the new filament. This is controlled by actin-nucleating proteins, including 
the actin-related protein 2/3 (Arp2/3) complex and formins. Each actin-nucleating 
protein acts in a distinctive mechanism. For example, Arp2/3 complex initiates a new 
actin filament that branches off an existing filament while formins promote nucleation of 
unbranched filaments at the barbed end (Firat-Karalar and Welch, 2011; Goley and 
Welch, 2006). 
The Arp2/3 complex is not an efficient nucleator and it requires the activity of 
nucleation promoting factor (NPF) proteins, including Wiskott-Aldrich Syndrome protein 
(WASP), neuronal WASP (N-WASP) and WASP-family verprolin-homologous protein 
(WAVE; also known as suppressor of cyclic AMP repressor (SCAR)) (Campellone and 
Welch, 2010; Firat-Karalar and Welch, 2011). These proteins have in common a WCA 
domain, which consist of a WASP-homology-2 (WH2 or W); and a central (also called 
cofilin-homology or connector) and acidic (CA) region. These regions are important to 
bring G-actin to the complex and to change the conformation of the Arp2/3 complex 
that leads to the initiation of actin polymerization. NPFs are regulated by other proteins, 
including Rho GTPases (Dominguez, 2009; Goley and Welch, 2006; Ladwein and 
Rottner, 2008; Suetsugu, 2013).  
Formins are large multidomain proteins defined by the presence of a catalytic formin 
homology 2 (FH2) domain. There are eight formin subfamilies identified in humans 
including Dia, FMNL and FHOD. Formins act both as nucleation and elongation factors. 
These proteins processively associate with barbed ends, allowing the addition of G-
actin while inhibiting capping proteins from ending elongation (Breitsprecher and 
Goode, 2013; Chesarone et al., 2010; Dominguez, 2009; Schonichen and Geyer, 
2010).  




Another family of proteins that control elongation is Enabled/vasodilator-stimulated 
phosphoprotein (Ena/VASP) proteins. All members of the family have an amino-
terminal Ena/VASP homology 1 (EVH1) domain followed by a proline-rich central 
region and a carboxy-terminal Ena/VASP homology 2 (EVH2) domain. Ena/VASP 
proteins elongate filaments that have been initiated by W-based filament nucleators 
such as an Arp2/3/NPF complex. These proteins are able to bind to both G-actin and 
F-actin. They act by binding at barbed ends of actin filaments and inhibiting filament 
capping by capping protein. Moreover, Ena/VASP proteins can control actin filament 
branching by reducing the density of Arp2/3-dependent actin filament branches (Chen 
et al., 2014b; Dominguez, 2009; Krause et al., 2003). 
Filaments grow until they are capped. Capping is important to control the length of the 
growing branches and localise where the filaments generate propulsive forces. The two 
main proteins involved in this process are capping protein (also known as CapZ in 
muscle) and gelsolin (Pollard and Borisy, 2003). Another process that controls the 
dynamics of the actin cytoskeleton is depolymerization. The actin-depolymerizing factor 
(ADF)/cofilin family are involved in this step. These proteins are known to sever 
filaments and elevate the levels of monomeric actin. Both ADF and cofilin bind to ADP-
bound subunits of the F-actin, promoting their disassembly. Cofilin can also bind to 
released ADP-actin monomers, controlling the recycling of disassociated actin 
subunits. The extent of depolymerization of the actin filaments relies on several factors 
including the relative concentration of other actin-binding proteins (Bamburg and 
Bernstein, 2010; Dos Remedios et al., 2003). The protrusive motility depends on the 
treadmilling of the actin filaments that consists in the addition of subunits at the barbed 
end and loss of subunits at the pointed end (Pollard and Borisy, 2003).  




1.1.2.1  Cell migration  
To illustrate the importance of Rho GTPases in the regulation of the actin cytoskeleton, 
the steps of cell migration of single cells will be briefly explained. Cell migration is a 
multistep process in which cells need to extend membrane protrusions in the cell front 
(lamellipodia, filopodia or membrane blebs), form new adhesions, contract the cell body 
and detach the cell rear from the surrounding environment (Figure 1.7). Rho GTPases 
are critical molecules in this process, sending signals from the membrane receptors to 
the cytoskeleton and cell adhesions (Ridley, 2001; Ridley et al., 2003). Single cells are 
able to migrate in two interchangeable modes of migration: amoeboid and 
mesenchymal (Pankova et al., 2010). RhoA has been implicated in both amoeboid and 
mesenchymal migration in 3D environments (Vega and Ridley, 2008). The amoeboid 
mode of migration is characterized by actomyosin-based cortical contractility mediated 
by Rho/ROCK signalling. The consistent tension results in blebbing, which contributes 
to cell motility (Pankova et al., 2010; Vega and Ridley, 2008). The mesenchymal mode 
of migration has an elongated fibroblast-like morphology that depends on cell adhesion 
dynamics and traction forces between both poles of the cell. Formation of focal 
adhesions and actomyosin-mediated contractility is controlled by Rho/ROCK signalling 
(Friedl and Wolf, 2003; Pankova et al., 2010).  
 
Figure 1.7 - Single cell migration 
Single cell migration is a multistep process in which cells need to extend membrane 
protrusions at the cell front (lamellipodia, filopodia or membrane blebs), form new 
adhesions, contract the cell body and detach the cell rear from the surrounding 
environment. Lamellipodium and filopodium formation involves the rearrangement of 
the actin cytoskeleton with the help of nucleators such as the Arp2/3 complex. Blebs 
are protrusions of the cell membrane due to actomyosin contractions of the cell cortex.   





Lamellipodia are transient structures and their formation is driven by actin 
polymerization. The Arp2/3 complex is associated with actin filaments throughout the 
cell front, and together with WAVE proteins, it stimulates the formation of a “dendritic” 
actin network that is important for lamellipodium extension (Ridley, 2011). Activation of 
Rac is necessary for lamellipodium formation. GTP-Rac binds directly to Sra1 protein, 
activating the WAVE regulatory complex (WRC) (hetero-pentameric complex formed by 
Sra1/Cyfit1, Nap1/Hem2/Kette, Abi2, HSPC300/Brick1 and WAVE1/SCAR) (Chen et 
al., 2014a; Krause and Gautreau, 2014). WRC activity is controlled by inhibition of the 
verprolin-homology, central and acidic (VCA) region. It is believed that the interaction of 
GTP-Rac with Sra1, and perhaps with the meander region of WAVE1 (a meandering 
path across a concave surface of Sra1 that is formed by five helices (α2-α6 and a 
series of intervening loops)), could lead to changes in the conformation of the complex 
and release of the VCA region, which is important for the activation of the Arp2/3 
complex (Chen et al., 2014a; Chen et al., 2010).  
The presence of PI(3,4,5)P3 increases GTP-bound Rac in several cell types. It is 
thought that PI(3,4,5)P3 promotes GTP loading on Rac through direct interaction with 
Rac GEFs. Several Rac GEFs, including Tiam-1, β-PIX and DOCK180, are known to 
activate Rac to induce lamellipodia. Rac activation also stimulates PI3K (Fritsch et al., 
2013), which leads to the production of PI(3,4,5)P3. This creates a positive feedback 
loop, accumulating active Rac at the cell front (Raftopoulou and Hall, 2004; Ridley, 
2011, 2015). Another example of a mechanism to control actin polymerization in the 
cell front is through the PAK family of serine/threonine kinases. Activation of Rac and 
Cdc42 activates PAKs, which then phosphorylate and activate LIM kinase (LIMK). 
Activation of LIMK leads to phosphorylation and inactivation of cofilin. Cofilin is an 
important protein to promote filament treadmilling at the leading edge (Bamburg and 
Bernstein, 2010; Raftopoulou and Hall, 2004). 




Formins are also involved in lamellipodium extension. It was found that mDia1, a RhoA 
effector, localises at the leading edge of some cells, including T-cells, and it can 
cooperate with the Arp2/3 complex to initiate lamellipodium formation (Heasman et al., 
2010; Isogai et al., 2015). RhoA is mainly active at the cell rear, but it has been shown 
to be active at the cell front as well. During membrane protrusion, RhoA is active at the 
leading edge, but it is inactivated during membrane retraction (Pertz, 2010). Activation 
of mDia1 by RhoA in the cell front could stimulate actin polymerization (Heasman et al., 
2010). 
In the rest of the cell, active RhoA is associated with focal adhesion formation (sites of 
contact of the cell with the extracellular matrix) and cell contractility during cell 
migration. One important Rho effector that is involved in actin-myosin filament 
assembly is serine/threonine kinase ROCK. Activation of ROCK leads to 
phosphorylation and activation of LIMK, which then phosphorylates and inactivates 
cofilin. ROCK also phosphorylates myosin light chain (MLC) phosphatase, inactivating 
it. This leads to an increase in the levels of phosphorylated myosin light chain (pMLC), 
which then stimulates the cross-linking of actin filaments by myosin II and generates 
contractile forces. Contraction promotes movements of the cell body and contribute to 
detachment of the cell rear (Ananthakrishnan and Ehrlicher, 2007; Raftopoulou and 
Hall, 2004). Another important effector of RhoA at the cell rear is mDia. This effector 
cooperates with ROCK for the assembly of actomyosin bundles such as stress fibres. 
mDia is found at the front and back of the cell, and its function is dependent on the cell 
type and conditions during cell migration (Narumiya et al., 2009; Raftopoulou and Hall, 
2004). 
Cell polarity is important for directional migration. Formation of protrusions and 
retraction of the cell rear are not enough to direct the cells to a specific place. The 
nucleus, Golgi apparatus and microtubule-organizing centre (MTOC) also need to be 
repositioned towards the leading edge (Vicente-Manzanares et al., 2005). Cdc42 has 




been shown to regulate MTOC positioning through recruitment of Par6 and aPKC to 
the leading edge (Etienne-Manneville and Hall, 2001). Nuclear movement can also be 
regulated by Cdc42, probably through actin flow controlled by actin-myosin regulatory 
kinase (MRCK) (Gomes et al., 2005; Luxton and Gundersen, 2011; Sit and Manser, 
2011). 
  




1.1.3 Other activities of Rho GTPases 
Rho GTPases have been reported to take part in signalling pathways that do not 
involve regulation of the actin cytoskeleton. For example, RhoA, Rac1 and Cdc42 are 
involved in signalling pathways that lead to the activation of a variety of transcription 
factors including activating protein-1 (AP-1) transcription factor (Benitah et al., 2004; 
Rajakyla and Vartiainen, 2014). AP-1 proteins are dimeric transcription factors formed 
by Jun, Fos or ATF subunits. AP-1 binds to the AP-1-binding sites on DNA and 
regulates the transcription of genes that are important for cell proliferation, death, 
survival and differentiation (Shaulian and Karin, 2002). It is well-known that Rac/Cdc42 
activates JNK/SAPK and p38 signalling cascades, leading to Jun phosphorylation. 
Phosphorylated Jun homodimers have high AP-1 activity and are responsible for the 
transcription of several genes (Coso et al., 1995; Minden et al., 1995). RhoA also has a 
role in Jun regulation, but at a transcriptional level. It has been shown that RhoA 
activates jun transcription through the activation of two different kinases, PKN and 
ROCK (Marinissen et al., 2001; Marinissen et al., 2004). Activation of AP-1 by RhoA, 
Rac1 and Cdc42 can also be achieved through serum response factor (SRF), a 
transcription factor that activates the fos promoter serum response element (SRE) (Hill 
et al., 1995).   
Another known pathway regulated by Rho GTPases is the activation of NFκB. NFκB 
proteins (RelA/p65, RelB, c-Rel, p50 (NF-κB1) and p52 (NF-kB2)) are transcription 
factors that are found as dimers. In the cytoplasm, they are associated with IκB 
proteins in an inactive state. After stimulation, NFκB dissociates from IκB and moves to 
the nucleus where it can control the transcription of genes that are important for the 
maintenance of the immune system, skeletal system and epithelium (Hayden and 
Ghosh, 2012). RhoA, Rac1 and Cdc42 are able to induce phosphorylation of IκBa 
which leads to the translocation of p50/p50 and p50/p65 dimers to the nucleus where 
they are active transcription factors (Perona et al., 1997). 




Atypical Rho GTPases may also regulate gene expression. Depletion of RhoBTB1 and 
RhoBTB2 in normal primary human keratinocytes leads to a decrease of CXCL14 
mRNA levels. CXCL14 is a homeostatic chemokine that has reduced expression in a 
wide range of epithelial tumours. Further analysis using head and neck squamous cell 
carcinoma (HNSCC) cell lines have shown that the levels of RhoBTB2 and CXCL14 in 
these cell lines were lower than the levels found in primary keratinocytes. Restoration 
of RhoBTB2 expression was able to increase the levels of CXCL14 in all HNSCC cell 
lines. The mechanism for this regulation is still unknown, but it does not involve cullin3, 
a known RhoBTB-binding protein (McKinnon et al., 2008).  
Rac also plays a role in the activation of NADPH oxidase enzyme complex. NADPH 
oxidase, the main component of the complex, generates superoxide radicals that are 
important to kill microorganisms that are phagocytosed by cells. Reactive oxygen 
species (ROS) are also known to be involved in the regulation of the cytoskeleton. One 
of the mechanisms appears to be through inhibition of RhoA which allows Rac1-
mediated cytoskeletal reorganization. Activation of NADPH relies on a protein 
multicomplex that consists of two integral membrane proteins, pg91phox and p21phox, 
and two cytosolic proteins, p67phox and p47phox. Rac1 has been shown to interact with 
p67phox and be the fifth component in the complex that leads to NADPH complex 
activation (Abo et al., 1991; Diekmann et al., 1994; Elnakish et al., 2013; Hall, 2012; 
Petry et al., 2009; Stanley et al., 2014).  
  




1.1.4 Crosstalk between Rho GTPases 
The signalling networks that are controlled by Rho GTPases are really dynamic and 
they need to be regulated in time and space. Members of the Rho GTPase family are 
known to overlap in many signalling pathways, acting sometimes in a cooperative 
manner and sometimes in an antagonistic manner. Because they act so close to each 
other, it is not surprising that there is a crosstalk regulation between the Rho GTPases. 
This interaction can occur in three different levels: regulation of activity; regulation of 
protein expression and stability; and regulation of downstream signalling pathways 
(Guilluy et al., 2011).  
The classic example of crosstalk that regulates GTPase activity is between RhoA and 
Rac1. For example, the Tiam1-mediated activation of Rac in NIH3T3 fibroblasts results 
in the downregulation of Rho activity at the GTP-level and leads to an epithelial-like 
morphology. Re-expression of RhoA reverses the phenotype to a migratory fibroblast-
like morphology without affecting Rac activity (Sander et al., 1999). However, it was 
observed that RhoA can also inhibit the activity of Rac through ROCK-mediated 
inhibition of FilGAP (Ohta et al., 2006). Although RhoA and Rac act in antagonistic 
ways most of the time, they can also positively regulate each other (Guilluy et al., 2011) 
(Figure 1.8). Other Rho GTPases can also crosstalk with RhoA and Rac, including 
RhoG and Rnd3. All these crosstalks are mainly mediated by the activation or inhibition 
of GEFs and GAPs (Guilluy et al., 2011).  
 







Figure 1.8 – Rac1 and RhoA crosstalk 
Crosstalk between Rac1 and RhoA involves a complex network that includes effectors, 
RhoGAPs and RhoGEFs. RhoA activates Rac1 through activation of mDia while 
activation of ROCK leads to inhibition of Rac1 through activation of FilGAP and 
ArhGAP22 and/or inhibition of Rac1 GEF β-PIX. Rac1 activates RhoA through 
activation of RhoA GEF Dbs. However, Rac1 inhibits RhoA through activation of 
p190RhoGAP. In addition, RhoA is also inhibited when Rac1 activates PAK proteins 
which leads to inhibition of Rho GEFs such as p115-RhoGEF, GEF-H1, RhoA GEF 
Net1 and PDZ-RhoGEF (re-drawn from Guilluy et al. (2011)).   
 
As mentioned above, levels of Rho GTPases can be regulated by ubiquitin-mediated 
degradation. One mechanism that Rho GTPases use to avoid degradation is binding to 
RhoGDIs. The limited amount of RhoGDIs can cause a competition among the Rho 
GTPases to avoid degradation. However, in some cases, the displacement of a Rho 
GTPase from the RhoGDI complex has a positive effect. The released Rho GTPase is 
activated and able to interact with other proteins (Garcia-Mata et al., 2011). 
Overexpression of only one Rho GTPase leads to competition with endogenous Rho 
proteins to bind RhoGDIs in a dose-dependent manner, showing that changes in the 




levels of a single protein can affect the equilibrium of the whole Rho GTPase network 
(Boulter et al., 2010; Garcia-Mata et al., 2011).  
The crosstalk of Rho GTPases can also be mediated by their effectors (Figure 1.8). 
Rho, Rac and Cdc42 share some common effectors and signalling pathways, leading 
to a dynamic downstream crosstalk. Depending on the cell type, the Rho GTPases can 
act in a synergistic or antagonistic way (Boulter et al., 2010).  
1.1.5 Rho GTPases in tumorigenesis 
Rho GTPases are important signal transducers in signalling pathways that regulate cell 
migration, proliferation, survival and death. All these cellular processes are crucial for 
maintenance of normal tissues. However, any misbalance in the control of these 
pathways could lead to the development of many diseases including cancer, 
cardiovascular disease, hepatic disease, developmental disorders and 
neurodegenerative disorders (Boettner and Van Aelst, 2002; DeGeer and Lamarche-
Vane, 2013; Sahai and Marshall, 2002; Toksoz and Merdek, 2002). 
The role of Rho GTPases in tumorigenesis will be discussed in more detail since these 
proteins are involved in all steps of tumour progression. The development of human 
tumours is a multistep process that consists in dysregulation of cell proliferation, 
resistance to growth suppressors, inhibition of cell death, uncontrolled replication 
leading to immortalization and activation of angiogenesis, invasion and metastasis 
(Hanahan and Weinberg, 2011).  
Accumulation of mutations in genes that affect proliferation and survival is one of the 
key steps for primary tumour formation. Until recently, it was believed that Rho 
GTPases were rarely mutated in human tumours. However, it was found that proline 29 
in Rac1 is mutated in a subset of melanomas, breast tumours and head and neck 
tumours (Alan and Lundquist, 2013). RhoA is also mutated in some tumours including 
diffuse gastric cancer and angioimmunoblastic T cell lymphoma (Kakiuchi et al., 2014; 




Sakata-Yanagimoto et al., 2014; Wang et al., 2014; Yoo et al., 2014; Zhou et al., 2014). 
Although these mutations seem to be important for tumour development, in most 
cases, Rho GTPases are found to be upregulated or to have their activity increased by 
misregulation of GAPs, GEFs and/or GDIs (Boettner and Van Aelst, 2002; Vega and 
Ridley, 2008). Several Rho GTPases are upregulated in human tumours including 
RhoA, RhoC, Rac1, Rac2, Rac3, Cdc42, RhoV and RhoF (Pajic et al., 2015; Vega and 
Ridley, 2008). 
The classical Rho GTPases, RhoA, Rac1 and Cdc42, are known to be essential for 
Ras-induced transformation in NIH 3T3 cells (Qiu et al., 1995a; Qiu et al., 1997; Qiu et 
al., 1995b). Moreover, they have been shown to be important for the progression and 
metastasis of different human tumours including breast cancer, liver cancer, 
melanoma, testicular cancer and ovarian cancer (Gomez del Pulgar et al., 2005; Kamai 
et al., 2004; Wang et al., 2007). 
RhoA appers to be involved in almost all stages of tumour progression. For example, in 
gastric cancer cell lines, RhoA is found to be hyperactive and its suppression leads to 
partially inhibition of the proliferation phenotype. This effect involves regulation of cell 
cycle through G1-S progression. Downregulation of the RhoA target mDia1 in gastric 
cancer cell lines leads to increase in the expression of cell cycle inhibitors p21Waf1/Cip1 
and p27Kip1 while downregulation of ROCK increases the levels of another family of cell 
cycle inhibitors called INK4 (Zhang et al., 2009). Several studies in vitro and in vivo 
suggest that RhoA has a role during tumour angiogenesis. One example is the 
knockout of Gα13 receptors in endothelial cells in mice, which causes a decrease in 
tumour growth and normalization of tumour vasculature. Gα13 induces expression of 
VEGF2 mediated by activation of RhoA which leads to transcription of NFκB (Sivaraj et 
al., 2013). Local invasion is an early step in the metastatic process by which cells need 
to detach from the primary tumour and migrate through the surrounding tissue. 
Although RhoA seems to play an active role in cancer progression, recent findings in 




diffuse gastric cancer and angioimmunoblastic T cell lymphoma have shown that 
mutations in RhoA that lead to loss of GTPase activity are important to drive cancer 
progression (Kakiuchi et al., 2014; Sakata-Yanagimoto et al., 2014; Wang et al., 2014; 
Yoo et al., 2014; Zhou et al., 2014). 
RhoC has also been found to promote tumour progression while RhoB seems to act as 
a tumour suppressor (Ridley, 2013). RhoC promotes tumour progression in some 
tumours including melanoma, ovarian cancer and head and neck cancer (Horiuchi et 
al., 2003; Islam et al., 2009; Ruth et al., 2006). RhoC is able to control invadopodium 
formation in tumour cells by locally regulating cofilin activity. Invadopodia are cell 
protrusions capable of penetrating and degrading the extracellular matrix, increasing 
the metastatic potential of tumour cells. RhoC activity is spatially regulated by 
activation of p190RhoGEF outside the invadopodia and activation of p190RhoGAP 
inside the invadopodium core. This leads to restriction of cofilin activity only inside the 
invadopodium core (Bravo-Cordero et al., 2011). RhoB, on the other hand, is often 
downregulated in human tumours (Huang and Prendergast, 2006; Vega and Ridley, 
2008). For example, the expression of RhoB in human lung tissues decreases going 
from normal tissue to invasive carcinoma. In addition, overexpression of RhoB in the 
lung cancer cell line A549 leads to inhibition of cell growth in vitro and in vivo (Mazieres 
et al., 2004). Also, overexpression of RhoB in gastric cancer cell lines inhibits 
proliferation, migration and invasion; and increases chemosensitivity while 
overexpression of RhoA and RhoC leads to opposite effects (Zhou et al., 2011).  
Rac1 is another Rho GTPase that is found altered in several stages of tumour 
progression. Deregulation of Rac signalling can be caused by changes in the upstream 
signalling including tyrosine kinase receptors, PI3Ks, GEFs and GAPs. One example is 
the activation of Rac1 by Rac GEF P-Rex1 after stimulation of tyrosine kinase 
receptors and GPCRs in breast cancer cells (Wertheimer et al., 2012). In colorectal 
tumours, the expression of a Rac1 splice variant, Rac1b, is increased in different 




stages of tumour progression (Jordan et al., 1999). Expression of Rac1b has also been 
found in breast cancer and lung cancer (Schnelzer et al., 2000; Zhou et al., 2013). 
Rac1b has been shown to be involved in MMP-3-mediated malignant transformation of 
mammary epithelial cells. MMP-3 induces the expression of Rac1b which increases the 
levels of cellular ROS, leading to expression of the transcription factor Snail, which 
induces epithelial-mesenchymal transition (EMT) as well as oxidative damage to DNA 
and genomic instability (Radisky et al., 2005).  
The role of Cdc42 in tumour progression may be tissue-specific. Cdc42 is found to be 
upregulated in many tumours including non-small cell lung cancer, colorectal 
adenocarcinoma, melanoma, breast cancer and testicular cancer. However, loss of 
Cdc42 in liver cancer leads to an increase in tumour development (Stengel and Zheng, 
2011; Vega and Ridley, 2008). Some other Rho GTPases also appear to have a dual 
role in tumorigenesis. Rnd3 is downregulated in some tumours and acts as a tumour 
suppressor (Grise et al., 2012; Karlsson et al., 2009; Muller et al., 2011; Villalonga et 
al., 2004). However, in some cases, Rnd3 has been shown to be upregulated and 
mediate drug resistance in cancer cells (Li et al., 2009; Zhang et al., 2007). RhoBTBs 
also do not have a well-defined role in tumorigenesis (see section 1.1.7).  
These examples illustrate how complex the role of Rho GTPases in tumour 
progression is. Their contribution is dependent on cell type, extracellular stimulus and 
signalling pathway involved in the cell transformation.  
  




1.1.6 Atypical Rho GTPases 
The atypical Rho GTPase subgroup consists of four subfamilies: RhoV and RhoU 
subfamily, RhoH subfamily, Rnd1, Rnd2 and Rnd3 subfamily; and RhoBTB1 and 
RhoBTB2 subfamily. Each subfamily will be briefly described in this section.  
RhoV (also known as Chp or Wrch2) and RhoU (also known as Wrch1) proteins are 
members of the RhoV and RhoU subfamily. These proteins have significant sequence 
identity to Cdc42 (~ 52-55%), but they contain extra N- and C- terminal extensions that 
are critical for their activity (Aronheim et al., 1998; Shutes et al., 2004). RhoV and 
RhoU have an extremely rapid intrinsic guanine nucleotide exchange activity, and are 
therefore found mainly in the GTP-bound form in cells (Shutes et al., 2004). So far, 
RhoV and RhoU GAPs and GEFs have not been identified. In addition, these proteins 
are palmitoylated instead of prenylated in their C-terminal domain as mentioned in 
section 1.1. This lipid modification is important to regulate their membrane localisation 
and activity. However, membrane localisation is not regulated by RhoGDIs like for the 
classic Rho GTPases (Berzat et al., 2005; Chenette et al., 2005; Chenette et al., 2006). 
Expression of RhoV and RhoU is regulated at the transcriptional level by Wnt-1; and 
RhoU has also been shown to be regulated by STAT3 (Faure and Fort, 2015; 
Schiavone et al., 2009; Tao et al., 2001). Like Cdc42, RhoV and RhoU affect the actin 
cytoskeleton (lamellipodium formation and filopodium formation, respectively), cell 
migration and formation of focal adhesions (Aronheim et al., 1998; Chuang et al., 2007; 
Saras et al., 2004; Tao et al., 2001). Although RhoV and RhoU are very similar, only 
RhoU binds to Grb2 through its N-terminal domain and is phosphorylated on tyrosine 
254 by Src in its C-terminal domain (Alan et al., 2010; Shutes et al., 2004). Other 
known binding partners are PAK1, PAK2, PAK4 and NCKβ (Aronheim et al., 1998; Dart 
et al., 2015; Saras et al., 2004; Tao et al., 2001). Another interesting feature in this 
subfamily is that the N-terminal domain is able to regulate RhoV and RhoU function in 




a negative way, a characteristic found for the first time in the Rho GTPase family 
(Chenette et al., 2005; Shutes et al., 2004). 
RhoH, also known as TTF (translocation three four), is normally expressed only in 
hematopoietic tissues, similar to Rac2 (Dallery-Prudhomme et al., 1997). RhoH is 
GTPase deficient, and is therefore constantly in a GTP-bound form (Li et al., 2002). 
The C-terminal region of RhoH has a CKIF motif (a typical CAAX motif) that can be 
prenylated in vitro (Fueller and Kubatzky, 2008; Roberts et al., 2008). Due to the lack of 
GTPase activity, RhoH is not regulated by GAPs and GEFs. However, RhoH is able to 
interact with RhoGDIs; and it has been shown to be regulated at the transcriptional 
level and by phosphorylation (Delestre et al., 2011; Gu et al., 2006; Li et al., 2002). 
RhoH is important in the regulation of proliferation, survival, migration and engraftment 
of murine hematopoietic progenitor cells (Gu et al., 2005); and it has been implicated in 
T-cell differentiation (Dorn et al., 2006). RhoH does not seem to have any direct effect 
on actin reorganization (Aspenstrom et al., 2004). However, RhoH can antagonize the 
activity of other Rho GTPases. For example, Rac1 and RhoA-mediated activation of 
NFκB is inhibited by RhoH through inhibition of IκB degradation (Li et al., 2002). Loss 
of RhoH in murine hematopoietic progenitor cells leads to an increase in Rac1-
mediated migration and cortical F-actin assembly (Chae et al., 2008).  
Rnd1, Rnd2 and Rnd3 (also known as RhoE) proteins are members of the Rnd 
subfamily. Although these proteins are highly similar to the classic Rho GTPases, Rnd 
proteins are GTPase deficient, and are therefore constitutively in the GTP-bound form; 
and they are modified by the farnesyl group instead of geranylgeranyl group in their C-
terminal domain (Foster et al., 1996; Riou et al., 2010). Rnd1 and Rnd3 are mainly 
associated with membranes and RhoGDIs do affect their localisation. Rnd2 seems to 
be localised predominantly in the cytoplasm (Chardin, 2006; Riou et al., 2010; Roberts 
et al., 2008). Since Rnd proteins have not been shown to interact with any GAPs or 
GEFs, these proteins should be regulated by other mechanisms such as 




phosphorylation, expression and localisation. In fact, it has been shown that Rnd 
proteins can be phosphorylated and phosphorylation (in combination with farnesylation) 
allows these proteins to interact with 14-3-3 proteins. This interaction leads to 
translocation of Rnd proteins from the plasma membrane to the cytosol, inactivating 
these proteins (Riou et al., 2013). Rnd3 is known to be phosphorylated on 5 serines 
and 1 threonine by ROCK1 and on serine 210 by PKC (Madigan et al., 2009; Riento et 
al., 2005). Moreover, expression of Rnd3 is induced by activation of Raf, leading to 
changes in the actin cytoskeleton (Hansen et al., 2000). One important function of 
Rnd1 and Rnd3 is that they can antagonize RhoA interaction with p190RhoGAP. This 
interaction leads to loss of stress fibres and cell rounding (Guasch et al., 1998; Nobes 
et al., 1998; Oinuma et al., 2012; Wennerberg et al., 2003). Other proteins also interact 
with Rnd proteins, which could also contribute to Rnd-induced responses.  
1.1.7 RhoBTB proteins 
In mammals, RhoBTB1 and RhoBTB2 form the RhoBTB subfamily. Members of the 
RhoBTB subfamily were identified during a study using a Dictyostelium discoideum 
model to identify Rho-related proteins. Orthologues of RhoBTB1 and RhoBTB2 are 
present in vertebrates and insects, but not in plants and fungi (Boureux et al., 2007; 
Rivero et al., 2001). Although RhoBTB3 shares some similarities with RhoBTB1 and 
RhoBTB2, this protein is not considered a Rho GTPase due to its low similarity to other 
Rho proteins (Boureux et al., 2007; Wennerberg and Der, 2004). 
RhoBTB1 gene is located in chromosome 10 while RhoBTB2 gene in chromosome 8. 
The coding sequence of these two proteins is split into 9 exons. Additional exons are 
placed upstream of the start codon, two in RhoBTB1 and one in RhoBTB2. The exon-
intron organization of RhoBTB1 and RhoBTB2 is very similar except for exon 4. This 
exon encodes the complete first BTB domain and it is 45 bp longer in RhoBTB2 
(Ramos et al., 2002). RhoBTB1 is ubiquitously expressed in human tissue, showing 




high levels in skeletal muscle, placenta, stomach, kidney, testis, adrenal gland and 
uterus. RhoBTB2 is overall weakly expressed with relatively high levels in neural and 
cardiac tissues (Berthold et al., 2008b; Ramos et al., 2002).  
RhoBTB1 and RhoBTB2 are atypical Rho GTPases as they do not cycle between a 
GTP-bound form and a GDP-bound form. The GTP-binding domain of RhoBTBs is 
Rho-related but is around 18 residues longer and rich in charged residues. Due to a 
deletion in a glutamine equivalent to Q61 in Ras and a substitution of a glycine 
equivalent to G12 in Ras by asparagine, the GTP-binding domain of RhoBTBs could be 
expected not to hydrolyse GTP (Berthold et al., 2008b). It has been reported that the 
GTP-binding domain of RhoBTB2 does not bind to GTP in vitro (Chang et al., 2006), 
but nothing has been published for RhoBTB1. RhoBTB1 (79 kDa) and RhoBTB2 (82 
kDa) are also bigger than classical GTPases (~ 20 kDa) due to the presence of 
extradomains in addition to the GTP (Rho) domain. The non-functional GTPase domain 
(Rho domain) is followed by a proline-rich motif (PRM), a tandem of 2 broad-complex, 




Figure 1.9 – Members of the RhoBTB subfamily 
Domain structure of the RhoBTB proteins. 
 





Proline-rich motifs are known to be important for protein-protein interaction. Proline-rich 
regions can bind to SH3 (Src homology 3), WW and EVH1 domains (Kay et al., 2000). 
All these domains are present in proteins that are important for regulating the actin 
cytoskeleton. The proline sequence found in RhoBTB1 is the PxxP motif (where x 
denotes any amino acid) and is classified as a class II motif. The PxxP motif is the core 
binding motif of the SH3 domain and this could indicate a potential interaction of 
RhoBTB1 with proteins with SH3 domains (Berthold et al., 2008b). 
The BTB domain, also known as Pox virus and Zinc finger (POZ) domain, is a 
conserved protein-protein motif present in proteins involved in transcription repression, 
cytoskeleton regulation and protein ubiquitination/degradation. Some proteins contain 
only the BTB domain, but it is more usual for BTB to be combined with other domains. 
The most frequent ones are MATH, Kelch, NPH3, Ion transport and Zinc finger (ZF) 
domains (Perez-Torrado et al., 2006). However, RhoBTB1 and RhoBTB2 have an 
unusual organization with a tandem of 2 BTB domains. The first BTB is divided in two 
by an extension of unknown function that has a different length and composition among 
RhoBTB proteins. It has been shown so far that the BTB domains in RhoBTB proteins 
are important for the formation of homodimers and heterodimers (Berthold et al., 
2008a) and for the interaction with cullin3, a scaffold protein in ubiquitin-ligase 
complexes (Berthold et al., 2008a). 
The C-terminal region is conserved in all members of the RhoBTB subfamily and it is 
not found in any other protein (Rivero et al., 2001). Although RhoBTBs have a potential 
nuclear localization signal (NLS) near the C-terminus, these proteins have not been 
reported to be found in the nucleus. Unlike the classical GTPases, RhoBTBs do not 
have a CAAX motif, a sequence important for post-translational modification that 
signals proteins to the membrane.  




The functions of RhoBTB1 and RhoBTB2 have not been well determined yet. Although 
RhoBTB1 and RhoBTB2 have domains that could interact with proteins involved in 
actin cytoskeleton regulation, these proteins do not interact with the CRIB domain of 
WASP and PAK or the Rho-binding domain of Rhotekin; and ectopic expression of 
RhoBTBs in primary aortic endothelial (PAE) cells does not seem to affect the 
organization of the actin filament system. Moreover, it was observed that RhoBTB1 and 
RhoBTB2 are localised in vesicles, suggesting that RhoBTBs might be involved in 
vesicle trafficking (Aspenstrom et al., 2004). It has been shown that RhoBTB2 is 
involved in transporting vesicular stomatitis virus glycoprotein (VSVG) in a microtubule-
dependent manner (Chang et al., 2006). RhoBTB2 has been studied more than 
RhoBTB1. It has been reported that RhoBTB2 has an active role in cell cycle 
progression and apoptosis through the transcription factor E2F1 (Freeman et al., 
2008). Moreover, RNA profiling using Hela cells has shown that RhoBTB2 affects cell 
cycle, apoptosis, cytoskeleton and membrane trafficking pathways (Siripurapu et al., 
2005). Because RhoBTB1 and RhoBTB2 share 79% homology, some of RhoBTB2 
functions could also be performed by RhoBTB1.  
One protein interaction that is common to the RhoBTBs is the interaction with cullin3. 
Both RhoBTB1 and RhoBTB2 bind to the N-terminus of cullin3 (Berthold et al., 2008a; 
Wilkins et al., 2004). The same has been reported for other BTB containing proteins 
and cullin3; and this interaction has been shown to be important for targeting proteins 
for ubiquitination and hence degradation (Geyer et al., 2003). Indeed, RhoBTB2 has 
been shown to be a substrate for the cullin3 ubiquitin ligase complex (Wilkins et al., 
2004).  
RhoBTB1 and RhoBTB2 have been described as tumour suppressors. RhoBTB2 is 
also known as ‘deleted in breast cancer 2’ (DBC2) and its levels are reduced in some 
breast cancers (Hamaguchi et al., 2002). RhoBTB1 is downregulated in some cancers 
like head and neck cancer (Beder et al., 2006), breast cancer and kidney cancer 




(Berthold et al., 2008b); but it has also been reported to be upregulated in some cancer 
cell lines (Ramos et al., 2002; Vega and Ridley, 2008). The RhoBTB2 gene has been 
shown to be a target of E2F1, a transcription factor involved in cell cycle and apoptosis 
(Freeman et al., 2008) and RhoBTB1 is a target of microRNA-31 (miR-31) in human 
colon cancer (Xu et al., 2013). PPARγ, a regulator of adipogenesis, can also regulate 
RhoBTB1. Overexpression of PPARγ increases mRNA levels of RhoBTB1 (Pelham et 
al., 2012). As mentioned above, RhoBTB2 is a substrate of the cullin3 ubiquitin ligase 
complex and it is degraded via the proteasome (Wilkins et al., 2004). Not much is 
known about RhoBTB regulation. Since they do not behave as typical GTPases, 
RhoBTBs are not regulated by GAPs, GEFs and GDIs. Unconventional mechanisms 
such as phosphorylation, SUMOylation, post-transcriptional regulation by microRNAs 
and ubiquitination could be involved in RhoBTB regulation, leading to 
inhibition/activation or degradation of the proteins.  
1.2 Ubiquitination and cullin3  
1.2.1 Ubiquitination process 
Ubiquitination is a three-step process in which ubiquitin, a highly conserved protein of 
8.5 kDa, becomes covalently attached to lysine residues of target proteins. This 
mechanism controls the stability and/or localisation of cellular substrates involved in the 
regulation of many cellular processes. Firstly, ubiquitin is activated in an ATP-
dependent reaction and it is bound to an E1 activating enzyme. Second, ubiquitin-
loaded E1 transfers the ubiquitin to an E2 ubiquitin conjugating enzyme. Ubiquitin is 
attached to the E2 catalytic cysteine residue through a trans(thio)esterification reaction. 
In the last step, E3 ubiquitin ligases facilitate the formation of an isopeptide bound 
between ubiquitin and substrate. In humans, there are 2 E1 enzymes, 37 E2 enzymes 
and more than 600 E3 ligases (Haglund and Dikic, 2005; Komander, 2009; Sarikas et 
al., 2011). E3 ubiquitin ligases are important to mediate substrate specificity. They are 




divided in several classes, the major ones are HECT (homologous to E6-associated 
protein C-terminus), RING (really interesting new gene) finger and U-box (a modified 
RING motif without the full complement of Zn2+-binding ligands) (Ardley and Robinson, 
2005).  
Ubiquitin modification can occur in three general ways: mono-ubiquitination (a single 
ubiquitin is attached), multi-mono-ubiquitination (several lysine residues are tagged 
with a single ubiquitin) and polyubiquitination (a chain of ubiquitins is attached to one or 
more lysines). Polyubiquitination is possible because there are seven lysines (Lys6, 
Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63) in the ubiquitin molecule that can be 
involved in chain formation. Polyubiquitination on lysine 48 signals for proteasomal 
degradation of the substrate. However, other types of ubiquitin modification are 
involved in the regulation of different processes such as endocytosis and DNA repair 
(Figure 1.10) (Haglund and Dikic, 2005; Komander, 2009).  
 
 
Figure 1.10 – Rotes of ubiquitin modifications in regulating proteins 




Ubiquitination of proteins can lead to different outcomes depending on the ubiquitin 
modification and lysine involved. There are three general types of ubiquitination: mono-
ubiquitination (a single ubiquitin is attached), multi-mono-ubiquitination (several lysine 
residues are tagged with a single ubiquitin) and polyubiquitination (a chain of ubiquitins 
is attached to one or more lysines). Mono and multi-mono-ubiquitination are involved in 
endocytosis, endosomal sorting, histone regulation, DNA repair, virus budding and 
nuclear export. Polyubiquitination on lysine 63 (K63) leads to DNA repair, endocytosis 
and activation of protein kinases while polyubiquitination on lysine 48 (K48) leads to 
proteasomal degradation.  
  





Cullin3 is part of the cullin family. The cullin family is evolutionarily conserved 
throughout bacteria and eukaryotes. In mammals, there are seven cullins (Cul1, Cul2, 
Cul3, Cul4a, Cul4b, Cul5, Cul7) and the closely related p-53-associated parkin-like 
cytoplasmic protein (PARC). All members have a signature cullin homology domain 
(CH) of about 200 amino acids. Cullin1 to cullin5 are considered classic cullins and 
they consist of an amino-terminal domain (NTD) with three cullin repeats (CR1 to CR3) 
and a globular carboxy-terminal domain (CTD) with the CH domain (Sarikas et al., 
2011). Cul7 and Parc are atypical cullins. Apart from the conserved CH domain, they 
have extra-domains such as DOC (destruction of cyclin B) domain and IBR (in-




Figure 1.11 - Cullin proteins 
Domain organization of cullin proteins in humans. 
 
 




Cullins are molecular scaffolds of CULLIN-RING ubiquitin ligases (CRLs), the most 
prevalent class of E3 ubiquitin ligases. CRLs are composed by a cullin that serves as a 
link between the catalytic module, formed by a RING finger domain protein that is 
responsible for recruiting an ubiquitin loaded E2 ubiquitin-conjugating enzyme; and a 
specific substrate recognition module, formed by a substrate recognition protein and an 
adaptor protein (Genschik et al., 2013; Petroski and Deshaies, 2005). In the case of 
cullin3-RING ubiquitin ligases (CRL3s), BTB/POZ proteins are the adaptor proteins that 
bind to cullin3 and bring the substrate to the complex; and Roc1-Rbx1-Hrt1 is the RING 
component (Genschik et al., 2013). CRL3s can be regulated by mechanisms such as 
inhibition/activation of cullins, dimerisation of cullin3 with BTB proteins; and post-
translational modification of substrates and adaptors (Genschik et al., 2013; Petroski 
and Deshaies, 2005).  
Cullins can be covalently modified at a conserved lysine residue in their C-terminus by 
the attachment of an ubiquitin-like protein called NEDD8 (Figure 1.11). A sequential 
action of a NEDD8-activating enzyme (NAE), the APPBP1-UBA3 heterodimer, and a 
NEDD8-conjugating enzyme, UBC12, is required for the neddylation. Roc1, the RING 
finger domain protein of this complex, it is also required for the neddylation. NEDD8 is 
removed from cullins by the isopeptidase activity of the zinc-dependent metalloenzyme 
called CSN5, a component of the COP9 signalosome (CSN) complex (Duda et al., 
2011; Genschik et al., 2013; Lyapina et al., 2001). Neddylation leads to changes in 
cullins leading to an “open” conformation. This increases recruitment of ubiquitin-
charged E2 enzymes and facilitates the positioning of the E2 active site for ubiquitin 
transfer onto substrates (Boh et al., 2011; Duda et al., 2008; Duda et al., 2011; 
Genschik et al., 2013). Another mechanism to regulate CRLs is through the binding of 
cullin-associated and neddylation-dissociated protein 1 (CAND1) to deneddylated 
cullins. CAND1 inhibits CRL assembly and NEDD8 activation. It has been shown that 
the C-terminus of CAND1 binds to cullin1 in the site that recruits the adaptor complex 




for substrate recognition; and the N-terminus of CAND1 binds at the junction between 
the RING component and cullin that is found only when cullin is deneddylated. CAND1 
also binds directly to the lysine in cullin1 where NEDD8 is supposed to bind (Duda et 
al., 2011). Probably the same occurs with cullin3 since it has been shown that CAND1 
can affect neddylation of cullin3 in Drosophila (Kim et al., 2010). It is believed that the 
neddylation/deneddylation cycle is important for the functionality of the cullin complex.  
Several CRL3s can dimerise through the BTB domains of their BTB adaptor proteins. 
One example is the ubiquitination of Nrf2 by the Keap1-cullin3 complex. The 
dimerisation of Keap1 is crucial for the binding of the substrate to the complex 
(McMahon et al., 2006). Moreover, it has been reported that cullin3 (Wimuttisuk and 
Singer, 2007) and other cullins (Chew et al., 2007) can also dimerise (Figure 1.12). In 
the case of cullin3, a substrate recognition unit is necessary for the dimerisation to 
occur. Cullin3 constructs that were unable to bind to BTB adaptor proteins could not 
form dimers (Chew et al., 2007). The dimerisation is believed not only to be important 
for substrate recruitment, but also to increase the avidity for substrate and to increase 
the concentration of associated E2, leading to an increase in the catalytic rate of 
ubiquitination (Genschik et al., 2013).   
 
Figure 1.12 - Dimerization of BTB-protein and dimerisation of cullin3 
A) CRL3 can dimerise through the BTB domains of their BTB adaptor proteins. One 
example is the ubiquitination of Nrf2 by the Keap1-cullin3 complex. The dimerisation of 
Keap1 is crucial for the binding of the substrate to the complex. B) Cullin3 can directly 
dimerise. A proposed model is that two cullins interact through the NEDD8 molecule 
attached to one of them.   




Post-translational modification of substrates and adaptor proteins is also an important 
mechanism to regulate CRLs. Substrates can be phosphorylated, glycosylated, and/or 
prolyl hydroxylated. These modifications can promote or inhibit affinity of the substrate 
for the adaptor protein (Duda et al., 2011). Adaptor proteins can also undergo 
modifications that affect their activity. One example is the modification of thiol groups in 
Keap1 cysteine residues after oxidative stress, leading to a decrease in E3 activity 
(Genschik et al., 2013).   
Cullin3 forms a BTB-cullin3-Rbx1 (BCR) ubiquitin ligase complex. This complex is best 
known to control the degradation of many proteins that are important in several cellular 
processes such as cell cycle, actin cytoskeleton regulation, apoptosis and oxidative 
stress (Bade et al., 2014; Furukawa and Xiong, 2005; Jin et al., 2009; Sumara et al., 
2007). It has been reported that RhoA, RhoBTB2 and Tiam1 are substrates of BCR 
complexes (Berthold et al., 2008b; Chen et al., 2009; Genau et al., 2015; Wilkins et al., 
2004). Recently cullin3 has been shown to be a regulator of the endolysosomal 
pathway. Knockdown of cullin3 leads to defects in trafficking of influenza A virus (IAV) 
and epidermal growth factor receptor (EGFR). However, the mechanisms through 
which cullin3 regulates endosome maturation are still unclear (Huotari et al., 2012).  
Knockdown of RhoBTB1 in MDA-MB-231 cells led to a decrease in cancer cell 
interaction with endothelial cells in vitro, leading to decrease in cell adhesion and 
transendothelial migration (Chapter 3) (Borda D'Agua, 2012). A decrease in RhoA 
protein levels and activity was also observed, without affecting its mRNA levels (Borda 
D'Agua, 2012). The mechanistic basis for the effect of RhoBTB1 depletion on cancer 
cells remains to be determined. Because cullin3 is involved in RhoA degradation (Chen 
et al., 2009) and RhoBTB1 is known to interact with cullin3, the hypothesis is that 
RhoBTB1 protects RhoA from degradation and this affects cancer cell/endothelial cell 
interaction. In addition, RhoBTB1 will be characterized based on what is published for 
RhoBTB2 and other potential binding partners will be explored.  




1.3 Aims of the project 
RhoBTB1 depletion in MDA-MB-231 and PC3 cancer cells reduces their adhesion to 
endothelial cells and transendothelial migration. RhoBTB1 depletion was also reported 
to reduce RhoA protein expression levels in MDA-MB-231 cells (Borda D'Agua, 2012). 
Based on these results, the initial aims of this project were to test the role of RhoBTB1 
in regulating the transendothelial migration of other breast cancer cell lines, to 
determine how RhoBTB1 regulates RhoA and how this relates to its function in 
transendothelial migration; and to investigate which targets of RhoBTB1 are critical for 
its effects on cancer-endothelial cell interaction and transendothelial migration.  
The first step of the project was to optimise different breast cancer cell lines in the 2D 
and 3D models used in the laboratory to study cancer cell-endothelial cell interaction 
and transendothelial migration. After finding the best conditions for each cell line, 
RhoBTB1 would be depleted in these cell lines and the results would be compared with 
the ones obtained for MDA-MB-231 cells (Borda D'Agua, 2012). However, as shown in 
Chapter 3, two out of the three breast cancer cell lines selected did not seem suitable 
to be used to study endothelial interaction with the laboratory protocols. In addition, 
depletion of RhoBTB1 in Cal51 cells did not reproduce the results obtained with MDA-
MB-231 cells: it did not decrease cancer cell adhesion to or intercalation between 
endothelial cells; or decrease RhoA expression.  
For these reasons, this project focused subsequently on the characterization of 
RhoBTB1 signalling to RhoA and in the interaction of RhoBTB1 with RhoA and 
ROCK1.  
 




2 Materials and Methods 
 
2.1 Materials 
2.1.1 Reagents and Kits 
Table 2-1 Reagents and Kits 
Reagents/Kits Supplier 
4-12% SDS-polyacrylamide gel (1.5 mm; 
10 wells/15 wells) 
Invitrogen 
32P-ATP PerkinElmer Health Sciences B.V. 
Agarose Sigma 
Ampicillin sodium salt Sigma 
Anti-c-Myc Agarose Affinity Gel antibody 
produced in rabbit 
Sigma 
Anti-FLAG® M2 Affinity Gel Sigma 
ATP, lithium salt 100 mM, pH 7 Roche 
Bovine Collagen I INAMED/BioMatrix 
Brilliant III Ultra-Fast SYBR® Green QRT-
PCR Master Mix 
STRATAGENE, Agilent Technologies 
Division 
Cell Dissociation Solution Non-enzymatic  Sigma 
Carboxyfluorescein succinimidyl ester 
(CFSE) 
Molecular Probes, Invitrogen 
Complete, mini EDTA-free protease 
inhibitor cocktail 
Roche Applied Science 
Coverslips (13, 25 mm) VWR 
Cycloheximide Calbiochem 
Dako Pen, S2002 Dako Cytomation 
www.dako.com 
DH5α Invitrogen 
Disuccinimidyl suberate (DSS) crosslinker Thermo Scientific Pierce 
DNA sample buffer (6x) Promega 
DNA-freeTM DNAse Treatment Kit Ambicon 
dNTP Mix Promega 
Dried, skimmed milk Marvel 
Dulbeco’s modified eagle medium (DMEM) 
(4500 mg/L glucose + 580 mg/L L-
glutamine + 25 mM HEPES) 
Gibco 
www.invitrogen.com 
Enhanced chemiluminescence (ECL) 
reagent 
GE Healthcare 
EndoFree Maxiprep Kit  Qiagen 
Endothelial cell basal medium-2 (EBM-2), 
supplemented with ascorbic acid, R3-IGF-
1, heparin, rhFGF-B, hydrocortisone, GA-
1000, rhEGF, VEGF, 2% fetal bovine 
serum. Supplements are provided as part 
of a bullet kit, purchased with the basal 
medium  
Clonetics®, Lonza 
Ethidium bromide Sigma 




Fetal calf serum (FCS) Biosera 
www.biosera.com 
Fibronectin  Sigma 
Fluorescent mounting medium Dako Cytomation 
www.dako.com 
GFP-Trap® chromotek   
www.chromotek.com 
Glutatione SepharoseTM GE Healthcare 
GST-ROCK1 17-535 SignalChem  
www.signalchem.com 




Kanamycin sulphate  Gibco 
L-Broth Sigma 
LDS Sample Buffer 4x Invitrogen 
LipofectamineTM2000 Invitrogen 
MG132 proteasomal inhibitor Cambridge Biosciences 
MLN4924 (NEDD8 E1 Activating Enzyme 
Inhibitor) 
BostonBiochem, R&D Systems 
Company 
Monoclonal Anti-HA Agarose Conjugate 
Clone HA-7 
Sigma 
Nitrocellulose membrane Amersham 
OligofectamineTM Invitrogen 
Opti-MEM + GlutaMaxTM-I Gibco 
Phosphate buffered saline (PBS) 
(-) CaCl2/MgCl2 (PBS -/-) 
(+)CaCl2/MgCl2 (PBS +/+) 
Gibco 
Penicillin (10.000 units/ml)/Streptomycin 
(10.000 μg/ml) 
Gibco 
Pfu DNA Polymerase  Promega  
Phosphatase cocktail inhibitors (II and IV) Calbiochem 
Polyethylenimine (PEI) Polisciences 
Precision PlusproteinTM standards Bio-Rad 
ProQ® Diamond Phosphoprotein Blot Stain 
Kit 
Invitrogen 
Protein G SepharoseTM 4 Fast Flow GE Healthcare 
PureCol®  Advanced BioMatrix 
Pyruvate 100 mM Thermo Scientific 
QIAEX II® Gel Extraction Kit Qiagen 
Quantum Prep® Plasmid Miniprep Kit Bio-Rad 
QuikChange II XL Site-Directed 
Mutagenesis Kit 
Agilent Technologies, Inc 
Rho Kinase Inhibitor (H1152) Calbiochem 
RNeasy Mini Kit Qiagen 
Roswell Park Memorial Institute (RPMI) 
1640 (+ 3000 mg/L L-glutamine + 25 mM 
HEPES) 
Gibco 
SYPRO® Ruby Protein Blot Stain Life Technologies 
T4 DNA ligase New England Biolabs (NEB) 
ThinCertTM, 8 µm pore Greiner bio-one 
Trypsin/EDTA 0.05% Gibco 
 




2.1.2 Buffers and solutions 
Table 2-2 Buffers and solutions 
Buffers and solutions Composition 
Lysis buffer 50 mM Tris-HCl pH 8, 150 mM NaCl, 
5 mM EGTA, 1% Triton X-100, 
supplemented with protease inhibitor 
cocktail (Roche), 25 mM NaF (Thr/Ser 
phosphatase inhibitor), 2 mM Na3VO4 
(Tyr phosphatase inhibitor) 
IP lysis buffer 1% Triton X-100, 20 mM Tris pH 8, 
130 mM NaCl, 1 mM DTT 
supplemented with protease inhibitor 
cocktail (Roche), 10 mM NaF (Thr/Ser 
phosphatase inhibitor) and 
phosphatase inhibitor cocktails II and 
IV (Sigma) 
Mg2+ lysis buffer (5x)  125 mM Hepes pH 7.5, 750 mM 
NaCl, 5% NP-40, 50 mM MgCl2, 5 
mM EDTA 
Mg2+ lysis buffer (1x) – Pull down 5x Mg2+ buffer supplemented with 
protease inhibitor cocktail (Roche), 1 
mM PMSF and 10% glycerol  
Buffer 1 200 mM Na2HPO4, 1.3 M NaCl, 90 
mM NaOH. Addition of buffer 1 to 
liquid collagen catalyses matrix 
polymerisation  
Cell lysis buffer  2% SDS, 150 mM NaCl, 10 mM Tris-
HCl, pH 8.0 supplemented with 2 mM 
Na3VO4, 50 mM NaF and protease 
inhibitor cocktail (Roche) 
Dilution buffer 10 mM Tris-HCl, pH 8.0, 150 mM 
NaCl, 2 mM EDTA, 1% Triton X-100 
Washing buffer 10 mM Tris-HCl, pH 8.0, 1 M NaCl, 1 
mM EDTA, 1% NP-40 
NuPAGE MES SDS Running Buffer (20x) 1 M MES, 1 M Tris, 69.3 mM SDS, 




20.5 mM EDTA 
Transfer buffer  25 mM Tris-HCl pH 8.3, 192 mM 
glycine, 20% methanol 
Tris-buffered saline (TBS) 5 mM Tris-HCl pH 7.6, 50 mM NaCl 
Tris-buffered saline – 0.1% Tween (TBS-T) TBS 1x + 0.1% Tween-20 
Stripping buffer 1 mM Tris-HCl, 0.15 M NaCl. Adjust 
to pH 2.0 
Tris-acetate-EDTA (TAE) (50x) 2 M Tris, 57.1 ml/l Glacial Acetic Acid, 
0.05 M EDTA pH 8 
GST beads lysis buffer 10 mM MgCl, 1 mM DTT, 1 mM 
PMSF complete volume with TBS 
GST beads washing buffer 10 mM MgCl, 1 mM DTT, 1 mM 
PMSF complete volume with TBS. 
Supplemented with protease inhibitor 
cocktail (Roche) 
Kinase assay buffer (2x) 40 mM MgCl2, 4 mM MnCl2, 60 mM 
Tris pH 7.4 
Kinase assay fixing solution 8.75% acetic acid, 25% ethanol 
Freezing solution 90% FCS, 10% dimethyl sulphoxide 
(DMSO) 
Fix solution (Pro-Q®) 7% acetic acid, 10% methanol 
Destain Solution (Pro-Q®) 50 mM sodium acetate, pH 4.0, 20% 
acetonitrile 
Conjugation buffer 20 mM Hepes, pH 7.0, 1% Triton X-
100 
Kanamycin 100x stock 50 mg in 1 ml of ddH2O 
Ampicillin 100x stock 100 mg in 1 ml of ddH2O 












Table 2-3 Primary antibodies 
Antigen Species Dilution Supplier 
CD29 (β1 integrin) mouse WB (1:1000) BD 
p-cofilin (Ser3) rabbit WB (1:1000) Cell Signalling 
Technologies 
cofilin rabbit WB (1:1000) Cell Signalling 
Technologies 
cullin3 mouse WB (1:1000) BD 
FLAG M2 rabbit WB (1:1000) Sigma 
GFP (B-2) mouse WB (1:1000) Santa Cruz 
GFP (FL) rabbit WB (1:1000) Santa Cruz 
GAPDH mouse WB (1:10000) Millipore 
HA (3H10) rat WB (1:1000) Roche 
p-LIMK1/2 rabbit WB (1:1000) Cell Signalling 
Technologies 




rabbit WB (1:1000) Cell Signalling 
Technologies 
MLC2 rabbit WB (1:1000) Cell Signalling 
Technologies 
myc (9E10) mouse WB (1:1000 Santa Cruz 
myc (A14) rabbit WB (1:1000) Santa Cruz 
PECAM-1 (CD31 –
clone JC70A) 
mouse IF (1:100) Dako 
RhoA rabbit WB (1:1000) Cell Signalling 
Technologies 
ROCK1 mouse WB (1:1000) BD 
ROCK2 mouse WB (1:1000) BD 
 
WB: western blot; IF: immunofluorescence 
 
Table 2-4 Secondary antibodies and reagents 
Antigen Species Conjugate Dilution Supplier 
mouse IgG sheep Horse radish peroxidase 1:5000 GE Healthcare 
rabbit IgG donkey Horse radish peroxidase 1:5000 GE Healthcare 
rat IgG goat Horse radish peroxidase 1:5000 GE Healthcare 
mouse IgG 
(H+L) 
goat Alexa Fluor® 546 1:1000 Molecular 
ProbesTM 
phalloidin  Alexa Fluor® 546 1/400 Molecular 
ProbesTM 
phalloidin  Alexa Fluor® 633 1/40 Molecular 
ProbesTM 
DAPI  N/A 1/10000 Molecular 
ProbesTM 
 





Table 2-5 siRNAs 
Gene Symbol Oligo number Sequence 
control  control siRNA UUCUCCGAACGUGUCACG 
cullin3 #3 CCGAACAUCUCAUAAAUAA 
#5 GAGAUCAAGUUGUACGUUA 
RhoA #1 AUGGAAAGCAGGUAGAGUU 
#2 GAACUAUGUGGCAGAUAUC 




ROCK1  #2 GAAGAAACAUUCCCUAUUC 
#3 GAGAUGAGCAAGUCAAUUA 
ROCK2 #5 GCAAAUCUGUUAAUACUCG 
#9 CAAACUUGGUAAAGAAUUG 
 
Table 2-6 qPCR primers 
Primer Sequence 5’-3’ 
RhoBTB1    forward 
                    reverse 
CAAGCAGTATTGGATTATCTC 
TGGTCAACTCCTGAACGG 
ROCK1       forward 
                    reverse  
CATGGTGATGGAATACATGC 
GTTATCAGGCTTCACATCTC 
ROCK2       forward 
                    reverse  
GCATGGTACATTGTGATACAG 
CCCACTAGCATCTCATAAAG 
GAPDH       forward 




Table 2-7 Mutagenesis primers 
Mutagenesis primers Sequences 5’-3’  
S69A     forward 
              reverse 
GAGGTCTTGGAGCGTGCTCGGGATGTTGTTG 
CAACAACATCCCGAGCACGCTCCAAGACCTC 
T398A   forward 
              reverse 
GGATGGGGCCCATGGCTGTGGTCAGGATG 
CATCCTGACCACAGCCATGGGCCCCATCC 
S480A   forward 
              reverse 
CGGATAAAAGAGTGTCTCGCCAAGGGAACGTTCTCGGA 
TCCGAGAACGTTCCCTTGGCGAGACACTCTTTTATCCG 
T483A   forward 
              reverse 
GTGTCTCAGCAAGGGAGCGTTCTCGGACGT 
ACGTCCGAGAACGCTCCCTTGCTGAGACAC 
S480A   forward 
T483A 
S485A   reverse             












Table 2-8 Cloning primers 









EcoRI RhoBTB1 1-427 
(Reverse) 
CGGAATTCTCATTCCTTTTCATCCAGTTGTCCCG 
HindIII RhoBTB1 266-696 
(Forward) 
CCGAAGCTTGCCGATGTTCTGTTCATCCTTCAG 















Table 2-9 Sequencing primers 
Sequencing primers Sequences 5’-3’ 
RhoBTB1 forward 1 CACGCAGTATCAGCTGCTG 
RhoBTB1 forward 2 CCACCGGTCATCAAATTCCAG 
RhoBTB1 forward 4 GCACCACATCTGCACCAACT 
RhoBTB1 forward 5 GAGAAGCAGAGCAGAGATTTC 
RhoBTB1 reverse 1 GCCTGAGAGAAACACTCACTTC 
BACURD1 forward 1 GAGGTTGGGTGCTGATTGAC 
2.1.5 Plasmids 
Table 2-10 Expression plasmids 
Construct Provided by 
pCAG-myc-ROCK1 Professor Shuh Narumiya 
pCAG-myc-ROCK1 1-1080 Professor Shuh Narumiya 
pCAG-myc-ROCK1 1-727  Professor Shuh Narumiya 
pCAG-myc-ROCK1 1-727 (K105A) Dr Ritu Garg 
pCAG-myc-ROCK1 1-540 Dr Ritu Garg 
pCAG-myc-ROCK1 1-420 Dr Ritu Garg 
pCAG-myc-ROCK1 1096-1354 Dr Ritu Garg 
pCAG-myc-ROCK1 375-727 Dr Ritu Garg 
pCAG-myc-ROCK2 Professor Shuh Narumiya 
CB6-GFP-RhoA Dr Ferran Valderrama 
pEGFP-RhoA-V14 Dr Ferran Valderrama  
pEGFP-RhoA-N19 Dr Ferran Valderrama 
pCMV5-FLAG-RhoA-N19 Dr Giles Cory 
pRK5-myc-RhoBTB1 Dr Pontus Aspenström 
pGEX2T-RhoBTB1 1-301 Dr Brad McColl 
pEGFP-RhoBTB2 Dr Ritu Garg 
pCMV-HA-ubiquitin Dr Matthias Krause 




2.1.6 Restriction Enzymes 
Table 2-11 Restriction enzymes 
Restriction Enzyme Restriction site 5’-3’ Supplier 
BamHI GGATCC New England Biolabs (NEB) 
BglII AGATCT NEB 
EcoRI GAATTC NEB 
HindIII AAGCTT NEB 
NotI GCGGCCGC NEB 




Illustrator CS3 Adobe 
ImageJ National Institutes of Health (NIH) 
LSM + Zen Software Zeiss 
Volocity Perkin Elmer, Improvision 
MxPro Agilent Technologies 
GraphPad Prism 4 GraphPad Software 
 
2.2 Methods: molecular biology 
2.2.1 Transformation of Escherichia coli (E. coli)  
100 ng of plasmid DNA were added to 50 µl of competent DH5α in a 1.5 ml microtube 
and incubated on ice for 30 minutes. The bacterial suspension was heat-pulsed at 
42°C for 45 seconds and then left on ice for 2 minutes. 800 µl of antibiotic-free L-Broth 
(LB) was added into the microtube and the cells were grown at 37°C for 1 hour. The 
microtubes were centrifuged and the pellet was resuspended in 100 µl. The cells were 
plated onto LB agar plates containing the appropriate antibiotic (100 µg/ml ampicillin or 
50 µg/ml kanamycin) and incubated at 37°C overnight. 
2.2.2 Extraction of plasmid DNA from bacteria 
For small-scale production of plasmid DNA, Quantum Prep® Plasmid Miniprep Kits 
were used following the manufacturer’s instructions. A single colony from an agar plate 
was transferred to 2 ml of LB medium containing 100 µg/ml ampicillin or 50 µg/ml 




kanamycin. The culture was incubated overnight at 37°C. 1.5 ml of the overnight 
culture was transferred to a microtube and the cells were pelleted by centrifugation at 
14,000 g for 30 secs. The supernatant was removed and 200 μl of cell resuspension 
solution was added. After mixing up and down until the cell pellet was completely 
resuspended, 250 μl of cell lysis solution was added and the microtube inverted gently. 
Immediately after 250 μl of neutralization solution was added and the cell debris was 
removed by centrifugation at 14,000 g for 5 minutes. The supernatant was transferred 
into a spin filter placed on a 2 ml tube. 200 μl of Quantum Prep matrix was added and 
solutions were mixed pippeting up and down. Tubes were centrifuged at 14,000 g for 
30 secs. The filtrated was discarded and 500 μl of wash buffer was added into the spin 
filter. Tubes were centrifuged at 14,000 g for 30 secs. The filtrated was discarded and 
500 μl of wash buffer was added again into the spin filter. Tubes were centrifuged at 
14,000 g for 2 minutes. The spin filter was placed in a new 1.5 ml collection and 100 μl 
of TE were added into spin filter. Samples were centrifuged for 1 minute at 14,000 g to 
elute the DNA. 
2.2.3 Determination of DNA concentration 
DNA concentration was determined spectrophotometrically using a Nano-Drop system 
(ND-1000, www.nanodrop.com). 1.5 µl of sample was pipetted onto the end of a fibre 
optic cable and the optical density (OD) was measured at 260 nm. The DNA 
concentration in ng/µl was automatically determined using the following formula: 
concDNA = OD260 x 50 µg/ml (Sambrook and Russel, Molecular Cloning, 3rd Edition).  
2.2.4 DNA amplification using Polymerase Chain Reaction (PCR) 
The PCR reaction containing 20 ng of DNA template, Pfu DNA Polymerase 10x 
Reaction Buffer with MgSO4, 25 pmol of each forward and reverse primers, 0.2 μM of 
each nucleotide (dATP, dTTP, dGTP and dCTP) was heated at 94ºC for 1 minute 




before the Pfu DNA Polymerase was added. The PCR conditions were 94ºC for 45 
secs, 50ºC for 1 minute and 72ºC for 2 minutes per kb for 35 cycles.  
2.2.5 Ethanol precipitation of DNA 
To purify and concentrate DNA, a 1:10 volume of 3 M sodium acetate pH 5.2 and a 2.5 
volume of cold 100% ethanol were added to the PCR product (section 2.2.4). The 
solution was incubated overnight at -20ºC. To recover the precipitated DNA the sample 
was centrifuged at 17,000 g for 10 minutes. The supernatant was discarded and the 
DNA pellet was washed with 500 μl of 80% ethanol. The sample was centrifuged at 
17,000 g for 10 minutes. The supernatant was discarded. The DNA pellet was air-dried 
and resuspended in distilled water.  
2.2.6 Digestion of DNA using restriction enzymes 
Plasmid DNA (0.5 to 2 µg) was digested using 1 unit/µg of restriction enzyme for 1 – 3 
hours at 37°C. When necessary the restriction enzyme was inactivated for 20 minutes 
at 65°C or 80°C. NEBcutter V2.0 (http://tools.neb.com/NEBcutter2/) and Double Digest 
Finder (https://www.neb.com/tools-and-resources/interactive-tools/double-digest-finder) 
tools were used to determined suitable enzymes and the best conditions for each 
digestion, respectively. After each digestion, an amount of the restriction product and 
the undigested DNA were resolved on a 1% agarose gel.  
2.2.7 Agarose gel electrophoresis 
DNA fragments were separated depending on their molecular weight using 1% agarose 
gels. The gels were prepared dissolving agarose in 1x TAE buffer by boiling the 
mixture in a microwave oven. The solution was cooled down and poured into a gel tank 
containing a well comb. Ethidium bromide (0.5 µg/ml) was added before the gel was 
solid. Ethidium bromide binds to the DNA allowing the visualization of DNA fragments 
on a UV-transilluminator. After the gel solidified, DNA samples were diluted in 6x DNA 




sample buffer and loaded into the wells. A 1 kb DNA ladder was run in parallel to 
identify the sizes of DNA fragments. Electrophoresis was carried out at 10-15 V/cm2 
until fragments were separated.  
2.2.8 Extraction of DNA from agarose gels 
Ethidium bromide-integrated DNA bands were visualised using UV light. Bands of 
interest were excised using a scalpel blade and the gel pieces were transferred to a 1.5 
ml microtube. QIAEX II® Gel Extraction Kit was used to recover the DNA. Gel pieces 
containing DNA were incubated with 3 volumes (3 times the weight of the gel pieces) of 
Buffer QX1. 5 μl of QIAEX II beads were added to the microtube. Samples were 
incubated at 50ºC for 10 minutes (vortexing every 2 minutes) to solubilise the agarose 
and bind the DNA. Samples were centrifuged at 5,000 g for 30 secs. Supernatant was 
discarded and 500 μl of Buffer PE was added to wash the pellet (beads containing the 
DNA). Samples were centrifuged at 5,000 g for 30 secs. Supernatant was discarded 
and the pellet was air-dried for 15 minutes. To elute the DNA, 8 μl of distilled water was 
added. Samples were heated at 50ºC for 5 minutes (vortexing every 2.5 minutes). 
Samples were centrifuged at 17,000 g for 30 secs. The supernatant containing the 
DNA was transferred to a new microtube. The DNA was used immediately for the 
ligation reaction or stored at -20ºC. 
2.2.9 DNA ligation 
DNA fragments were ligated into the desired vector using 400 units of T4 DNA ligase in 
1x T4 DNA Ligase Reaction Buffer at 16ºC for 16 hours. The ratio of insert and vector 
was 3:1. The following website was used to calculate the amount of insert that should 
be used considering the amount of vector was 25 ng: http://www.insilico.uni-
duesseldorf.de/Lig_Input.html. DH5α competent cells were transformed with the 
product of the reaction (section 2.2.1). The next day 2-6 colonies from the agar plates 
were transferred to 2 ml of LB containing the appropriate antibiotic and incubated at 




37ºC overnight. Plasmid DNA was extract from the bacteria (section 2.2.2) and the 
presence of the gene of interest was confirmed by sequencing (section 2.2.11).  
2.2.10 Site-directed mutation 
Single or multiple amino acid substitutions were introduced into myc-RhoBTB1 using 
QuikChange II XL Site-Directed Mutagenesis Kit following the manufacturer’s 
instructions. Forward and reverse primers were designed using QuikChange Primer 
Design Program (http://www.genomics.agilent.com/). The primers were approximately 
25 to 45 bases in length, contained the appropriated altered base, and had a minimum 
GC content of 40% and a predicted melting temperature (Tm) of > 78ºC. PCR reactions 
contained 10 ng of DNA template, 125 ng of each primer, 1 μl of dNTP mix, 5 μl of 10x 
reaction buffer and 3 μl of QuikSolution reagent in a total reaction volume of 50 μl. 1 μl 
of PfuUltra HF DNA polymerase (2.5 U/μl) was added to each sample reaction just 
before the PCR started. PCR conditions were 95ºC for 1 minute for 1 cycle; 95ºC for 50 
secs, 60ºC for 50 secs, and 68ºC for 1 minute per kb of plasmid length for 18 cycles; 
68ºC for 7 minutes for 1 cycle. 1 μl of Dpn I restriction enzyme (10 U/μl) was added to 
the PCR product to digest methylated wild-type parental DNA. The digestion was 
carried out at 37ºC for 1 hour. XL10-Gold ultracompetent cells were transformed with 2 
μl of Dpn I-treated DNA (section 2.2.1). The next day 2-6 colonies from the agar plates 
were transferred to 2 ml of LB containing the appropriate antibiotic and incubated at 
37ºC overnight. DNA was extract from the bacteria (section 2.2.2) and the correct 
mutational changes were confirmed by sequencing (section 2.2.11).  
2.2.11 Sequencing 
DNA sequencing was carried out by MWG-Biotech (http://www.mwg-biotech.com/). 
DNA template and primers were sent to the company and results were returned by e-
mail.  
 




2.2.12 GFP-RhoBTB1 and GFP-RhoBTB1 S3T2A subcloning 
RhoBTB1 cDNA was subcloned from a myc-pRK5 to a pEGFP-C1 vector. pEGFP-C1 
was digested using BglII and HindIII and pRK5-myc-RhoBTB1 or pRK5-myc-RhoBTB1 
S69A/T398A/S480A/T483A/S485A (S3T2A) was digested using BamHI and HindIII. 
Fragments were separated on agarose gels (section 2.2.7). After extraction of DNA 
from the gels (section 2.2.8), RhoBTB1 cDNA was ligated into pEGFP-C1 (section 
2.2.9). Competent DH5α cells were transformed (section 2.2.1) with 10 μl of ligation 
reaction. Clones were verified by sequencing (section 2.2.11).  
 
Figure 2.1 - Schematic diagram of RhoBTB1 subcloning into pEGFP-C1 
pRK5-myc-RhoBTB1 was digested with BamHI and HindIII restriction enzymes; and 
pEGFP-C1 was digested with BglII and HindIII restriction enzymes. RhoBTB1 was 
ligated into pEGFP-C1 using T4 DNA ligase. 
 
  
2.2.13 Cloning of KCTD13 (BACURD1) into N-GFP-CB6 vector 
N-GFP-CB6-BACURD1 was prepared using PCR. pBlueScript-KCTD13 (GE 
Healthcare) was used as a template. BACURD1 was amplified by PCR using primers 
HindIII BACURD1 (Forward)/ EcoRI BACURD1 (Reverse). The PCR products were 
obtained as described in section 2.2.4. PCR products and N-GFP-CB6 vector were 
digested with HindIII and EcoRI (2.2.6). BACURD1 fragment was ligated into N-GFP-
CB6 vector using T4 DNA ligase (2.2.9). Competent DH5α cells were transformed 
(section 2.2.1) with 10 μl of ligation reaction. Clones were verified by sequencing 
(section 2.2.11).  






Figure 2.2 - Schematic diagram of BACURD1 cloning into N-GFP-CB6 
BACURD1 fragment and N-GFP-CB6 were digested with HindII and EcoRI restriction 
enzymes. BACURD1 fragment was ligated into N-GFP-CB6 using T4 DNA ligase. 
 
 
2.2.14 Construction of RhoBTB1 1-210, RhoBTB1 1-427, RhoBTB1 
266-696 and RhoBTB1 485-696 fragments using N-GFP-CB6 
vector 
N-GFP-CB6-RhoBTB1 1-210, N-GFP-CB6-RhoBTB1 1-427, N-GFP-CB6-RhoBTB1 
266-696 and N-GFP-CB6-RhoBTB1 485-696 constructs were prepared using PCR. 
pRK5-myc-RhoBTB1 was used as a template. RhoBTB1 1-210 and RhoBTB1 1-427 
were amplified by PCR using primers XhoI RhoBTB1 1-210/1-427 (Forward)/ EcoRI 
RhoBTB1 1-210 (Reverse) and XhoI RhoBTB1 1-210/1-427 (Forward)/ EcoRI 
RhoBTB1 1-427, respectively. RhoBTB1 266-696 and RhoBTB1 485-696 were 
amplified by PCR using primers HindIII RhoBTB1 266-696 (Forward)/ BamHI RhoBTB1 
266-696/485-696 (Reverse) and HindIII RhoBTB1 485-696 (Forward)/ BamHI 
RhoBTB1 266-696/485-696 (Reverse), respectively. The PCR products were obtained 
as described in section 2.2.4. For RhoBTB1 1-210 and RhoBTB1 1-427, PCR products 
and N-GFP-CB6 vector were digested with XhoI and EcoRI (section 2.2.6). For 
RhoBTB1 266-696 and RhoBTB1 485-696, PCR products and N-GFP-CB6 vector were 
digested with HindIII and BamHI (section 2.2.6). RhoBTB1 fragments were ligated into 
N-GFP-CB6 vector using T4 DNA ligase (section 2.2.9). Competent DH5α cells were 
transformed (section 2.2.1) with 10 μl of ligation reaction. Clones were verified by 
sequencing (section 2.2.11).  





Figure 2.3 - Schematic diagram of RhoBTB1 cloning into N-GFP-CB6 
A) RhoBTB1 fragments and N-GFP-CB6 were digested with XhoI and EcoRI restriction 
enzymes. B) RhoBTB1 fragments and N-GFP-CB6 were digested with HindIII and 
BamHI restriction enzymes. RhoBTB1 fragments were ligated into N-GFP-CB6 using 
T4 DNA ligase.  
 
2.2.15 Extraction of total RNA from mammalian cells 
Extraction of total RNA from cells was performed using the RNeasy Mini Kit following 
the manufacturer’s instructions. After 72 hours of siRNA transfection cells were washed 
twice with cold PBS-/- and 350 µl of RLT buffer were added to each well. Cells were 
scraped and lysates were transferred to a 1.5 ml microtube. 350 µl of 70% ethanol 
were added to each tube and samples were homogenized by pipetting. The total 700 µl 
was transferred to an RNeasy spin column placed on a 2 ml collection tube. Samples 
were centrifuged for 15 s at 8,000 g. The filtrated was discarded and 700 µl of RW1 




buffer were added to the spin column. Samples were centrifuged for 15 secs at 8,000 
g. In this step there is enrichment in mRNA, since RNAs smaller than 200 nucleotides 
are excluded from the silica-based membrane. The filtrated was discarded and 500 µl 
of RPE buffer were added to the spin column. Samples were centrifuged for 15 secs at 
8,000 g to wash the spin column membrane. The filtrated was discarded and the spin 
column membrane was washed again with 500 µl of RPE buffer. Samples were 
centrifuged for 2 min at 8,000 g. The spin column was placed in a new 1.5 ml collection 
tube and 30 μl of RNase-free water were added directly to the spin column membrane. 
Samples were centrifuged for 1 minute at 8,000 g to elute the RNA.  
RNA was purified using a DNA-freeTM DNAse Treatment Kit, in order to remove 
contaminating DNA. 0.1 volume of 10x DNAse1 buffer and 1 μl of DNAse1 were added 
to the RNA. Samples were gently mixed and incubated at 37ºC for 30 minutes. 0.1 
volume of DNA Inactivation Reagent beads were added and samples were incubated 
for another 2 minutes at 37ºC. Samples were centrifuged for 1 minute at 10,000 g. The 
supernatant was transferred into a new 1.5 ml microtube. RNA concentration was 
determined using a Nano-Drop spectrophotometer by determining the absorbance at 
260 nm. Samples were stored at -80ºC or immediately used.  
2.2.16 qPCR 
Extraction of mRNA (section 2.2.15) from the cells was performed 72 hours after siRNA 
transfection (section 2.3.1.3). qPCR was carried out using Brilliant III Ultra-Fast SYBR® 
Green QRT-PCR Master Mix. qPCR reactions contained 100 ng of experimental RNA, 
2x SYBR Green QRT-PCR master mix, 300 mM of each primer, 1 mM DTT and 1 μl of 
RT/RNase block. Each condition was carried out in triplicate and GAPDH was used as 
a reference gene (internal control). The assay was carried out using the Stratagene 
MX3500PTM sequence detection system and the amplification cycles were carried out 
following the manufacturer’s instructions: 50ºC for 10 minutes for 1 cycle (cDNA 




synthesis); 95ºC for 3 minutes for 1 cycle; 95ºC for 10 secs and 60ºC for 20 secs for 40 
cycles; 95ºC for 15 secs, 60ºC for 20 secs and 95ºC for 15 secs for 1 cycle 
(dissociation stage). The dissociation stage was added in order to obtain the 
dissociation curve and confirm that each primer pair amplified only one single product. 
For the analysis of raw data the MxPro software was used. Quantification of the 
amplified cDNA was achieved by comparing the number of amplification cycles (Ct) 
after which the fluorescent signal crossed a threshold level. The following formula was 
applied to quantify the results: 
 
2-∆∆CT = [(Ct gene of interest – Ct internal control) sample A – (Ct gene of interest – 
Ct internal control) sample B)] 
 
2.3 Methods: cell biology 
2.3.1 Cell culture 
2.3.1.1 Thawing and freezing cells 
To thaw cells, a cryovial was taken from liquid nitrogen and thawed at 37ºC in a 
waterbath. The cells were then transferred to a 75 cm2 tissue culture flask and 10 ml of 
the appropriate cell culture medium was added. The medium was changed the next 
day. In the case of cell lines, cells were passaged at least two times before being used 
for experiments. In the case of primary human umbilical vein endothelial cells 
(HUVECs), cells were used between passage 1-4.  
To freeze cells, cells were detached using trypsin and pelleted at 800 g for 5 minutes. 
Cells from a 75 cm2 flask were resuspended in 1 ml of freezing solution and aliquoted 
into cryovials. Cryovials were inserted into a cryo freezing container and stored at -
80ºC to allow slow freezing overnight. The cells were then transferred to liquid nitrogen 
for long-term storage.  




2.3.1.2 Growing and passaging cells 
Cells were grown using different protocols depending on the cell type. HUVECs were 
grown on fibronectin-coated flasks (10 μg/ml in PBS+/+ for 1 hour at 37ºC) in EBM-2 at 
37ºC and 5% CO2. Medium was replaced 24 hours after thawing. HUVECs were 
passaged by removing the medium from the flask and washing cells with PBS-/-. Cells 
were detached with 1 ml of trypsin/EDTA at 37ºC for 3 minutes and 9 ml of medium 
were added to the flask to inactivate the trypsin. Cells were diluted to the desired 
concentration and added to a new flask with fresh medium. Cells were not diluted more 
than 1:4 during passage. PC3 cells (kind gift from Prof John Masters) and HCC1954 
(kind gift from Prof Joy Burchell) were grown in RPMI containing 10% FCS and 
penicillin (100 IU/ml)/ streptomycin (100 μg/ml); MDA-MB-231, MCF-7, Cos7, Hela 
(kind gift from Prof Ulrike Eggert) and HEK293 cells were grown in DMEM containing 
10% FCS, penicillin (100 IU/ml)/ streptomycin (100 μg/ml) and 1% pyruvate; and Cal51 
cells were grown in DMEM containing 20% FCS, penicillin (100 IU/ml)/ streptomycin 
(100 μg/ml) and 1% pyruvate. Cells were grown at 37ºC and 5% CO2. For passaging, 
cells were washed with PBS-/- and incubated with 1 ml of trypsin/EDTA at 37ºC until 
they detached. 9 ml of growth medium were added to inactivate trypsin and cells were 
diluted 1/10 or 1/5, according to their growth rate. Cells were passaged every 3-4 days, 
depending on their confluence.  
2.3.1.3 Synthetic siRNA transfection using OligofectamineTM 
Cells were transfected on a 6-multiwell plate with different siRNA oligonucleotides 
using OligofectamineTM (following the manufacturer’s instructions). The desired volume 
of siRNA from a 20 µM stock solution was diluted in 200 – 500 µl of Opti-MEM (solution 
A) while the desired volume of OligofectamineTM (1.3 times the volume of siRNA) was 
added to 200 – 500 µl of Opti-MEM (solution B). The final concentration of siRNA used 
was 50 nM. Solutions were incubated for 5 minutes at room temperature (RT). Solution 




B was mixed into solution A and incubated for 20 minutes. The medium of the cells was 
replaced by medium without antibiotics and immediately after the mixture of solution A 
and B was added drop wise to the well. After 6 hours, the transfection medium was 
replaced for a fresh complete medium. After 48 or 72 hours of transfection, cells were 
either used for the motility assays, or lysed for mRNA extraction or for cell lysate 
preparation. 
2.3.1.4 DNA transfection using LipofectamineTM2000 
MDA-MB-231 and Hela cells were transfected on a 6-multiwell plate or on a 10 cm dish 
with different DNA plasmids using LipofectamineTM2000 (following the manufacturer’s 
instructions). The desired amount of DNA plasmid was diluted in 200 – 500 µl of Opti-
MEM (solution A) while the desired volume of LipofectamineTM2000 (ratio 1 μg of DNA: 
2 μl of LipofectamineTM2000) was added to 200 – 500 µl of Opti-MEM (solution B). 
Solutions were incubated for 5 minutes at RT. Solution B was mixed into solution A and 
incubated for 20 minutes. The medium of the cells was replaced by medium without 
antibiotics and immediately after the mixture of solution A and B was added drop wise 
to the well or dish. After 6 hours, the transfection medium was replaced for a fresh 
complete medium. After 24 or 48 hours of transfection, cells were either lysed for cell 
lysate preparation or fixed for immunostaining. 
2.3.1.5 DNA transfection using PEI 
Cos7 cells were transfected on a 10 cm dish with different DNA plasmids using 
polyethylenimine (PEI). The desired amount of DNA plasmid was diluted in 1 ml of 
Opti-MEM together with PEI in a ratio of 1 μg of DNA: 4 μl of PEI. The mixture was 
incubated for 20 minutes and added drop wise to the dish. After 24 hours, cells were 
lysed for cell lysate preparation.  




2.3.2 Treatment of cells with inhibitors 
MLN4924 treatment: Cells were treated for 2 hours with 1 μM or 2 μM of MLN4924 
(dissolved in DMSO) diluted in complete medium. As control, cells were treated in 
parallel with same volume of DMSO.  
H1152 treatment: Cells were treated for 4 hours with 5 μM H1152 (dissolved in 
ddH2O) diluted in complete medium.  
Cycloheximide treatment: Cells were treated for 6 hours with 50 μg/ml cycloheximide 
(dissolved in DMSO) diluted in complete medium. 
MG132 treatment: Cells were treated for 4 hours with 10 μM MG132 inhbitor 
(dissolved in DMSO) diluted in complete medium.  
2.3.3 Morphology assay 
2.3.3.1 3D-Morphology-Based assay 
The protocol was based on an assay established in the laboratory (Colomba and 
Ridley, 2014; Reymond et al., 2012). A 96-well plate was coated with 40 µl of a 7.5 
mg/ml Matrigel solution. The plate was incubated at 37°C for 1 hour. Cancer cells 
transfected with siRNA oligonucleotides 48 hours before the assay were detached 
using trypsin, counted and re-suspended in the appropriated medium without FCS in a 
final concentration of 5 x 106 cells/ml. For each well, 100 µl of cancer cells and 100 µl 
of a 7 mg/ml Matrigel solution were mixed by pipetting up and down. The 200 µl of cells 
mixed with the Matrigel was transferred into one of the wells in the Matrigel-coated 
plate. The plate was incubated at 37°C. After 2 hours, 100 µl of appropriated medium 
without FCS was added to each well. The plate was kept in the incubator at 37°C for 24 
hours. Images were acquired using a Nikon TE2000-E microscope with a Plan Fluor 
10x objective (Nikon) and a Hamamatsu Orca-ER digital camera. 




2.3.4 Motility and Transmigration assays 
2.3.4.1 Adhesion assay 
The protocol was based on an assay established in the laboratory (Borda D'Agua, 
2012; Reymond et al., 2012). 96-well plates were coated with collagen I (50 µg/ml for 1 
hour at 37ºC) and HUVECs were seeded to form a monolayer one day before the 
experiment. Cancer cells labelled with CFSE (10 µM)/PBS+/+ solution were detached 
using non-enzymatic dissociation solution and seeded so that each condition could be 
tested in triplicate. Some extra wells were left without cancer cells to allow HUVEC 
auto-fluorescence to be determined. Cancer cells were incubated with endothelial cells 
for 5, 10, 15 and 30 minutes or only for 15 minutes. Adhesion was stopped by 
aspirating the medium carefully and the remaining cells were washed with PBS+/+. 
Wells containing only cancer cells, kept to determine the total number of cancer cells 
added per condition, were not aspirated. Fluorescence levels of the attached cells were 
measured, as well as the wells containing just cancer cells or just HUVECs, using a 
plate reader (Fusion αFP plate reader). The background fluorescence of HUVECs 
alone was subtracted from each value and then each value was normalized by the total 
number of cells that was added per condition (cancer cells alone).  
2.3.4.2 Intercalation assay – fixed cell imaging 
The protocol was based on an assay established in the laboratory (Borda D'Agua, 
2012; Reymond et al., 2012). HUVECs were seeded on coverslips coated with collagen 
type I (50 µg/ml for 1 hour at 37ºC), one or two days before the experiment, to form a 
monolayer. Cancer cells were staining using a CFSE (10 µM)/PBS+/+ solution, 
detached using non-enzymatic dissociation solution, counted and re-suspended in 
0.1% FCS-containing DMEM or RPMI medium at 2.5x104/100 µl. Cells were kept in 
suspension for about 30 minutes before starting the intercalation assay, to allow them 
to recover from the CFSE staining. Cancer cells were allowed to interact with the 




HUVECs for 60 minutes. Cells were aspirated carefully and washed with PBS+/+. Cells 
were fixed for 15 minutes at RT with 4% paraformaldehyde (PFA) and immunostained 
(section 2.3.5). Images were acquired using Zeiss LSM510 confocal laser-scanning 
microscope.  
2.3.4.3 Intercalation assay – live cell imaging 
The protocol was based on an assay established in the laboratory (Borda D'Agua, 
2012; Reymond et al., 2012). HUVECs were seeded on a 24-well plate coated with 
collagen type I (50 µg/ml for 1 hour at 37ºC), one or two days before the experiment, to 
form a monolayer. The 24-well plate was inserted into a humidified chamber (37ºC and 
5% CO2) on the timelapse microscope at least 30 minutes before the beginning of the 
assay. Several fields of acquisition were chosen based on the confluence and 
appearance of the endothelial cells before adding the cancer cells, and saved for 
subsequent recording during cancer cell interaction. Cancer cells, labelled or not with 
CFSE, were detached using a non-enzymatic dissociation solution, counted and added 
against the multi-well walls without disturbing or shaking the plate to avoid changes to 
the pre-established positions and focus. Timelapse movies were acquired over a period 
of up to 6-7 hours using a Nikon TE2000-E microscope with a Plan Fluor 10x objective 
(Nikon), a Hamamatsu Orca-ER digital camera and Volocity software. Cancer cells in 
the movies were subsequently tracked on top of the endothelial cells using ImageJ 
software. A cancer cell was considered intercalated when it changed from phase bright 
to phase dark, and the cell shape was no longer rounded but spread between 
endothelial cells.  
2.3.4.4 Transwell-based 3D invasion assay 
A 3D model for cancer cell invasion analysis was adapted by Barbara Borda D’Agua 
from the protocol established in the laboratory for leukocyte 3D transendothelial 
migration (TEM) analysis (Cain et al., 2010). Collagen type I gels were prepared mixing 




9 parts of PureCol® with 1 part of cold Buffer 1. The final concentration of collagen I in 
the gel was 2 mg/ml. To obtain the desired concentration, collagen I at a concentration 
of 2.7 mg/ml was diluted with cold EGM-2 medium. Around 250 µl of the liquid matrix 
was added to a transwell where a hydrophobic barrier was manually drawn inside the 
upper insert (ThinCertTM) using a pen (Dako Pen, S2002): the ink provides a barrier to 
liquids, avoiding meniscus formation. The matrix was incubated at 37ºC in the absence 
of CO2 for at least 4 hours. The gel became opaque when totally polymerized. After 
polymerization, gels were hydrated with warm cell medium for at least 6 hours before 
performing the invasion assays. Cancer cells were stained using a (CFSE, 10 
µM)/PBS+/+ solution, detached using a non-enzymatic dissociation solution, counted 
and re-suspended in 0.1% FCS-containing DMEM or RPMI medium at 2.5x104/100 µl. 
Before seeding the cells, 400 µl of fresh medium was added on top of the gel. DMEM 
or RPMI containing 10% FCS was added to the bottom, in order to create a gradient of 
FCS to act as a chemoattractant for cancer cells. Cancer cells were added on top of 
the gel and allowed to invade for 24 hours. To measure invasion, cells were fixed with 
4% PFA, permeabilised with 0.1% Triton X-100 in PBS+/+ and stained with DAPI 
(nucleus). The samples were imaged using Zeiss LSM510 confocal laser-scanning 
microscope. 
2.3.4.5 Transwell-based 3D TEM assay 
The assay was performed as described in section 2.3.4.4, except that before adding 
the CFSE-labelled cancer cells, a HUVEC monolayer was established on top of the 
collagen I gels. The whole experiment was performed using EBM-2 medium. To 
evaluate TEM of cancer cells, samples were fixed and stained following the protocol 
described in section 2.3.4, with the exception that the HUVECs were stained for 
PECAM-1. Samples were analysed with a Zeiss LSM510 confocal laser-scanning 
microscope. 





Cells were fixed in 4% PFA for 15 minutes at RT. Fixed cells were washed with PBS+/+ 
and then permeabilised in 0.1% Triton X-100/PBS+/+ for 5 minutes at 4ºC. After 
washing with PBS+/+, cells were blocked in 3% BSA/PBS+/+ for 30 minutes at RT. 
Primary antibodies were diluted in 3% BSA/PBS+/+ and incubated for 2 hours at RT. 
Fluorophore-conjugated secondary antibodies, phalloidin (to label F-actin) and DAPI 
(nuclei) were prepared in the same way as primary antibodies and incubated for 45-60 
minutes at RT. Coverslips were then washed and mounted onto glass slides using 
fluorescent mounting medium. 
2.3.6 Confocal microscopy 
A Zeiss LSM510 confocal laser-scanning microscope and the ZEN software were used 
to take images of fluorescently stained cells. Images were taken with 512x512 pixels 
resolution and objectives EC Plan-Neofluar 20x/0.50 M27 and Plan-Aprochromat 
63x/1.40 Oil DIC M27 were used depending on the type of experiment. Laser and 
appropriate filters were used as shown in Table 2-12. All images were acquired using 
the range indicator in ZEN software to avoid saturation and high background when 
adjusting gain and amplification. 
 
Table 2-12 Lasers and filters used for confocal microscopy 
Fluorophore Laser Excitation (nm) Emission (nm) 
GFP/Alexa 488 Argon 488/494 520/517 
Alexa 546 Helium/Neon 556 573 
Alexa 633 Helium/Neon 632 647 
DAPI Diode 405/30 405 430 
 




2.4 Methods: cell biochemistry 
2.4.1 Preparation of cell lysates 
Cells were washed with cold PBS-/- and lysed on ice with a cell scraper after adding 
lysis buffer. Lysates were collected and transferred to a fresh 1.5 ml microtube. 
Samples were centrifuged at 8,000 g at 4ºC for 10 minutes. NuPAGE® LDS Sample 
Buffer (4x) containing 5% β-mercaptoethanol was added to each sample and samples 
were boiled for 5 minutes. Samples were used immediately or stored at -20ºC.   
2.4.2 SDS-PAGE and western blot 
Samples were resolved in 4-12% SDS-polyacrylamide gels and electrophoretically 
transferred to nitrocellulose membranes of 0.45 µm pore. Membranes were blocked for 
1 hour at RT in 5% (w/v) dried skimmed milk powder in TBS-T. Membranes were 
incubated overnight at 4ºC with primary antibodies. Membranes were washed 3 times 
for 10 minutes with TBS-T before incubation with the secondary horseradish 
peroxidise-conjugated anti-mouse or anti-rabbit antibodies for 1 hour at RT. 
Membranes were washed again for three times, 10 minutes each; and developed using 
enhanced chemiluminescence (ECL) western blotting detection reagent. Protein levels 
on the immuno-blots were analysed by densitometry using ImageJ.  
 
2.4.3 Stripping of western blot 
Nitrocellulose membranes were washed three times for 10 minutes with stripping buffer 
at RT. To remove any residual stripping buffer, membranes were washed with TBS-T 
for 10 minutes at RT. Blots were re-blocked with 5% dried skimmed milk powder in 
TBS-T for 1 hour at RT and then the protocol was carried out as described in section 
2.4.2.  




2.4.4 Preparation of GST-fusion proteins 
Competent DH5α cells were transformed with pGEX-2T-RhoBTB1 1-301 and plated 
onto LB agar plates containing 100 μg/ml ampicillin. One colony was transferred to 50 
ml LB containing 100 μg/ml ampicillin and grown overnight at 37ºC. The overnight 
culture was diluted 1/10 into 500 ml of fresh LB containing 100 μg/ml ampicillin and 
grown for 3 hours at 37ºC. To induce protein expression, 0.3 mM of isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added and the culture incubated at 37ºC for 3 hours. 
Cells were pelleted in 50 ml tubes by centrifugation at 1,500 g for 20 minutes at 4ºC 
and cells were immediately lysed or stored at -40ºC for future use. Cells were lysed to 
extract GST-fused proteins with GST beads lysis buffer. After all the pellets were 
resuspended, the lysate was sonicated (SONICS Vibracell VCX130 Ultrasonic Cell 
Disrupter) on ice for 10 minutes (70% intensity with 10s pulses). Subsequently 1% 
Triton X-100 was added and the lysate was incubated for 30 minutes at 4ºC with gentle 
mixing. The lysate was then centrifuged at 3,500 g for 30 minutes at 4ºC. The 
supernatant was incubated with glutathione sepharose beads (previously washed with 
GST beads washing buffer) for 1 hour at 4ºC under rotation.  The supernatant was 
removed and the beads washed three times with GST beads washing buffer. The 
beads were resuspended in GST beads washing buffer and kept at 4ºC for up to two 
weeks. GST-fusion proteins were used for pull down assays.  
2.4.5 Pull down 
For the pull down using GST-RhoBTB1 1-301, Cos7 cells in 10 cm dishes were 
transfected with full length myc-ROCK1 and myc-ROCK1 deletion mutants (section 
2.3.1.5). After 24 hours, cells were washed with PBS-/- and 1x Mg2+ lysis buffer was 
added to the dishes. Cells were lysed on ice with a cell scraper. The lysate was 
transferred to a 1.5 ml microtube and centrifuged at 17,000 g for 10 minutes at 4ºC. A 
small aliquot of the total lysate was kept to check total protein levels by immunoblotting. 




The lysates were incubated with 40 μl of GST-RhoBTB1 1-301 for 2 hours at 4ºC under 
rotation. Beads were washed three times with 1x Mg2+ lysis buffer. Proteins were eluted 
by boiling the samples after addition of NuPAGE® LDS Sample Buffer (2x) containing 
β-mercaptoethanol. Pull down samples and loading control samples were analysed by 
western blotting (section 2.4.2).   
 
2.4.6 Immunoprecipitation and co-immunoprecipitation 
Cells in a 10 cm dish were transfected with one or more plasmids containing the 
gene(s) of interest. After 24 hours, cells were washed with PBS+/+ and 1 ml of IP lysis 
buffer was added to each dish. After 10 minutes of incubation, cells were scraped and 
lysates were collected into 1.5 ml microtubes. Samples were centrifuged at 8,000 g at 
4ºC for 10 minutes and the supernatant transferred to a new microtube. A small aliquot 
of the total lysate was kept to check total protein levels by immunoblotting. Cell lysates 
were incubated with 10 μl of anti-myc agarose beads, GFP-Trap®, anti-FLAG agarose 
beads or anti-HA agarose beads (pre-washed with IP lysis buffer) per sample for 2 
hours at 4ºC with rotation. Beads were washed three times with IP lysis buffer. After 
the last wash, immunocomplexes were dissociated from the beads by boiling with 
NuPAGE® LDS Sample Buffer (2x) containing β-mercaptoethanol. The samples 
analysed by western blot (section 2.4.2), or processed further as needed.  
 
2.4.7 Ubiquitination assay in vivo 
The assay was performed as described in Choo and Zhang (2009). Briefly, cells 
transfected with vectors encoding GFP, HA-ubiquitin, GFP-RhoA-N19, GFP-RhoBTB1, 
GFP-RhoBTB2 and myc-RhoBTB1 were treated with MG132 inhibitor for 4 hours 
(section 2.3.2). Cells were lysed with cell lysis buffer and then transferred to a 1.5 ml 
microtube. Samples were boiled for 10 minutes and sonicated (SONICS Vibracell 
VCX130 Ultrasonic Cell Disrupter) for 15 secs. Dilution buffer was added to each tube 




and samples were incubated at 4ºC for 30 minutes with rotation. Diluted samples were 
centrifuged at 17,000 g for 30 minutes and the supernatant was transferred to a new 
microtube. A small aliquot of the total lysate was kept to check total protein levels by 
immunoblotting. Cell lysates were incubated with 10 μl of anti-myc agarose beads or 
anti-HA agarose beads (pre-washed with dilution buffer) per sample at 4ºC overnight 
with rotation. Samples were centrifuged at 5,000 g for 5 minutes and supernatant was 
aspirated. Beads were washed twice with washing buffer. After the last wash, 
immunocomplexes were dissociated from the beads by boiling with NuPAGE® LDS 
Sample Buffer (2x) containing β-mercaptoethanol. The samples analysed by western 
blotting (section 2.4.2). 
2.4.8 In vitro kinase assay with radiolabeled ATP 
myc-RhoBTB1, myc-ROCK1 1-727, myc-ROCK1 1-727 (K105A), myc-ROCK1 1-540, 
GFP, GFP-RhoBTB1, GFP-RhoBTB1 S3T2 were expressed in Cos7 cells (section 
2.3.1.5) and purified by immunoprecipitation using anti-myc-agarose beads or GFP-
binding protein coupled to agarose (GFP-trap®) (section 2.4.6). Beads were combined 
depending on the conditions of the experiment (e.g. myc-RhoBTB1 beads were 
combined with myc-ROCK1 1-727 beads). Samples were washed five times with IP 
lysis buffer and twice in kinase buffer 1x. Beads were then pelleted by centrifugation 
and resuspended in 29 μl of kinase mix (kinase buffer 2x, 30 μM ATP, 0.1 μCi/μl [32P] 
γATP). 1 μl of recombinant GST-ROCK1 17-535 was added in some of the conditions. 
Samples were incubated at 30ºC for 30 minutes with gently vortexing every 15 
minutes. 30 μl of NuPAGE® LDS Sample Buffer (2x) containing β-mercaptoethanol was 
added and samples were boiled for 5 minutes. Samples were resolved in 4-12% SDS-
polyacrylamide gels and fixed in kinase assay fixing solution for 30 minutes. Gels were 
dried for 2 hours at 70ºC and analysed by autoradiography.  





Samples were resolved in 4-12% SDS-polyacrylamide gels and electrophoretically 
transferred to Immobilon-FL PVDF membranes (low fluorescence). After 
electroblotting, membranes were allowed to dry completed before proceeding with the 
Pro-Q® Diamond Phosphoprotein Blot Stain Kit. Following the manufacturer’s 
instructions, membranes were pre-wet in methanol and proteins on membranes were 
fixed by incubation with Fix Solution for 10 minutes. Membranes were washed 4 times 
for 5 minutes with distilled water. Phosphoproteins were stained by incubating the 
membranes with Pro-Q® Diamond reagent diluted 1/1000 in Pro-Q® Diamond blot stain 
buffer for 15 minutes. Membranes were washed 3 times for 5 minutes in Destain 
solution. After the final wash, membranes were allowed to dry completely before 
visualising the phosphoproteins in the blot with a UV-transilluminator. 
2.4.10 DSS crosslinking 
Cos7 cells were transfected with empty vector or vector encoding myc-RhoBTB1 
(section 2.3.1.5). After 24 hours, cells were washed with PBS-/- and lysed with 
conjugation buffer. Samples were centrifuged at 8,000 g at 4ºC for 10 minutes. 
Clarified lysates were transferred to fresh tubes and disuccinimidyl suberate (DSS) 
crosslinker was added to final concentrations of 0.05 mM, 0.1 mM and 0.25 mM. 
Samples were incubated for 30 minutes with rotation at RT. Reactions were stopped by 
adding 20 mM Tris-HCl (pH 7.5) and incubation for 15 minutes at room temperature. 
NuPAGE® LDS Sample Buffer (4x) containing 5% β-mercaptoethanol was added to 
each sample and cross-linked products were detected by western blotting (section 
2.4.2). 




3 RhoBTB1 and cancer cell interaction with endothelial cells 
 
3.1 Introduction 
According to the World Health Organization (WHO), metastasis is the most common 
cause of death for cancer patients. It is a multi-step process in which cancer cells need 
to detach from the primary tumour, interact and invade into the surrounding tissue to 
reach the vessels, intravasate, survive the shear stress, extravasate and grow in a new 
site of the body (Sahai, 2007; Steeg, 2006). Most of the cells that disseminate from the 
primary tumour are resistant to existing therapeutic agents, making metastatic disease 
incurable in most cases. Successful cancer treatment is highly dependent on the 
capacity of new treatments to affect metastatic cells (Valastyan and Weinberg, 2011). 
One of the key steps of metastasis is the exit of cancer cells from the blood vessels 
into new tissues. The cells can either disrupt the walls of the vessels after a micro-
colony of cancer cells is formed on top of the endothelium; or the cancer cells can 
cross the endothelium individually and reach the stromal microenvironment. The latter 
step is known as extravasation (Sahai, 2007; Valastyan and Weinberg, 2011). 
Extravasation is a well-studied process in leukocytes, due to its importance in the 
inflammatory response, but less is known in cancer cells. In vitro, cancer cells have 
been observed to adhere to endothelial cells, intercalate between endothelial cells and 
transmigrate (Figure 3.1). The firm adhesion between the cancer cells and the 
endothelium followed by the diapedesis through the endothelial monolayer is part of a 
complex process called transendothelial migration (TEM) (Miles et al., 2008). 





Figure 3.1 - Cancer cell extravasation 
In vitro, cancer cells under fluid flow are able to adhere, intercalate between endothelial 
cells and transmigrate. 
 
Relatively little is known regarding signalling pathways involved in TEM. One group of 
proteins that has been linked to this process is the Rho GTPase family. Because TEM 
involves dynamic shape changes (Reymond et al., 2012), it is not surprising that Rho 
GTPases play an important role in this step. Some classic Rho GTPases have been 
described to regulate TEM in vitro. For example, RNAi-mediated depletion of RhoA in T 
cells decreases TEM (Heasman et al., 2010). However, the opposite effect is observed 
in PC3 prostate cancer cells, in which cells expressing shRNA targeting RhoA have 
increased invasion and TEM (Sequeira et al., 2008). Rac1 in endothelial cells has been 
shown to be important in regulating endothelial permeability and leukocyte TEM (Cain 
et al., 2010).  
Breast cancer is the most commonly diagnosed cancer in women worldwide (World 
Health Organization - WHO). Metastatic breast cancer is incurable in most cases and 
conventional therapy has only a palliative effect on metastases (Mego et al., 2010). 
Breast cancer is a heterogeneous disease. Based on gene expression profile and 
immuno-histochemical expression of oestrogen receptor (ER), progesterone receptor 
(PR) and human epidermal growth factor receptor (HER2), breast cancer is classified 
into at least five subtypes: luminal A, luminal B, HER2+, basal and claudin-low. As 




shown in Table 3-1, each subtype responds differently to treatment and has a different 
prognosis (Eckhardt et al., 2012; Holliday and Speirs, 2011).  
Table 3-1 Molecular classification of breast cancers 
Subtype Marker expression Characteristics 
Luminal A ER+/PR+/HER2- Endocrine responsive*, 
often chemotherapy 
responsive 
Luminal B ER+/PR+/-/HER2+/- Usually endocrine 
responsive, variable to 
chemotherapy, HER2+ is 
trastuzumab** responsive 
Basal ER-/PR-/HER2- Endocrine nonresponsive, 
often chemotherapy 
responsive 
Claudin-low ER-/PR-/HER2- Intermediate response to 
chemotherapy 
HER2+ ER-/PR-/HER2+ Trastuzumab responsive, 
chemotherapy responsive 
ER: oestrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2. * 
Hormone therapy, e.g. tamoxifen; ** Trastuzumab: monoclonal antibody that interferes with HER2 
receptor. 
 
Recently, the atypical Rho GTPase RhoBTB1 was one of several hits in a siRNa 
screen performed to determine the effect of Rho GTPases on the adhesion of cancer 
cells to endothelial cells. Using a pool of siRNAs, RhoBTB1 depletion led to decrease 
of more than 25% in adhesion of PC3 prostate cancer cells to endothelial cells 
(Reymond et al., 2012). Depletion of RhoBTB1 using two different siRNAs led to a 
decrease in TEM of MDA-MB-231 breast cancer and PC3 prostate cancer cells (Borda 
D'Agua, 2012). In addition, a decrease in expression of β1 integrin and reduced 
expression and acitivity of RhoA was observed following RhoBTB1 depletion in MDA-
MB-231 cells (Borda D'Agua, 2012). However, most of these results were only 
observed in a single cell line, and thus it is important to determine whether they are 
reproducibly observed in other cell lines. RhoBTB1 could have an important role in 
breast cancer progression, since RhoBTB2, also a member of the RhoBTB subfamily, 
was first described as a gene deleted in breast cancer (Hamaguchi et al., 2002). 




To explore more the role of RhoBTB1 in breast cancer cell TEM, other breast cancer 
cell lines were selected to be used in 2D and 3D models to study cell adhesion, 
intercalation and transmigration into a monolayer of endothelial cells. Because of the 
number of breast cancer subtypes, cell lines were selected based on their profile of 
marker expression, in order to compare the effects of RhoBTB1 depletion on breast 
cancer cell lines derived from different subtypes (Figure 3.2). Each cell line was first 
tested for their behaviour in several assays, and subsequently one cell line that 
behaved similarly to MDA-MB-231 cells was selected to analyse the effects of 




Figure 3.2 – Morphology of breast cancer cell lines 
MDA-MB-231 cell line is a claudin-low subtype, MCF-7 cell line is luminal A subtype, 
Cal51 cell line is basal-like subtype and HCC1954 cell line is HER2 positive 
(Koochekpour et al., 2014; Neve et al., 2006; Sharpe et al., 2011). 




3.2 Interaction of MCF-7, Cal51 and HCC1954 breast cancer cells with a 
matrix of collagen I 
One important step during metastasis is the ability of the cancer cells to interact with 
the surrounding environment (Reymond et al., 2013). Collagen I is one of the major 
components of the stromal environment that surrounds both primary and secondary 
tumours (Hooper et al., 2006; Sabeh et al., 2009). To evaluate if MCF-7, Cal51 and 
HCC1954 cells could invade into a 3D collagen I matrix, cells stained with the 
fluorescent dye carboxyfluorescein succinimidyl ester (CFSE) were added on top of 




Figure 3.3 - Diagram of transwell 3D invasion assay 
CFSE-stained cells are added to a 2.0 mg/ml collagen I matrix in a transwell. FCS is 
used as a chemoattractant (0.1% FCS in the top chamber and 10% FCS in the bottom 
chamber). Cells are left to invade for 24 hours. The collagen I matrix is removed from 
the transwell, stained for DAPI (nuclei) and analysed in a confocal microscope (section 
2.3.4.4).  
 
MDA-MB-231 cells were used as a control, because it is known that these cells can 
invade collagen I (Mierke et al., 2011). Cells from all four different cell lines could 
adhere to collagen I. However, only HCC1954 and MDA-MB-231 cells invaded into the 
collagen I within 24 hours (Figure 3.4).  
 






Figure 3.4 - Invasion of breast cancer cell lines into collagen I  
CFSE-labelled cancer cells were seeded on top of 2.0 mg/ml of collagen I in transwells. 
Gels were fixed after 24 hours and stained with DAPI to label the nuclei. XYZ 
projections of the cancer cells on the 3D matrices were obtained from confocal 
microscopy z-stacks using Volocity software. Images are representative of two 
independent experiments. Scale bar = 1 unit = 45.7µm. 
  




3.3 Optimization of adhesion, intercalation and transendothelial 
migration with MCF-7, Cal51 and HCC1954 cell lines 
 
3.3.1 MCF-7, Cal51 and HCC1954 breast cancer cells intercalate 
between confluent human umbilical endothelial cells 
The ability of MCF-7, Cal51 and HCC1954 cells to adhere and intercalate between 
endothelial cells (HUVECs) was then investigated using an intercalation assay with live 
cell imaging (Reymond et al., 2012). Timelapse acquisition for 6 hours showed that 
MCF-7, Cal51 and HCC1954 cells adhered to the HUVECs. A cancer cell is considered 
adhered when the cell body is really rounded and phase-bright and stays at one 
specific position on the endothelial cells (Figure 3.5), contrasting with the phase-dark 
and flat monolayer of HUVECs. When the cancer cells intercalate, they become phase-




Figure 3.5 - Intercalation assay - live cell imaging 
Cancer cells were added on top of an endothelial monolayer (time point = 0 minutes). 
Orange arrow: monolayer of HUVECs; grey arrow: cancer cells. Scale bar = 100 μm. 
 
 
MDA-MB-231 cells were used as a control, since this cell line was previously used in 
our laboratory to identify a role of RhoBTB1 in intercalation (Chapter 3.1). After 1 hour, 
almost 50% of MDA-MB-231 cells had intercalated and by the end of 6 hours 
approximately 80% of cells had intercalated (Figure 3.6A and 3.6B, movies 3.1). The 
only cell line that had a similar pattern of intercalation to MDA-MB-231 cells was Cal51. 
Almost 80% of Cal51 cells intercalated after 6 hours (Figure 3.6C and 3.6D, movie 3.2). 






Figure 3.6 - Intercalation of MDA-MB-231 and Cal51 cells into HUVECs  
MDA-MB-231 and Cal51 cells were monitored by timelapse microscopy acquiring an 
image every 3 to 5 min over 6 hours. A) and C) Zoomed images of representative time 
points (0, 30 and 60 minutes). White stars indicate examples of cells that intercalate. 
White arrows indicate the cells at the time of intercalation. Intercalation rates were 
analysed using ImageJ software. B) and D) Quantification of intercalated cells at the 
indicated time points from two independent experiments. Nine different fields of each 
condition were analysed per experiment (~30 cells per field). Values represent mean ± 
SD. Scale bar = 50 μm. 
 
Analysis of HCC1954 cells indicated that almost 90% of cells had flattened and 
become phase-dark after 6 hours (Figure 3.7B). However, when the movies were 
analysed more closely, it was clear that not all of these cells intercalated. Instead, 
some cells were spread on top of the HUVECs (Figure 3.7A, movie 3.3). It was difficult 
to quantify the percentage of intercalated and spread cells separately. Once the cancer 
cells become part of the monolayer, it is difficult to differentiate all the cells from the 
endothelial cells. To try to overcome this problem, HCC1954 cells were stained with 
CFSE. However, when these cells spread and intercalate, they become very flat, so 
that is difficult to detect the CFSE fluorescence (Figure 3.8). Modifications in the 
protocol are necessary to study this cell line.  







Figure 3.7 - Spreading and intercalation of HCC1954 cells into HUVECs  
HCC1954 cells were monitored by timelapse microscopy acquiring an image every 3 
min over 6 hours. A) Zoomed images of representative time points (0, 30 and 60 
minutes). White stars indicate cells that intercalate or spread. White arrow indicates the 
moment of intercalation and orange arrows indicate the moment of spreading. 
Intercalation rates were analysed using ImageJ software. B) Quantification of 
intercalated and spread cells at the indicated time points from two experiments. Nine 
different fields were analysed in the experiment (~30 cells per field). Values represent 
mean ± SD. Scale bar = 50 μm. 
 
 
Figure 3.8 - Spreading and intercalation of HCC1954 cells stained with CFSE into 
HUVECs  
HCC1954 cells stained with CFSE were monitored by timelapse microscopy acquiring 
an image every 3 min over 6 hours. Images are representative of the time points in the 
beginning and middle of the experiment. Orange arrow indicates a cell for which CFSE 
staining is no longer detectable after spreading/intercalating.   




MCF-7 cells have a luminal A subtype phenotype (Neve et al., 2006) and grow in 
groups (Figure 3.2). When added to the endothelial monolayer, the groups pushed 
away the endothelial cells, making large gaps in the monolayer (Figure 3.9). 
Nevertheless, when an MCF-7 cell was not in a group, it intercalated in the same way 
as MDA-MB-231 and Cal51 cells (Figure 3.6 - white arrow). It was difficult to quantify 
the intercalation of MCF-7 cells because there were so many groups of cells, therefore 
the images were not analysed.  
 
Figure 3.9 - Intercalation of MCF-7 cells into HUVECs  
MCF-7 cells were monitored by timelapse microscopy acquiring an image every 3 min 
over 6 hours. Images are representative of the time points in the beginning, middle and 
end of the experiment. One white star indicates a single cell that will intercalate. White 
arrow indicates the timepoint of intercalation. Two white stars indicate a group of cells 
that will spread and form a hole in the endothelial monolayer. Nine different fields were 
analysed in the experiment. Scale bar = 100 μm. 
 
3.3.2 Breast cancer cell morphology on endothelial cells 
To investigate in more detail how each breast cancer cell line interacts with endothelial 
cells, CFSE-stained cancer cells were added to HUVECs and then fixed after 1 hour, 
stained for PECAM-1 (endothelial cell junctions) (Muller et al., 2002) and F-actin and 
analysed by confocal microscopy. Orthogonal projections show the side view of 
migrating cells, allowing cancer cells below the endothelial monolayer to be observed.  
Unexpectedly, Cal51 cells were observed to cross the endothelial cells either through 
paracellular migration or transcellular migration (Figures 3.10 and 3.11). There are two 
routes that cells can transmigrate across endothelial cells: between the endothelial 
cells, which is known as paracellular migration and involves disruption of endothelial 




cell-cell junctions; or through the endothelial cells, called transcellular migration (Figure 
3.12). Leukocytes can transmigrate either by paracellular or transcellular migration 





Figure 3.10 - Interaction of Cal51 cells with HUVECs - transcellular migration  
HUVECs were grown to confluency on collagen I-coated glass coverslips. CFSE-
labelled Cal51 cells were added to the monolayer for 1 hour. Non-adherent cells were 
washed off and the cells that remained adhered were fixed and permeabilized. Cells 
were stained for F-actin, PECAM-1 and nuclei (DAPI). Images were acquired by 
confocal microscopy using Zen software (Zeiss) with a 63x oil immersion objective and 
are representative of random fields from three independent experiments. A) xy view of 
the 3D projection of a z-stack of 20 images. Scale bar = 20 µm. B) xy and orthogonal 
projections of the same fields shown in (A). The beige and white lines across x-y are 
the regions in the image that are represented in the z-projection. Scale bar = 20 µm.   
 






Figure 3.11 - Interaction of Cal51 cells with HUVECs - paracellular migration  
HUVECs were grown to confluency on collagen I-coated glass coverslips. CFSE-
labelled Cal51 cells were added to the monolayer for 1 hour. Non-adherent cells were 
washed off and the cells that remained adhered were fixed and permeabilized. Cells 
were stained for F-actin, PECAM-1 and nuclei (DAPI). Images were acquired by 
confocal microscopy using Zen software (Zeiss) with a 63x oil immersion objective and 
are representative of random fields from three independent experiments. A) xy view of 
the 3D projection of a z-stack of 30 images. Scale bar = 20 µm; B) xy and orthogonal 
projections of the same field shown in (A). The beige and white lines across x-y are the 












Figure 3.12 - Routes of transendothelial migration 
Cells can transmigrate across endothelial cells using two routes: paracellular migration 
and trancellular migration. Paracellular migration involves disruption of endothelial cell-
cell junctions and cells migrate between endothelial cells. In transcellular migration, 
cells cross the endothelium through the endothelial cells.  
 
 
Quantification of Cal51 cells that underwent paracellular or transcellular migration 
through the endothelial monolayer at 1 hour (~ 40% cells intercalated – Figure 3.6D) 
showed that most cells used the paracellular route to migrate (~75%) (Figure 3.13). 
 
Figure 3.13 - Quantification of Cal51 cell paracellular migration versus 
transcellular migration 
Graph shows data from three independent experiments. At least 100 cells that were 
transmigrating at 1 hour after addition of HUVECs were counted in each experiment. 









Although in movies some HCC1954 cells spread on top of endothelial cells, it was 
possible to observe intercalating HCC1954 cells when they were fixed and analysed by 
confocal microscopy. After 1 hour, HCC1954 cells were either spread on top of 
endothelial cells or intercalated (Figure 3.14).  
 
 
Figure 3.14 - Interaction of HCC1954 cells with HUVECs 
HUVECs were grown to confluency on collagen I-coated glass coverslips. CFSE-
labelled HCC1954 cells were added to the monolayer for 1 hour. Non-adherent cells 
were washed off and the cells that remained adhered were fixed and permeabilized. 
Cells were stained for F-actin, PECAM-1 and nuclei (DAPI). Images were acquired by 
confocal microscopy using Zen software (Zeiss) with a 63x oil immersion objective and 
are representative of random fields from three independent experiments. A) xy view of 
the 3D projection of a z-stack of 11 images. Green arrows indicate cells that 
intercalated and orange arrow indicates a cancer cell on top of an endothelial cell. 
Scale bar = 20 µm; B) xy and orthogonal projections of the same field shown in (A). 
The beige and white lines across x-y are the regions in the image that are represented 
in the z-projections. Scale bar = 20 µm.  




MCF-7 cells, as observed in the movies (Figure 3.9, movie 3.3), formed holes in the 




Figure 3.15 - Interaction of MCF-7 cells with HUVECs  
HUVECs were grown to confluency on collagen I-coated glass coverslips. CFSE-
labelled MCF-7 cells were added to the monolayer for 1 hour. Non-adherent cells were 
washed off and the cells that remained adhered were fixed and permeabilized. Cells 
were stained for F-actin, PECAM-1 and nuclei (DAPI). Images were acquired by 
confocal microscopy using Zen software (Zeiss) with a 63x oil immersion objective and 
are representative of random fields from three independent experiments. White arrows 
indicate the holes formed by the cancer cells. Scale bar = 20 µm. 
 
 
To obtain as many single cells as possible, MCF-7 cells were treated with EGTA before 
being added to the monolayer of HUVECs. EGTA was added to the cell media in a final 
concentration of 5 nM and left to act for 1 hour. Cells were resuspended in fresh media 
and added to the monolayer of endothelial cells. EGTA chelates calcium, which is 
important for cell-cell junction formation (Gonzalez-Mariscal et al., 1990). Treatment 
with EGTA breaks the cell-cell junctions, making it easier to separate the cells. When 
single MCF-7 cells interacted with the endothelial monolayer, they could intercalate 
(Figure 3.16). 
 





Figure 3.16 - Interaction of EGTA-treated MCF-7 cells with HUVECs 
HUVECs were grown to confluency on collagen I-coated glass coverslips. Before 
CFSE-labelled MCF-7 cells were added to the monolayer for 1 hour, 5 nM of EGTA 
was added to the cells. Non-adherent cells were washed off and the cells that 
remained adhered were fixed and permeabilized. Cells were stained for F-actin, 
PECAM-1 and nuclei (DAPI). Images were acquired by confocal microscopy using Zen 
software (Zeiss) with a 63x oil immersion objective and are representative of random 
fields from two independent experiments. Scale bars = 20 µm. 
 
3.3.3 Adhesion timecourse of HCC1954 and Cal51 cells to 
endothelial cells 
All 3 types of breast cancer cells were able to adhere to endothelial cells as observed 
in the movies. Adhesion of cells to endothelial cells is one of the earlier steps of TEM 
(Reymond et al., 2013). This step involves proteins that are expressed on the cell 
surface and are not necessarily the same ones involved in other steps of this process. 
To determine the best time point to evaluate adhesion of cancer cell lines to HUVECs, 
a timecourse experiment was performed. The adhesion assay is based on the 
comparison of the fluorescence of total CFSE-labelled cells versus fluorescence of 
remaining cells after washing (Figure 3.17).  
 





Figure 3.17 - Diagram of adhesion assay 
CFSE-stained cancer cells are added to a monolayer of HUVECs and washed off after 
15 minutes. Wells with only a monolayer of HUVECs were used to subtract the 
background fluorescence. Percentage of adhesion was calculated subtracting the 
fluorescence of HUVEC background from the fluorescence of cancer cells after 
washing. Then, this value was divided by the fluorescence of total cancer cells and 
multiplied by 100 (section 2.3.4.1).   
 
Because MCF-7 cells grow in groups and it is difficult to prepare the solutions with the 
desired number of cells, the fluorescence signal was too strong, and it was difficult to 
obtain reliable results. MCF-7 cells were therefore not used in this assay (Figure 3.18). 
 
 
Figure 3.18 - Adhesion timecourse of HCC1954 and Cal51 cells to HUVECs 
HUVECs were grown to confluence on collagen I-coated plates. CFSE-labelled cancer 
cells were added to the HUVECs and allowed to adhere for 5, 10, 15 and 30 minutes. 
Non-adherent or loosely adherent cells were washed off and the levels of fluorescence 
were measured on a plate reader. Graphs show data from three independent 
experiments, each carried out in triplicate. Values represent mean ± SEM. 100% 
corresponds to the signal of total number of cells in the wells that were not washed.  




Although Cal51 and HCC1954 cells showed a tendency to increase adhesion over 
time, only at 30 minutes did Cal51 cells have a significant increase in adhesion 
compared to 5 minutes. The results were quite variable, as indicated by the large error 
bars. A possible reason for this variability between experiments is that the CFSE 
staining varies between each experiment. However, the results were used to choose 
the best time point to perform adhesion assays. The 15 minute time point was chosen 
because more than 50% of the cells have adhered but only around 10% have 
intercalated (Figure 3.6D).  
 
3.3.4 Breast cancer cell interaction with endothelial cells on a thick 
layer of collagen 
The behaviour of the MDA-MB-231, MCF-7, Cal51 and HCC1954 cells was 
investigated in a 3D TEM model (Cain et al., 2011) which includes all the steps of 
transendothelial migration (adhesion, intercalation and transmigration). Transmigration 
under the endothelium was observed for MDA-MB-231, Cal51 and HCC1954 cells 
(Figure 3.19, 3.20 and 3.21).  






Figure 3.19 - Interaction of MDA-MB-231 cells with endothelial cells on a thick 
collagen I layer 
CFSE-labelled cancer cells were added to a confluent monolayer of HUVECs seeded 
on top of a thick 2 mg/ml collagen I matrix. After 24 hours, cells were fixed and stained 
for PECAM-1 (red) and with DAPI (blue). Images of four different fields were acquired 
by confocal microscopy using Zen software. xyz projections of a z-stack of 40 images 
of the cancer cells on the 3D matrices were obtained using Volocity software. Images 
on the left represent the top and side views of xyz projections during intercalation. 
Images on the right represent the side and bottom views of xyz projections after 
transmigration. Scale bar = 1 unit = 45.7 µm. Images are from one experiment.   
 
 





Figure 3.20 - Interaction of Cal51 cells with endothelial cells on a thick collagen I 
layer 
CFSE-labelled cancer cells were added to a confluent monolayer of HUVECs seeded 
on top of a thick 2 mg/ml collagen I matrix. After 24 hours, cells were fixed and stained 
for PECAM-1 (red) and with DAPI (blue). Images of four different fields were acquired 
by confocal microscopy using Zen software. xyz projections of a z-stack of 40 images 
of the cancer cells on the 3D matrices were obtained using Volocity software. Images 
on the left represent the top and side views of xyz projections during intercalation. 
Images on the right represent the top and side views of xyz projections after 









Figure 3.21 - Interaction of HCC1954 cells with endothelial cells on a thick 
collagen I layer 
CFSE-labelled cancer cells were added to a confluent monolayer of HUVECs seeded 
on top of a thick 2 mg/ml collagen I matrix. After 24 hours, cells were fixed and stained 
for PECAM-1 (red) and with DAPI (blue). Images of four different fields were acquired 
by confocal microscopy using Zen software. xyz projections of a z-stack of 40 images 
of the cancer cells on the 3D matrices were obtained using Volocity software. Images 
represent the top and side views of xyz projections after transmigration. Scale bar = 1 






















Due to the formation of holes in the monolayer of endothelial cells by the MCF-7 cells, 
it was difficult to assess if the cancer cells were transmigrating (Figure 3.22).  
 
 
Figure 3.22 - Interaction of MCF-7 cells with endothelial cells on a thick collagen I 
layer 
CFSE-labelled cancer cells were added to a confluent monolayer of HUVECs seeded 
on top of a thick 2 mg/ml collagen I matrix. After 24 hours, cells were fixed and stained 
for PECAM-1 (red) and with DAPI (blue). Images of four different fields were acquired 
by confocal microscopy using Zen software. xyz projections of a z-stack of 40 images 
of the cancer cells on the 3D matrices were obtained using Volocity software. Images 
on the left represent the top and side views of xyz projections of a group of cells. 
Images on the right represent the top and side views of xyz projections of a single cell. 
Scale bar = 1 unit = 45.7 µm. Images are from one experiment. 
  




3.4 Effects of RhoBTB1 depletion in Cal51 cells on endothelial 
interaction 
To determine how RhoBTB1 depletion affected breast cancer cell interaction with 
endothelial cells, Cal51 cells were chosen. Both MDA-MB-231 and Cal51 cell lines are 
triple negative (ER-, PR-, HER2-, Table 3.1), but they do not belong to the same 
subtype (Figure 3.2). Although the morphology of MDA-MB-231 and Cal51 cells is not 
similar in 2D culture, these cells behaved in a similar way when added on top of 
endothelial cells. Almost 80% of MDA-MB-231 and Cal51 cells were intercalated after 6 
hours. These cells intercalate as single cells and they do not damage the endothelium 
during intercalation and TEM (Figure 3.6, 3.19 and 3.20).  
RhoBTB1 was depleted in Cal51 cells using four different siRNA oligos targeting 
RhoBTB1. RhoBTB1 mRNA levels in Cal51 cells were reduced by around 50% using 
oligos #1, #2 and #3 at 72 hours after siRNA transfection, similar to the results 
obtained in MDA-MB-231 cells (Figure 3.23). Since oligos #1 and #2 were used for 
functional assays with MDA-MB-231 cells (Borda D'Agua, 2012), these oligos were 
also used for Cal51 cells. Protein levels were not analysed because there is no 
antibody available that can detect endogenous RhoBTB1 in these cell lines.  
            
Figure 3.23 - RhoBTB1 depletion in MDA-MB-231 and Cal51 cells 
MDA-MB-231 and Cal51 cells were transfected with siRNA control or siRNA oligos #1 
and #2 and oligos #1, #2, #3 and #4 targeting RhoBTB1, respectively. After 72 hours, 
the relative amount of RhoBTB1 mRNA was determined by quantitative PCR. Graphs 
show data from three independent experiments. All values were normalized to siRNA 
control. Values represent mean ± SEM.  




Adhesion and intercalation of Cal51 cells into a monolayer of HUVECs was analysed 
after depletion of RhoBTB1. Adhesion was affected only by depletion of RhoBTB1 
using oligo #2 (Figure 3.24A). Intercalation of Cal51 cells appeared to be slightly 
reduced at early time points, but there was no significant different between the 
conditions at any time point (Figure 3.24B). 
 
Figure 3.24 - Adhesion and intercalation of Cal51 cells into endothelial cells 
A) HUVECs were grown to confluence on collagen I-coated plates. CFSE-labelled 
Cal51 cells were added to the HUVECs and allowed to adhere for 15 minutes. Non-
adherent or loosely adherent cells were washed off and the levels of fluorescence were 
measured. Graphs show data from four independent experiments, each carried out in 
quintuplicate. Values represent mean ± SEM. B) Cal51 cells were monitored by 
timelapse microscopy acquiring an image every 3-5 min over 6 hours. The graph 
shows the percentage of intercalated cells at the indicated time points from three 
independent experiments. Nine different fields of each condition were analysed per 
experiment (~ 30 cells per field). Values represent mean ± SEM. 




3.4.1 RhoBTB1 effects on β1 integrin and RhoA levels 
One of the proteins affected by RhoBTB1 depletion in MDA-MB-231 cells was β1 
integrin. β1 integrin is known to be involved in adhesion of PC3 prostate cancer cells to 
endothelial cells (Reymond et al., 2012). Integrin receptors are heterodimers of α and β 
subunits that are well-known to bind to extracellular matrix ligands, connecting the 
extracellular matrix to the actin cytoskeleton (Campbell and Humphries, 2011). 
Integrins have also been shown to bind receptors on other cells. For example, VCAM-1 
in the endothelial cell can interact with α4β1 in cancer cells (Miles et al., 2008). 
Depletion of RhoBTB1 in MDA-MB-231 cells led to a decrease in β1 integrin levels, 
which in turn, could be the cause of the decrease in adhesion of cancer cells to 










Figure 3.25 - Effects of RhoBTB1 depletion in β1 integrin expression and cancer 
cell adhesion to endothelial cells in MDA-MB-231 cells 
A) MDA-MB-231 cells were siRNA transfected and 72 hours after cells were lysed and 
equal amounts of protein analysed by immunoblotting with antibody to β1 integrin 
subunit. Blot was re-probed for GAPDH. Blot is representative of three independent 
experiments. B) siRNA- transfected MDA-MB-231 cells were detached 72 hours after 
transfection and stained for β1 integrin subunit surface levels with a specific antibody. 
The background levels were detected by including a second population of control and 
depleted cells labelled with mouse Alexa-488. Levels were measured by flow cytometry 
from three independent experiments. β1 integrin subunit surface levels were quantified. 
Results are expressed relative to IgG secondary antibody. Values represent mean ± 
SEM. **p<0.01, *p<0.05, compared to siRNA control, determined by unpaired Student’s 
t-test. C) HUVECs were grown to confluence on collagen I-coated plates. CFSE-
labelled cancer cells were added to the HUVECs and allowed to adhere for 15 minutes. 
Non-adherent or loosely adherent cells were washed off and the levels of fluorescence 
were measured. Graphs show data from three independent experiments, each carried 
out in triplicate. Red bars represent the hits. Values represent mean ± SEM. 
***p<0.001, **p<0.01, *p<0.05, compared to siRNA control, determined by unpaired 








Endogenous levels of β1 integrin were compared in different breast cancer cell lines. 
MDA-MB-231 cells had the highest levels, followed by Cal51 cells. MCF-7, T47D and 
HCC1954 cells had similar levels of β1 integrin (Figure 3.26). MDA-MB-231 and 
HCC1954 cells had only one band while MCF-7, T47D and Cal51 cells have two 
bands. The two bands could be differentially glycosylated forms of β1 integrin, or and 
alternatively spliced isoforms (de Melker and Sonnenberg, 1999; Zhao et al., 2008). 
T47D cell line was included to analyse if cell lines from the same subtype (luminal A) 
have similar β1 integrin band pattern. In this case, both T47D and MCF-7 cells had two 
bands for β1 integrin (Figure 3.26).  
 
 
Figure 3.26 - Expression of β1 integrin in breast cancer cell lines 
Breast cancer cells were lysed and protein expression was analysed by western 
blotting. GAPDH is used as a loading control. Graph shows the quantification of the 











Levels of β1 integrin in Cal51 cells after RhoBTB1 depletion were analysed. A decrease 




Figure 3.27 - Expression of β1 integrin in Cal51 cells after RhoBTB1 depletion 
Cal51 cells were transfected with siRNA control or siRNA oligos #1 and #2 targeting 
RhoBTB1.  After 72 h, cells were lysed and protein expression was analysed by 
western blotting. GAPDH is used as a loading control. Graph shows the quantification 
of the bands density of three independent experiments, normalised to GAPDH and 




Another protein that was affected by RhoBTB1 depletion in MDA-MB-231 cells was 
RhoA. Depletion of RhoBTB1 led to a decrease in RhoA levels and depletion of RhoA 
decreased intercalation of cancer cells into endothelial cells (Figure 3.28 – Results 
from Borda D'Agua (2012)). The hypothesis is that RhoA is involved in cancer 
cell/endothelial cell interaction during intercalation. RhoA is known to be involved in 
actin cytoskeleton rearrangement, affecting cell motility (Wheeler and Ridley, 2004) 
(Chapter 1, section 1.1.2).  





Figure 3.28 - Effects of RhoBTB1 depletion in RhoA expression and activity; and 
cancer cell intercalation into endothelial cells in MDA-MB-231 cells 
A) MDA-MB-231 cells were siRNA transfected and after 72 hours cells were lysed and 
equal amounts of protein were analysed by immunoblotting with antibody to RhoA. Blot 
was re-probed for GAPDH. Blots are representative of three independent experiments. 
Graph show RhoA levels relative to GAPDH. Value represent mean ± SEM. *p<0.05, 
compared to siRNA control, determined by unpaired Student’s t-test. B) MDA-MB-231 
cells were siRNA transfected for RhoBTB1 and RhoA. 72 hours after transfection cells 
were lysed and incubated with GST-Rhotekin-RBD beads to pull down active RhoA. 
Immunoblots were probed for RhoA and total lysates membranes were rre-probed for 
GAPDH. Total lysate of siRNA control sample was used for pull down positive control, 
using pre-loading of GTPases in lysate with GTPγS. Blots are representative of three 
independent experiments. Graphs show total RhoA levels relative to GAPDH and 
active RhoA levels relative to total RhoA. Values represent mean ± SEM. ***p<0.001, 
**p<0.01, *p<0.05, compared to siRNA control, determined by unpaired Student’s t-
test. C) siRNA-transfected MDA-MB-231 cells were monitored acquiring an image 
every 3 minutes for 6 hours. Graphs show data from three independent experiments. 
Three different fields of each condition were analysed per experiment (100-150 cell per 
experiment; ~ 50 cells per field). Values represent mean ± SEM. ***p<0.001, **p<0.01, 
*p<0.05, compared to siRNA control, determined by unpaired Student’s t-test. Results 
from Borda D'Agua (2012).  




Levels of RhoA in Cal51 cells after RhoBTB1 depletion were analysed. There was no 






Figure 3.29 - Expression of RhoA in Cal51 cells after RhoBTB1 depletion 
Cal51 cells were transfected with siRNA control or siRNA oligos #1 and #2 targeting 
RhoBTB1.  After 72 h, cells were lysed and protein expression was analysed by 
western blotting. GAPDH is used as a loading control. Graph shows the quantification 
of the band density of three independent experiments, normalised to GAPDH and 
relative to siRNA control. Values represent mean ± SEM.  
  





To investigate whether RhoBTB1 affected cancer cell invasion or cancer cell interaction 
with endothelial cells, functional assays were performed using breast cancer cell lines. 
After optimization of three breast cancer cell lines using the 2D and 3D models in our 
laboratory to study adhesion, intercalation and transmigration, Cal51 cells were chosen 
to be used in the RhoBTB1 depletion experiments.  
3.5.1 Characterization of breast cancer cell lines with endothelial 
cells 
Depletion of RhoBTB1 in MDA-MB-231 cells decreases cell adhesion and intercalation 
into an endothelial monolayer (Figure 3.25 and 3.28 from Borda D'Agua (2012)). To 
determine whether RhoBTB1 could affect the interaction of other breast cancer cell 
lines with endothelial cells, three cell lines (MCF-7, Cal51 and HCC1954) were first 
tested regarding their ability to interact with collagen I matrix and endothelial 
monolayers. The results with MCF-7, Cal51 and HCC1954 cell lines showed promising 
and interesting results indicating that they could be used in studies of cancer cell 
interaction with endothelial cells. All three cell lines were able to interact with a collagen 
I matrix and endothelial cells. However, modifications in the protocol are necessary for 
some of the cell lines.  
The Cal51 cell line was the one that showed the most interesting and unexpected 
results. In the live cell imaging intercalation assay, this cell line showed a similar 
behaviour to MDA-MB-231 cells. Although the two cell lines are not from the same 
breast cancer cell subtype (Figure 3.2), they are both triple negative, were isolated 
from pleural effusions and are highly tumorigenic (Cailleau et al., 1974; Gioanni et al., 
1990; Neve et al., 2006). These common characteristics could be important during the 
cancer cell intercalation step. In addition, in the confocal images it was possible to 
observe that Cal51 cells could cross the endothelial monolayer using either a 




paracellular or transcellular migration route. The transcellular route is quite difficult to 
observe for cancer cells in vitro, but for this cell line almost 25% of the cells 
transmigrated through the transcellular route. Transcellular migration is still not well 
understood. In leukocytes, there seems to be more than one mechanism that these 
cells use to cross through the endothelial cell. One mechanism is using “invadosome-
like protrusions” that are fused with intracellular vesicular structures similar to caveolae 
and vesiculo-vacuolar organelles (VVOs) (Carman, 2009; Feng et al., 2002; Millán and 
Ridley, 2005). Another one is the transcellular migration mediated by the lateral border 
recycling compartment (LBRC) of the endothelial cells. A membrane containing 
PECAM, JAM-A and CD99 is recruited from the LBRC and surrounds the leukocyte 
that is transmigrating (Mamdouh et al., 2009). Although these mechanisms differ in 
some aspects, they both require an enrichment of ICAM-1 and PECAM-1 around the 
cell that is transmigrating (Carman, 2009; Mamdouh et al., 2009; Millan et al., 2006). In 
cancer cells, E-selectin and MLCK have been implicated in transcellular extravasation 
and transcellular intravasation, respectively (Khuon et al., 2010; Tremblay et al., 2008). 
It would be interesting to study if any of these molecules is involved in transcellular 
migration of Cal51 cells. Moreover, Cal51 cells could transmigrate between endothelial 
cells cultured on top of thick collagen, but it was not possible to observe any invasion 
into the collagen I matrix after 24 hours. Cal51 cells have not been reported to invade 
collagen I matrices. Perhaps these cells interact more with other components of the 
stroma such as fibronectin or other types of collagen (Psaila and Lyden, 2009).   
The HCC1954 cell line was able to transmigrate across the endothelial cells and invade 
into the collagen I matrix in the 3D model after 24 hours. However, in the intercalation 
assay using fixed cells, some cells spread on top of the endothelial cells. It is not 
known whether this affects the transmigration or if it is a different way that the cells use 
to transmigrate. One possible explanation is that HCC1954 cells express different 
receptors from the other cell lines analysed that are important for stable cancer cell-




endothelial cell adhesion. HCC1954 cell line is the only one studied that is originated 
from a primary tumour (Neve et al., 2006). Several receptors have been implicated in 
the stable cancer cell-endothelial cell adhesion, including integrins, CD44 and MUC1 
(Reymond et al., 2013). Therefore, it would be interesting to test the roles of these 
receptors through RNAi screening in the future. Further experiments are necessary to 
study better the behaviour of HCC1954 cells.  
MCF-7 cells caused more problems during the experiments. Most of the cells grow as 
groups which made it difficult to analyse the transmigration of single cells. During the 
live imaging intercalation assay, it was possible to see that the cell groups form holes in 
the monolayer, pushing away the endothelial cells. It is known that MCF-7 cells secret 
a lipid (12(s) hydroxyeicosatetraenoic acid – HETE) that induces retraction of the 
endothelial monolayer (Uchide et al., 2007). This could explain the effect of MCF-7 
cells in the monolayer observed in the intercalation images and in the 3D TEM images. 
Because there are many cell groups, it was difficult to control the exact number of cells 
that were in each well. Trying to work with as many single cells as possible, cells were 
treated with EGTA before performing the experiment. However, the fluorescence 
values obtained were too low. To study this cell line, changes in the protocol are 
necessary.   
3.5.2 Effects of RhoBTB1 depletion in Cal51 cells on endothelial 
interaction  
Based on the characterization of the breast cancer cell lines with endothelial cells, 
Cal51 cells were chosen to be used in additional functional assays to study the effects 
of RhoBTB1 depletion in these cells. Cal51 cell line is a basal-like breast cancer 
subtype obtained from a pleural effusion. Cal51 cells are triple negative (ER-, PR- and 
HER2-) similar to MDA-MB-231 cells. Both cell lines form experimental metastasis in 
the lung when injected in the tail vein of mice. However, MDA-MB-231 cells have been 
used more than Cal51 cells in studies in vitro and in vivo.  




Initial functional assays have shown that adhesion of Cal51 cells to endothelial cells 
were affected only by one oligo targeting RhoBTB1 (oligo #2). A decrease of around 
50% was observed. According to previous studies in MDA-MB-231 cells, depletion of 
RhoBTB1 leads to a decrease in cancer cell adhesion to endothelial cells of around 
30% and β1 integrin is one of the proteins that might be involved in cancer 
cell/endothelial cell interaction in this model (Figure 3.25 from Borda D'Agua (2012)). 
Decrease in β1 expression after Cdc42 depletion has also shown to affect adhesion of 
PC3 cells to endothelial cells, causing a decrease in approximately 40% of cancer cell 
adhesion (Reymond et al., 2012). For that reason, levels of β1 integrin were analysed in 
different breast cancer cell lines. Expression of this protein in MDA-MB-231 cells is 
higher than in Cal51 cells. This could indicate that β1 integrin might have a more 
important role in MDA-MB-231 cells than in Cal51 cells. However, when the levels of β1 
integrin were analysed after RhoBTB1 depletion, there was a decrease only with 
siRhoBTB1 #2, the same siRNA that decreased Cal51 cell adhesion to endothelial 
cells. These results could indicate that there is an off-target effect of oligo #2 targeting 
RhoBTB1. Other siRNA oligos need to be tested in the future. In addition, it seems that 
RhoBTB1 has no effect in the levels of β1 integrin in Cal51 cells. It would be interesting 
to investigate whether β1 integrin depletion reduces adhesion or intercalation of Cal51 
cells to endothelial cells. 
Intercalation of Cal51 cells into a monolayer of endothelial cells was also analysed. 
Studies with MDA-MB-231 cells have shown that depletion of RhoBTB1 significantly 
reduces cancer cell intercalation into a monolayer of endothelial cells in the first 2 
hours of experiment. Depletion of RhoA is also able to decrease intercalation of MDA-
MB-231 cells into endothelial cells (Figure 3.28 from Borda D'Agua (2012)). Based on 
these findings, expression and activity of RhoA in MDA-MB-231 cells were analysed 
after depletion of RhoBTB1. Both expression and activity of RhoA are reduced after 
knockdown of RhoBTB1 in these cells (Figure 3.28 from Borda D'Agua (2012)). 




Interaction of RhoA and RhoBTB1 will be further explored in Chapter 5. The lack of 
phenotype in Cal51 cells could mean that RhoBTB1 is not able to regulate RhoA in 
these cells. And in fact, depletion of RhoBTB1 in Cal51 cells does not affect total RhoA 
levels. Because no phenotype was observed in the adhesion and intercalation assays, 
the transmigration assay was not performed with the Cal51 cell line.  
Problems in RhoBTB1 knockdown in Cal51 cells could be one possible explanation for 
the fact that depletion of RhoBTB1 does not affect adhesion and intercalation of these 
cells into endothelial cells. The efficiency of RhoBTB1 mRNA knockdown 
(approximately 50% decrease in mRNA levels) obtained in Cal51 cells is similar MDA-
MB-231 cells. However, the protein levels could be different. Another possible 
explanation is that the signalling by RhoBTB1 in MDA-MB-231 cells is different in Cal51 
cells, so that RhoBTB1 is not important for endothelial interaction. More experiments 
are necessary to explore this possibility. It is also important in the future to repeat some 
experiments comparing directly MDA-MB-231 and Cal51 cells.  
 




4 Characterization of RhoBTB1 
4.1 Introduction 
Since RhoBTB1 depletion in Cal51 breast cancer cells did not reproduce the results 
described for MDA-MB-231 cells concerning interaction with endothelial cells (as 
reported in Chapter 3), the focus of the project changed to characterise RhoBTB1 
signalling, based initially on what has been reported for RhoBTB2 and RhoBTB3. 
These three proteins share a similar domain organization: a GTPase domain which is 
followed by a proline-rich region, a tandem of two BTB domains and a conserved C-
terminal region (Berthold et al., 2008a). However, only RhoBTB1 and RhoBTB2 are 
considered part of the Rho GTPase family, since the GTPase domain of RhoBTB3 
shows very low similarity to the other Rho GTPase proteins (Boureux et al., 2007; 
Wennerberg and Der, 2004). RhoBTB3 is considered a separate member of the Ras 
superfamily (Boureux et al., 2007). 
In this chapter, some already known properties of RhoBTB1 were tested such as 
interaction with cullin3 and localisation to vesicles. All three RhoBTB proteins are 
known to bind cullin3 (Berthold et al., 2008a) and RhoBTB2 has been shown to be a 
substrate of a cullin3 ubiquitin ligase complex (Wilkins et al., 2004). RhoBTB3 seems to 
act as a BTB adaptor protein, since it forms a complex with cullin3 which mediates 
ubiquitination of cyclin E on the Golgi (Lu and Pfeffer, 2013). However, it has also been 
shown that RhoBTB3 protects 5-HT7a receptor from proteasomal degradation (Matthys 
et al., 2012). Apart from the interaction with cullin3, there is no evidence that RhoBTB1 
is either a substrate or a BTB adaptor protein of cullin3 ubiquitin ligase complexes.  
Overexpressed myc-epitope tagged RhoBTB1 and RhoBTB2 have been shown to 
localise to vesicles, with almost no effect on the actin cytoskeleton in PAE cells 
(Aspenstrom et al., 2004). As mentioned in Chapter 1 (section 1.1.7), RhoBTB2 is 
involved in transporting VSVG in a microtubule-dependent manner (Chang et al., 




2006). This suggests that the localisation of RhoBTB proteins to vesicles could be 
related to their cellular functions. 
It has been reported that RhoBTB2 and RhoBTB3 can form homodimers and 
heterodimers through their BTB domains (Berthold et al., 2008a). However, this has not 
been tested for RhoBTB1. The physiological relevance of RhoBTB dimerisation is still 
unknown. One possible role for these dimers would be as part of the cullin3 complex, 
since it is known that some BTB adaptor proteins dimerise to interact with either cullin3 
or the substrate (McMahon et al., 2006). Regulation of RhoBTB proteins is poorly 
understood. These proteins do not cycle between an active GTP-bound form and an 
inactive GDP-bound form (Berthold et al., 2008a), and therefore are not regulated by 
GAPs and GEFs. They are not prenylated and so do not interact with GDIs (Rivero et 
al., 2001). To better understand how RhoBTB1 could be regulated, some post-
translational modifications were tested including ubiquitination and phosphorylation.  




4.2 RhoBTB1 homodimerises and heterodimerises 
 
To test whether RhoBTB1 can form dimers, RhoBTB1 tagged with either GFP or myc 
at the N-terminus was used, because there is no commercially available antibody that 
detects endogenous RhoBTB1. Cos7 cells were co-transfected with vectors encoding 
myc-RhoBTB1 and GFP-RhoBTB1. myc-RhoBTB1 and GFP-RhoBTB1 co-
immunoprecipitated, suggesting that RhoBTB1 can homodimerise (Figure 4.1). 
 
Figure 4.1 - Interaction of GFP-RhoBTB1 with myc-RhoBTB1 
Cos7 cells were transfected with empty pEGFP and myc-pRK5 or vectors encoding 
myc-RhoBTB1 and/or GFP-RhoBTB1. After 24 hours, cells were lysed and incubated 
with anti-myc-agarose beads. Total lysates (input) and immunoprecipitates (myc-IP) 
were probed with anti-myc and anti-GFP antibodies to show levels of myc-RhoBTB1 
and GFP-RhoBTB1. The interaction between myc-RhoBTB1 and GFP-RhoBTB1 is 
shown in the immunoprecipitates. GAPDH is used as a loading control. Blots are 
representative of three independent experiments. 




As an alternative method to detect dimerisation, cells lysates were treated with the 
crosslinker disuccinimidyl suberate (DSS) after transfection with vector encoding myc-
RhoBTB1. DSS contains two N-hydroxysuccinimide esters that are reactive towards 
primary amines and it is used to crosslink proteins (Leitner et al., 2010). This allows the 
detection of protein complexes that are not normally retained under denaturing 
conditions. Dimers (~ 150 kDa) and tetramers (~ 300 kDa) of myc-RhoBTB1 were 
detected following DSS treatment (Figure 4.2). The crosslinking assay is a good tool to 
observe protein complexes, but it does not distinguish between homodimers and 
interactions with other proteins. If RhoBTB1 forms a complex with other proteins apart 




Figure 4.2 - RhoBTB1 can form homodimers and homotetramers 
Cos7 cells were transfected with empty myc-pRK5 or vector encoding myc-RhoBTB1. 
After 24 hours, cells were lysed and treated with different concentrations (0.05, 0.1 and 
0.25 mM) of disuccinimidyl suberate (DSS) crosslinker or DMSO as a control. Total 
lysates were probed with anti-myc antibody. GAPDH is used as a loading control. Blots 
are representative of two independent experiments. MOCK: untreated cells.  
 




To determine the region of RhoBTB1 that is important for the formation of homodimers, 
RhoBTB1 from myc-RhoBTB1 was subcloned into a pEGFP-C1 vector (section 2.2.12) 
and RhoBTB1 deletion mutants were cloned into a GFP-CB6 vector (section 2.2.14) 
(Figure 4.3). The deletion mutants were first cloned into a pEGFP-C1 vector. However, 
no protein expression was observed for any of the mutants, because the sequences 





Figure 4.3 - Domain structure of GFP-RhoBTB1 and GFP-RhoBTB1 deletion 
mutants  
RhoBTB1 1-210 = Rho domain; RhoBTB1 1-427 = Rho domain and first BTB domain; 
RhoBTB1 266-696 = first BTB domain, second BTB domain and C-terminus; RhoBTB1 
485-696 = second BTB domain and C-terminus.  
 
Cos7 cells were co-transfected with vectors encoding myc-RhoBTB1, full length GFP-
RhoBTB1 and GFP-RhoBTB1 deletion mutants. Only GFP-RhoBTB1 1-210 was not 
able to interact with myc-RhoBTB1 (Figure 4.4). This is the only construct that does not 
encode a protein with at least one BTB domain, suggesting that BTB domains are 
necessary for RhoBTB1 dimerisation. This experiment needs repeating to confirm the 
results.  
 






Figure 4.4 - Interaction of RhoBTB1 with RhoBTB1 deletion mutants 
Cos7 cells were transfected with vectors encoding myc-RhoBTB1, GFP-RhoBTB1 and 
GFP-RhoBTB1 deletion mutants. After 24 hours, cells were lysed and incubated with 
anti-myc-agarose beads. Total lysates (input) and immunoprecipitates (myc-IP) were 
probed to show levels of myc-RhoBTB1 and endogenous cullin3. The interaction 
between myc-RhoBTB1 and GFP-RhoBTB1 deletion mutants is shown in the 
immunoprecipitates. GAPDH is used as a loading control. Blots are from one 
experiment. 




Interaction of RhoBTB1 with RhoBTB2 was also studied to test the formation of 
heterodimers. Cos7 cells were co-transfected with vectors encoding myc-RhoBTB1 
and GFP-RhoBTB2. myc-RhoBTB1 was able to immunoprecipitate with GFP-RhoBTB2 
(Figure 4.5). These initial results suggest that RhoBTB1 could form homodimers and 
heterodimers. However, more experiments are necessary to prove these observations.  
 
 
Figure 4.5 - Interaction of RhoBTB1 with RhoBTB2 
Cos7 cells were transfected with empty myc-pRK5 or vectors encoding myc-RhoBTB1 
and/or GFP-RhoBTB2. After 24 hours, cells were lysed and incubated with anti-myc-
agarose beads. Total lysates (input) and immunoprecipitates (myc-IP) were probed to 
show levels of myc-RhoBTB1 and GFP-RhoBTB2. The interaction between myc-
RhoBTB1 and GFP-RhoBTB2 is shown in the immunoprecipitates. GAPDH is used as 
a loading control. Blots are from one experiment. 
 
 




4.3 Interaction of RhoBTB1 with cullin3 
 
It has been shown that RhoBTB proteins can interact with cullin3, a scaffold protein in 
ubiquitin ligase complexes (Berthold et al., 2008a). To confirm this interaction, Cos7 
cells were transfected with a vector encoding myc-RhoBTB1 and lysates 
immunoprecipitated with anti-myc-agarose beads. myc-RhoBTB1 was able to interact 
with endogenous cullin3 (Figure 4.6). As mentioned in section 1.2.2, the activity of 
CRLs can be regulated by NEDD8, an ubiquitin-like polypeptide which covalently binds 
to a conserved lysine residue in cullins (Wu et al., 2005). The higher molecular weight 




Figure 4.6 - Interaction of RhoBTB1 and cullin3 
Cos7 cells were transfected with empty myc-pRK5 or vector encoding myc-RhoBTB1. 
After 24 hours, cells were lysed and incubated with anti-myc-agarose beads. Total 
lysates (input) and immunoprecipitates (myc-IP) were probed to show levels of myc-
RhoBTB1 and endogenous cullin3. The interaction between myc-RhoBTB1 and cullin3 
is shown in the immunoprecipitates. GAPDH is used as a loading control. Blots are 
representative of three independent experiments. 




To determine the region of RhoBTB1 that is important for the interaction with cullin3, 
Cos7 cells were transfected with vectors encoding full length GFP-RhoBTB1 and GFP-
RhoBTB1 deletion mutants. Endogenous cullin3 was only able to interact with full 
length GFP-RhoBTB1 and more weakly with GFP-RhoBTB1 266-696. This is 
consistent with what has been observed for other proteins where cullin3 is able to 
interact with these proteins through their BTB domain (Pintard et al., 2004). These two 
constructs are the only ones that encode proteins with the two BTB domains, 
suggesting that both BTB domains of RhoBTB1 are necessary for its interaction with 
cullin3 (Figure 4.7). 
 
Figure 4.7 - Interaction of RhoBTB1 deletion mutants and cullin3 
Cos7 cells were transfected with vectors encoding GFP-RhoBTB1 and GFP-RhoBTB1 
deletion mutants. After 24 hours, cells were lysed and incubated with GFP-binding 
protein coupled to agarose (GFP-trap®). Total lysates (input) and immunoprecipitates 
(GFP-IP) were probed to show levels of GFP-RhoBTB1 and endogenous cullin3. The 
interaction between GFP-RhoBTB1 and cullin3 is shown in the immunoprecipitates. 
GAPDH is used as a loading control. Blots are representative of two independent 
experiments. 




As neddylation of cullin3 is important for its activity (Wu et al., 2005), its role in cullin3 
interaction with RhoBTB1 was tested. Neddylation was inhibited by the addition of 
MLN4924, an inhibitor of NAE which adds NEDD8 to lysine of cullins (Zhao et al., 
2012). The efficiency of the treatment is measured by the decrease in the intensity of 
the higher molecular weight band of cullin3. Inhibition of cullin3 neddylation did not 
prevent the interaction between myc-RhoBTB1 and endogenous cullin3 (Figure 4.8). 
 
 
Figure 4.8 - Interaction of RhoBTB1 and cullin3 after MLN4924 treatment 
Cos7 cells were transfected with empty myc-pRK5 or vector encoding myc-RhoBTB1. 
After 24 hours, cells were treated with 1 μM of MLN4924 (+) or DMSO (-) for 2 hours. 
Cells were lysed and incubated with anti-myc-agarose beads. Total lysates (input) and 
immunoprecipitates (myc-IP) were probed to show levels of myc-RhoBTB1 and 
endogenous cullin3. The interaction between myc-RhoBTB1 and cullin3 is shown in the 
immunoprecipitates. GAPDH is used as a loading control. Blots are representative of 
three independent experiments. 
  




4.4 Ubiquitination of RhoBTB1 
 
One of the post-translational modifications that Rho GTPases can undergo is 
ubiquitination (Chapter 1, section 1.1.1). RhoBTB2 has already been shown to be 
ubiquitinated and it is known to be a substrate for cullin3-RING ubiquitin ligases 
(Wilkins et al., 2004). However, the ubiquitination site has not been identified yet. 
Ubiquitination of RhoBTB1 has not been studied, although it also interacts with cullin3. 
Using the GG Base website (https://ggbase.hms.harvard.edu/) and the PhosphoSite 
Plus website (www.phosphosite.org), it was found that RhoBTB1 has a potential 
ubiquitination site in its Rho domain (K119). The ubiquitination of RhoBTB1 was 
therefore analysed. Cos7 cells were transfected with vectors encoding HA-ubiquitin 
and GFP-RhoBTB1 or myc-RhoBTB1. GFP-RhoA-N19, a dominant negative mutant, 
and GFP-RhoBTB2 were used as controls, since it is known that GDP-RhoA and 
RhoBTB2 can be ubiquitinated (Chen et al., 2009; Wang et al., 2003; Wilkins et al., 
2004). HA-ubiquitin was immunoprecipitated using anti-HA-agarose beads. GFP-
RhoBTB1 was able to associate with ubiquitin (Figure 4.9A). Although there are 
multiple RhoBTB1 bands (lane 6), there was not a molecular-weight ladder as 
observed in RhoA-N19 (lane 8) which suggests the presence of polyubiquitinated 
proteins. Bands for RhoBTB2 were not very clear, probably due to the low expression 
of GFP-RhoBTB2. The strongest band observed for RhoBTB1 (lane 6) is around 112 
kDa. Since GFP-RhoBTB1 is 100 kDa and ubiquitin is 8.5 kDa, this increase in 
molecular weight could indicate the presence of RhoBTB1 bound to one ubiquitin 
molecule (Figure 4.9A, orange arrow). RhoBTB1 ubiquitination was also investigated 
by immunoprecipitating myc-RhoBTB1 and blotting for HA-ubiquitin. Several bands for 
RhoBTB1 were observed by this method (Figure 4.9B). However, a band around 87 
kDa was present which could indicate the presence of RhoBTB1 bound to one ubiquitin 
molecule (myc-RhoBTB1 is 79 kDa) (Figure 4.9B, red arrow). The different band sizes 
observed in each experimental approach could represent different types of 




ubiquitination on RhoBTB1 (reviewed in Chapter 1). Another possibility is that other 
ubiquitinated proteins bind to RhoBTB1 (e.g. RhoBTB2) and are detected in the blots.  
 
 
Figure 4.9 - Ubiquitination of RhoBTB1  
A) Cos7 cells were transfected with empty pEGFP or vectors encoding HA-ubiquitin, 
GFP-RhoBTB1, GFP-RhoBTB2 or GFP-RhoA-N19. After 24 hours, cells were lysed 
and incubated with anti-HA-agarose beads. Total lysates (input) and 
immunoprecipitates (HA-IP) were probed to show levels of HA-ubiquitin, GFP-
RhoBTB1, GFP-RhoBTB2 and GFP-RhoA-N19. GAPDH is used as a loading control. 
Blots are from one experiment. B) Cos7 cells were transfected with empty vector or 
vectors encoding HA-ubiquitin and myc-RhoBTB1. After 24 hours, cells were lysed and 
incubated with anti-myc-agarose beads. Total lysates (input) and immunoprecipitates 
(myc-IP) were probed to show levels of HA-ubiquitin and myc-RhoBTB1. Blots are 
representative of three experiments. Lanes are from the same blot.   




4.5 Phosphorylation of RhoBTB1 
 
Using the PhosphoSite Plus website (www.phosphosite.org) which shows data from 
high-throughput mass spectrometry analysis (Hornbeck et al., 2015), seven 




Figure 4.10 - Possible phosphorylation sites on RhoBTB1  
Possible phosphorylation sites on RhoBTB1 obtained from www.phosphosite.org 
website (data from high-throughput mass spectrometry analysis).  
 
To determine whether RhoBTB1 could be phosphorylated, the ProQ® Diamond dye 
was used. The dye is described to bind directly and selectively to the phosphate moiety 
(Patent number: US 7,102,005 B2). It is possible to detect phosphoserine-, 
phosphothreonine- and phosphotyrosine-containing proteins with this reagent. This 
reagent has previously been used in our laboratory for Rnd3 (Riou et al., 2013). myc-
RhoBTB1 was immunoprecipitated using anti-myc-agarose beads, and phosphorylated 
RhoBTB1 was detected using ProQ® Diamond (Figure 4.11). Phosphorylation of 










Figure 4.11 - Phosphorylation of RhoBTB1  
Cos7 cells were transfected with empty myc-pRK5, or vector encoding myc-RhoBTB1. 
After 24 hours, cells were lysed and incubated with anti-myc-agarose beads. Total 
lysates and immunoprecipitated lysates were resolved on a 4-12% polyacrylamide gel 
and transferred to a low fluorescence PVDF membrane. Membrane was incubated with 
ProQ Diamond reagent followed by incubation with SyPro Ruby (total protein). Images 
were taken using a dual intensity ultraviolet transilluminator. Blots are from one 
experiment. MOCK: untransfected cells. 
 
  




4.6 Localisation of RhoBTB1 
 
To investigate the localisation of RhoBTB1 and whether it alters the actin cytoskeleton, 
Hela cells were used, because they are well spread in 2D culture conditions and have 
stress fibres. These cells have been used before to study changes in actin cytoskeleton 
(Ishizaki et al., 2001). Hela cells were transfected with vector encoding GFP-RhoBTB1. 
After 24 hours, cells were fixed and stained for F-actin to observe stress fibres (Figure 
4.12A). In approximately 60% of the transfected cells (Figure 4.12B), GFP-RhoBTB1 
was localised mainly in the cytoplasm.  The rest of the cells had GFP-RhoBTB1 
localised either in the cytoplasm and punctate localisation (~ 25%) or mainly with a 
punctate localisation (~ 15%) (Figure 4.12B). This punctate localisation could suggest 
the association of RhoBTB1 with vesicles. Because some cells with punctate GFP-
RhoBTB1 localisation had abundant stress fibres, the percentage of cells with stress 
fibres was determined in control and RhoBTB1-overexpressing cells. However, no 
significant changes were observed (Figure 4.12C). More experiments are necessary to 
study this effect because the number of cells analysed was low.  
 
 






Figure 4.12 - Localisation of RhoBTB1  
A) Hela cells were transfected with a vector encoding GFP-RhoBTB1. After 24 hours, 
cells were fixed and stained for F-actin and nuclei (DAPI). Images are representative of 
two independent experiments. Scale bar = 20 μm. B) Quantification of localisation of 
GFP-RhoBTB1 in transfected Hela cells. Graph shows data from two independent 
experiments. Around 10 cells that were expressing GFP-RhoBTB1 were counted in 
each experiment. Values represent mean ± SD. C) Quantification of stress fibres in 
transfected and untransfected Hela cells. Graph shows data from two independent 
experiments. 20 cells were counted in each experiment. Values represent mean ± SD. 
   
 




To explore the effect of RhoBTB1 domains on protein localisation, Hela cells were 
transfected with vectors encoding GFP-RhoBTB1 and GFP-RhoBTB1 deletion 
mutants. After 24 hours, cells were fixed and stained for F-actin to observe stress fibres 
(Figure 4.13). GFP-RhoBTB1 1-427, GFP-RhoBTB1 266-696 and GFP-RhoBTB1 485-
696 mutants were found mainly in the cytoplasm and in some cells, had a punctate 
localisation that might represent vesicles. Moreover, GFP-RhoBTB1 1-210 
predominantly had a punctate localisation. Whether these are vesicles, or other 
structures, needs to be determined, since these structures could also be protein 
aggregates. Another interesting observation is the presence of full length RhoBTB1 
and RhoBTB1 deletion mutants in the nucleus. However, GFP-RhoBTB1 1-427 lacks 
the C-terminal domain where the potential NLS region of RhoBTB1 is found (Figure 
1.9). Therefore, it is possible that another region of RhoBTB1 could be responsible for 
its localisation in the nucleus.  






Figure 4.13 - Localisation of RhoBTB1 and RhoBTB1 deletion mutants  
Hela cells were transfected with a vector encoding GFP-RhoBTB1, GFP-RhoBTB1 1-
210, GFP-RhoBTB1 1-427, GFP-RhoBTB1 266-696 and GFP-RhoBTB1 485-696. After 
24 hours, cells were fixed and stained for F-actin and nuclei (DAPI). Images are 
representative of two independent experiments. White arrows indicate punctate 
structures. Scale bar = 20 μm.  
 





Within the Rho family, RhoBTB1 is one of the least studied member. Apart from its 
interaction with cullin3, there are no other interacting partners or effector proteins 
known for RhoBTB1 and little is known about its regulation. In addition to GEFs, GAPs 
and GDIs, expression and activity of Rho GTPases can be controlled by transcriptional, 
post-transcriptional and post-translational regulations (Liu et al., 2012). RhoBTB1 
expression has been shown to be regulated by the microRNA-31 in human colon 
cancer (Xu et al., 2013) and by PPARγ in a mouse model (Pelham et al., 2012). In this 
chapter, the interaction between cullin3 and RhoBTB1 was further explored, as well as 
the formation of RhoBTB1 homodimers. Possible mechanisms for RhoBTB1 regulation 
were also studied.  
Initially, the interaction between RhoBTB1 and cullin3 was confirmed. RhoBTB2 is 
known to interact with cullin3 through its first BTB domain. Using different RhoBTB1 
deletion mutants, it was observed that RhoBTB1 needs both of its two BTB domains to 
interact with endogenous cullin3. It is possible that RhoBTB1 containing only one BTB 
domain is still able to interact with cullin3, but in a weaker manner so that endogenous 
cullin3 was not detected under the conditions used here. The experiment for RhoBTB2 
was performed overexpressing cullin3 which could facilitate the interaction of the first 
BTB domain with cullin3, even if the binding was weaker. Another possible explanation 
is that RhoBTB1 and RhoBTB2 interact with cullin3 in a slightly different manner: 
RhoBTB1 needs both BTB domains while RhoBTB2 interacts only with the first BTB 
domain. The identity between the first BTB domain of RhoBTB1 and RhoBTB2 is 38% 
while for the second BTB domain it is 68%.  
Another condition analysed for RhoBTB1 and cullin3 interaction was the importance of 
cullin3 activation. As mentioned in section 1.2.2, one of the mechanisms to activate 
cullin proteins is through covalent addition of NEDD8. Treatment with the neddylation 




inhibitor MLN4924 completely depletes the higher molecular weight form (cullin3-
NEDD8) of cullin3. However, RhoBTB1 was still able to interact with the unneddylated 
form. It has been reported before that interaction of cullin3 with its adaptor proteins 
does not require cullin3 activation. For example, neddylation of cullin3 is not important 
for its interaction with the BTB adaptor protein Keap1 (Chew et al., 2007).  
Some proteins containing BTB domain have been shown to form homodimers and 
heterodimers through their BTB domains (Stogios et al., 2005). The formation of BTB 
protein homodimers in some cases is important for the assembly of the ubiquitin ligase 
complex (Canning et al., 2013). Results shown here suggest that RhoBTB1 was able to 
homodimerise and heterodimerise with RhoBTB2. Similarly, RhoBTB2 can form 
homodimers and heterodimers with RhoBTB3 (Berthold et al., 2008a). The use of a 
crosslinker implied the presence of RhoBTB1 tetramers. However, the presence of 
these structures could be either due to the high amount of ectopic RhoBTB1 in cells or 
the detection of a protein complex that RhoBTB1 is part of. The BTB domains are 
essential for the dimerisation of RhoBTB1 since their deletion (GFP-RhoBTB1 1-210) 
prevented the formation of homodimers. More experiments using recombinant 
RhoBTB1 are necessary to confirm these results. Solving the crystal structure of 
RhoBTB proteins would be very useful to study the dimerisation of these proteins. The 
relevance of these findings for RhoBTB1 function is still unclear. One possible role for 
dimer formation could be related to the potential involvement of RhoBTB proteins in the 
ubiquitination of substrates through their interaction with cullin3 (Figure 4.14) as shown 
for other BTB adaptor proteins (Figure 1.12).  






Figure 4.14 - Model of interaction between RhoBTB1 homodimer and cullin3 
RhoBTB1 dimer interacts with the substrate through its Rho domain and with cullin3 
through its BTB domains.  
 
Exogenous expression of GFP-RhoBTB1 in Hela cells has shown that this protein is 
localised mainly in the cytoplasm and nucleus and in some cells, it is also observed to 
vesicles. These results are in agreement with other studies using PC3, Cos7 and PAE 
cells (Aspenstrom et al., 2004; Borda D'Agua, 2012). The lack of a CAAX box or the 
report of any lipid modification in RhoBTB1 are good indicators that this protein is likely 
to be found in the cytosol and not on membranes. The presence of RhoBTB1 on 
vesicle-like structures only in some cells could reflect different functions depending on 
protein localisation. If RhoBTB1 is on vesicles, it will associate indirectly unless there is 
a previously unrecognised lipid modification or lipid-binding domain. Data generated in 
our laboratory (not published) indicates that RhoBTB1 might have a role in β1 integrin 
recycling and it is able to associate with some endosomal markers. RhoBTB2 has 




already been shown to be involved in transporting VSVG from the endoplasmic 
reticulum to the Golgi apparatus (Chang et al., 2006).  Using GFP-RhoBTB1 deletion 
mutants, the role of each of the domains of RhoBTB1 on its localisation was analysed. 
The only mutant that had a striking difference when compared to the full length protein 
was GFP-RhoBTB1 1-210. This mutant encodes only the Rho domain of RhoBTB1 and 
the protein was mainly localised to punctate structures. Because the expression of the 
protein is high, the structures could be protein aggregates. Co-staining using vesicle 
markers (e.g. EEA1, LAMP1, Rab4, Rab11) is necessary to determine the localisation 
of GFP-RhoBTB1 1-210. If it is on vesicles, this would indicate that the Rho domain of 
RhoBTB1 is important for its localisation.  
No clear differences in cell morphology or actin cytoskeleton were observed in 
RhoBTB1-overexpressing cells. However, the number of cells analysed was too low to 
draw any conclusions. In addition, as shown in Chapter 5, RhoBTB1 depletion in MDA-
MB-231 and PC3 cells led to elongation of these cells when embedded in Matrigel, 
suggesting a role for RhoBTB1 in regulating the actin cytoskeleton. This is discussed in 
more detail in Chapter 5.  
Possible mechanisms for RhoBTB1 regulation include post-translational modifications, 
since these proteins do not cycle between an active GTP-bound form and an inactive 
GDP-bound form (Berthold et al., 2008a). On websites with high throughput mass 
spectrometry data, potential phosphorylation and ubiquitination sites were observed for 
RhoBTB1. Based on these data, preliminary assays were performed to determine 
whether RhoBTB1 could be phosphorylated and/or ubiquitinated. Using 
immunoprecipitation assays, it was possible to observe ubiquitination of RhoBTB1. 
However, depending on the protein being immunoprecipitated, the pattern of the bands 
in the blots was different. One possible explanation for these two different results is that 
RhoBTB1 can be both monoubiquitinated and polyubiquitinated. The lack of a 
molecular-weight ladder in the ubiquitin immunoprecipitated assay could mean that 




there is more monoubiquitinated than polyubiquitinated RhoBTB1 which would then 
appear stronger in the blot. Different ubiquitin modifications can lead to different 
outcomes. As mentioned in Chapter 1, monoubiquitinated proteins are involved in 
endocytosis, endosomal sorting, histone regulation, DNA repair, virus budding and 
nuclear export while polyubiquitinated protein are targeted to DNA repair, endocytosis 
and activation of protein kinases (lysine 63) or protein degradation (lysine 48). 
Therefore, ubiquitination of RhoBTB1 could mean that this protein could be involved in 
very different processes in cells. Phosphorylation of RhoBTB1 was initially analysed 
using the reportedly phosphospecific protein stain ProQ® Diamond. A band for 
RhoBTB1 was observed, and thus it could be phosphorylated on one or more sites. 
Further analysis of RhoBTB1 phosphorylation is described in Chapter 6.  
Although more experiments are necessary to confirm the findings in this chapter, it is 
possible to speculate that some of the results could be linked to each other. For 
example, localisation of RhoBTB1 could be influenced by ubiquitination and/or 
phosphorylation. Phosphorylation could also affect RhoBTB1 ubiquitination, if 
phosphorylation is necessary for interaction between RhoBTB1 and cullin3. In addition, 
dimerisation of RhoBTB1 might be important for cullin3 interaction which in turn would 
affect RhoBTB1 ubiquitination and this could lead to changes in RhoBTB1 localisation 
or degradation.  




5 Role of RhoBTB1 in RhoA regulation 
5.1 Introduction 
Depletion of RhoBTB1 in MDA-MB-231 cells was described to lead to a decrease in 
RhoA expression (Borda D'Agua, 2012). However, the mechanisms linking RhoBTB1 
to RhoA are unknown. One option that was explored in this chapter is the possible role 
of RhoBTB1 in the degradation of RhoA mediated by thecullin3 ubiquitin ligase 
complex. RhoA is known to be a substrate of the BACURD/cullin3 complex (Chen et 
al., 2009), which leads to ubiquitination of RhoA and consequent degradation by the 
proteasome. Since RhoBTB1 binds to cullin3, the possibility that RhoBTB1 interacts 
with RhoA and affects its degradation was analysed.  
RhoA is one of the best-studied members of the Rho GTPase family.  RhoA is closely 
related to RhoB and RhoC. The RhoA, RhoB and RhoC genes were identified in 1985 
(Madaule and Axel, 1985) and since then, a great volume of knowledge has been 
generated. RhoA is a 21 kDa protein and it is ubiquitously expressed (Narumiya, 1996). 
It is localised to the plasma membrane and the cytoplasm (Adamson et al., 1992), and 
as a classic Rho GTPase, RhoA is a molecular switch which cycles between an active 
GTP-bound form and an inactive GDP-bound form (Hall, 2012). The N-terminal region 
is the part of the protein involved in GTP binding and hydrolysis (Wheeler and Ridley, 
2004). This cycling is controlled by GAPs, GEFs and GDIs (Cherfils and Zeghouf, 
2013). RhoA has a CAAX box near its C-terminus which undergoes prenylation 
(addition of a geranylgeranyl group). This lipid modification allows the protein to 
translocate between the plasma membrane and the cytosol (Adamson et al., 1992). 
RhoGDIs control the localisation of RhoA, since they bind to the prenyl group, 
preventing the protein localising to the membrane. Once in the membrane, RhoA is 
activated and is able to interact with several effectors (Aspenström, 1999; Bishop and 
Hall, 2000). The GTP-bound form of RhoA interacts with at least 11 proteins that are 




involved in many different cellular processes including regulation of the actin 
cytoskeleton, gene transcription, cell-cell contacts, G1 cell-cycle progression and cell 
transformation (Braga, 1999; Hill et al., 1995; Qiu et al., 1995b; Ridley and Hall, 1992; 
Welsh et al., 2001) 
5.1.1 RhoA effectors  
The main effectors involved in the ability of RhoA to control cytoskeletal rearrangement 
and cell morphology are Rho-associated kinase (ROCK) and mammalian homolog of 
Drosophila diaphanous (mDia). ROCKs are serine/threonine kinases: mammals have 
two ROCKs, ROCK1 and ROCK2. Both ROCK1 and ROCK2 have been shown to bind 
to active RhoA (Ishizaki et al., 1996; Matsui et al., 1996). This interaction leads to 
activation of ROCKs and phosphorylation of their downstream targets including myosin 
phosphatase and myosin light chain (MLC) (Amano et al., 1996a; Kimura et al., 1996). 
Phosphorylation of myosin phosphatase inhibits this enzyme, allowing MLC to be 
phosphorylated which increases actin-activated ATPase activity of myosin II (Amano et 
al., 1996a; Tan et al., 1992). Myosin interacts with actin in an ATP-dependent manner 
to generate movement, leading to cell contraction (Citi and Kendrick-Jones, 1987). 
However, it has recently been proposed that RhoA is not involved in activation of 
ROCK (Truebestein et al., 2015). mDia1 is a member of the formin protein family, and 
has two close relatives in mammals, mDia2 and mDia3. These proteins consist of a 
Rho GTPase-binding domain (RBD), three formin homology domains (FH1-3), two 
coiled-coil domains and an intramolecular interaction domain at the C-terminal region 
that can interact with the N-terminal region to inhibit mDia activity (Krebs et al., 2001). 
mDia1 is able to interact with active-RhoA and profilin (Watanabe et al., 1997). RhoA 
binds to the N-terminal region of mDia1 and releases it from the intramolecular 
inhibitory interaction with the C-terminal region. Once active, mDia1 interacts with 
profilin through the FH1 domain and induces actin polymerization via the FH2 domain 
(Breitsprecher and Goode, 2013; Higashida et al., 2004; Krebs et al., 2001).  The FH2 




domain of mDia1 has been shown to be important for microtubule orientation and 
coordination with actin filaments. However, the mechanism for this process remains 
unknown (Ishizaki et al., 2001). ROCKs and mDia1 appear to cooperate with each 
other during Rho-mediated stress fibre formation. The balance of these two proteins 
can influence the thickness and density of stress fibres (Watanabe et al., 1999). G1 
progression mediated by RhoA is also dependent on the ROCK/mDia1 activation 
balance. Inhibition of ROCK activity leads to an increase in mDia1 function which 
promotes G1 progression (Mammoto et al., 2004).  
RhoA can interact and activate other kinases including protein kinase N (PKN), citron 
kinase and phosphatidylinositol-4-phosphate 5-kinase (PIP5K). PKN1, PKN2 and 
PKN3 are also serine/threonine kinases that can interact with RhoA (Amano et al., 
1996b; Vincent and Settleman, 1997; Watanabe et al., 1996). The N-terminal region of 
these proteins interacts with active RhoA (Flynn et al., 1998; Maesaki et al., 1999). 
PKN proteins are involved in several cellular processes including cytoskeletal 
regulation, cell adhesion, vesicle transport, glucose transport and transcriptional 
activation (Mukai, 2003).  
Initially, active RhoA was found to interact with citron, a protein very similar to the 
ROCK family of kinases apart from the lack of a kinase domain (Madaule et al., 1995). 
However, a splice variant of citron was identified with a kinase domain in its N-terminal 
domain. Citron kinase is found in the midbody between two dividing daughter cells and 
it is important for cytokinesis (Madaule et al., 1998). This kinase has been shown to 
also phosphorylate MLC but not myosin phosphatase, and this phosphorylation could 
be involved in citron kinase role during cytokinesis (Yamashiro et al., 2003).  
PIP5K is another kinase regulated by RhoA (Chong et al., 1994). This kinase catalyses 
the last step in phosphatidylinositol (4,5)-bisphosphate (PIP2) synthesis (Oude 
Weernink et al., 2004). PIP2 is a membrane phospholipid and it is a substrate of two 




important enzymes, PI-phospholipase C (PI-PLC) and type I PI3-kinases. In addition, 
PIP2 is able to bind to a large number of effector domains that are involved in the 
regulation of actin polymerization, endocytosis and exocytosis, turnover of focal 
adhesions and activity of potassium channels (Downes et al., 2005). PIP5K binds 
RhoA regardless of whether it is in the active or inactive form. However, the activation 
of PIP5K is mediated only by GTP-bound RhoA with involvement of ROCK as well 
(Ren et al., 1996; Weernink et al., 2004; Weernink et al., 2000). The role of other RhoA 
effectors including rhotekin and rhophilin is less well understood.  
5.1.2 RhoA in transendothelial migration 
As mentioned in Chapter 3, TEM is one of the steps of cell extravasation from blood 
vessels. RhoA has been implicated in this process in both leukocytes and cancer cells. 
In leukocytes, Rho/ROCK signalling was initially described as being important for 
monocyte tail retraction during transmigration into an endothelial monolayer 
(Worthylake et al., 2001). Later, it was shown that depletion of RhoA in T-cells leads to 
loss of polarization and defects in the ability of the cells to crawl on endothelial cells 
and transmigrate. In this study, RhoA was found to be active not only in the rear of 
transmigrating cells but also in the cell front (Heasman et al., 2010). RhoA has also 
been implicated in the transmigration of cancer cells into an endothelial monolayer. 
Inhibition of RhoA prenylation affects transendothelial migration of MDA-MB-231 cells 
into a monolayer of calf pulmonary arterial endothelial cells (Kusama et al., 2006). 
RhoA lacking the lipid modification is not able to translocate to the membrane and be 
activated. In the prostate cancer cell line PC3, RhoA/ROCK signalling is also involved 
in transendothelial migration in vitro (Brown et al., 2014).   
5.1.3 Regulation of RhoA 
As a classic Rho GTPase, RhoA is regulated by several GEFs, GAPs and GDIs. These 
proteins control the activity and localisation of Rho GTPases inside the cell. In addition, 




levels of total protein can be regulated by expression and degradation. As described in 
Chapter 1, RhoA is a target of miRNAs and it can also undergo ubiquitination with 
consequent proteasomal degradation. Moreover, post-translational modifications can 
influence the fate of proteins. For example, phosphorylation of RhoA by PKA leads to 
increase in binding to RhoGDIs, protecting RhoA from ubiquitination (Rolli-Derkinderen 
et al., 2005) while phosphorylation of RhoA by Erk2 facilitates ubiquitination mediated 
by SCFFBXL19 E3 ubiquitin ligase (Wei et al., 2013). Therefore, regulation of RhoA is a 
complex network that can be controlled in many different ways.   




5.2 Depletion of cullin3 and RhoBTB1 leads to a decrease in RhoA total 
levels 
Cullin3 and RhoBTB1 were depleted in MDA-MB-231 cells and the levels of RhoA 
expression were analysed with and without cycloheximide treatment (6 hours). 
Cycloheximide is a protein synthesis inhibitor in eukaryotes, allowing the analysis of 
protein levels at specific time points without new expression. Depletion of cullin3 
increased levels of RhoA consistent with results obtained by Chen et al. (2009), but 
when protein synthesis was blocked, RhoA levels remained at basal levels (siRNA 
control) (Figure 5.1). This indicates that new protein synthesis is required for RhoA 














                      
                       
            
Figure 5.1 - Expression of RhoA in MDA-MB-231 cells after cullin3 depletion 
Cells were transfected with siRNA control or siRNA oligos #3 and #5 targeting cullin3. 
After 48 hours, cells were treated with cycloheximide (50 μg/ml) for 6 hours. Cells were 
then lysed and protein expression was analysed by western blotting. GAPDH is used 
as a loading control. Graph shows the quantification of the band density of five 
independent experiments. Values represent mean ± SEM. *p<0.05, **p<0.01 compared 
to siRNA control (- cycloheximide), determined by unpaired one-way ANOVA, followed 
by Dunnett´s test. 
 




In addition, inhibition of cullin3 activity with MLN4924 also affected levels of RhoA as 
expected (Figure 5.2). Inhibition of cullin3 activity led to an increase in RhoA total 
protein levels.  
 
Figure 5.2 - Inhibition of cullin3 affects RhoA total protein levels in MDA-MB-231 
cells 
MDA-MB-231 cells were treated with 1 μM or 2 μM of MLN4924 or DMSO for 2 hours. 
Cells were lysed and protein expression was analysed by western blotting. GAPDH is 
used as a loading control. Graph shows the quantification of the band density of three 
independent experiments, normalised to GAPDH and relative to DMSO. Values 
represent mean ± SEM. *p<0.05, compared to DMSO, determined by unpaired one-
way ANOVA, followed by Dunnett´s test. 
 
Borda D'Agua (2012) observed that depletion of RhoBTB1 in MDA-MB-231 cells led to 
a decrease in activity and expression of RhoA (Figure 3.28). However, under the 
conditions used here, depletion of RhoBTB1 did not affect RhoA levels in untreated 
cells. Only when cells were treated for 6 hours with cycloheximide was it possible to 
observe a decrease in RhoA levels. Treatment with cycloheximide did not affect levels 
of RhoA in the siRNA control (Figure 5.3). 
 




   
    
 
Figure 5.3 - Expression of RhoA in MDA-MB-231 cells after RhoBTB1 depletion 
Cells were transfected with siRNA control or siRNA oligos #2 and #4 targeting 
RhoBTB1. After 72 hours, cells were treated with cycloheximide (50 μg/ml) for 6 hours. 
Cells were then lysed and protein expression was analysed by western blotting. 
GAPDH is used as a loading control. Graph shows the quantification of the band 
density of five independent experiments. Values represent mean ± SEM. *p<0.05, 
****p<0.0001, compared to siRNA control (- cycloheximide) and *p<0.05, compared to 
siRNA control (+ cycloheximide), determined by unpaired one-way ANOVA, followed 
by Dunnett´s test. 
 
It has been shown that GDP-RhoA can be ubiquitinated by the BACURD/cullin3 
ubiquitin ligase complex and degraded by proteasomal degradation (Chen et al., 2009). 
BACURDs are BTB adaptor proteins that bind to substrates and bring them to the 
cullin3 complex to be ubiquitinated. Like BACURDs, RhoBTB proteins have BTB 
domains and they could potentially act in a similar way, bringing substrates to be 
ubiquitinated by the cullin3 ubiquitin ligase complex. As shown above, depletion of 
RhoBTB1 reduces levels of RhoA in the presence of cycloheximide, suggesting that 
RhoBTB1 normally protects RhoA from degradation rather than stimulating its 
degradation.   




To test whether RhoBTB1 interacted with RhoA, the two proteins were co-
overexpressed in Cos7 cells, followed by immunoprecipitation. myc-RhoBTB1 was co-
transfected with three different constructs encoding RhoA: GFP-RhoA, GFP-RhoA-N19 
(threonine to arparagine, dominant negative) (Coso et al., 1995) and GFP-RhoA-V14 
(glycine to valine, constitutively active) (Ihara et al., 1998; Ridley and Hall, 1992). 
RhoBTB1 interacted only with the dominant-negative form of RhoA (GFP-RhoA-N19). 
Cullin3 was used as a control to confirm the efficiency of the immunoprecipitation 
(Figure 5.4). Total expression of GFP-RhoA-N19 is lower than GFP-RhoA and GFP-
RhoA-V14 probably because RhoA-N19 is more targeted for degradation. Co-
transfection of myc-RhoBTB1 and GFP-RhoA leads to lower total expression of both 
proteins when compared to single transfection. This could be caused by competition for 
expression. However, levels of myc-RhoBTB1 in the myc-IP are consistent in all the 
conditions.  






Figure 5.4 - Interaction of RhoBTB1 and RhoA mutants 
Cos7 cells were co-transfected with empty myc-pRK5 and pEGFP or vector encoding 
myc-RhoBTB1, GFP-RhoA, GFP-RhoA-N19, GFP-RhoA-V14, myc-RhoBTB1/GFP-
RhoA, myc-RhoBTB1/GFP-RhoA-N19 or myc-RhoBTB1/GFP-RhoA-V14. After 24 
hours, cells were lysed and incubated with anti-myc-agarose beads. Total lysates 
(input) and immunoprecipitates (myc-IP) were probed to show expression of myc-
RhoBTB1, GFP-RhoA, GFP-RhoA-N19, GFP-RhoA-V14. The interaction between myc-
RhoBTB1 and GFP-RhoA-N19 is shown in the immunoprecipitates (myc-IP). GAPDH is 
used as a loading control. Blots are representative of two independent experiments.  
 




To determine the region of RhoBTB1 that is important for the interaction with RhoA, 
Cos7 cells were co-transfected with vectors encoding full length GFP-RhoBTB1, GFP-
RhoBTB1 deletion mutants (Figure 5.5A) and FLAG-RhoA-N19. Only constructs 
encoding proteins containing the Rho domain of RhoBTB1 were able to interact with 
FLAG-RhoA-N19 (Figure 5.5B). It was also observed that the presence of RhoBTB1 
constructs led to an increase in FLAG-RhoA-N19 expression. This effect could be a 
result of RhoBTB1 protection over RhoA degradation. However, it is important to 
observe that RhoBTB1 deletion constructs were cloned into a different plasmid from 
the full length RhoBTB1.  
  






Figure 5.5 - Interaction of RhoBTB1 deletion mutants and RhoA dominant 
negative mutant (RhoA-N19) 
A) Domain structure of GFP-RhoBTB1 and GFP-RhoBTB1 deletion mutants B) Cos7 
cells were co-transfected with empty pEGFP or vector encoding FLAG-RhoA-N19, 
GFP-RhoBTB1 and GFP-RhoBTB1 deletion mutants. After 24 hours, cells were lysed 
and incubated with GFP-binding protein coupled to agarose (GFP-trap®). Total lysates 
(input) and immunoprecipitates (GFP-IP) were probed to show expression of FLAG-
RhoA-N19, GFP-RhoBTB1 and GFP-RhoBTB1 deletion mutants. The interaction 
between FLAG-RhoA-N19 and GFP-RhoBTB1, FLAG-RhoA-N19 and GFP-RhoBTB1 
1-210, and FLAG-RhoA-N19 and GFP-RhoBTB1 1-427 are shown in the 
immunoprecipitates (GFP-IP). GAPDH is used as a loading control. Blots are 
representative of three independent experiments.  




As shown above (Figure 5.3), RhoBTB1 interacts with dominant negative RhoA-N19, 
which is believed to mimic the GDP-bound form of RhoA. Since RhoBTB1 interacts 
with cullin3 (Chapter 4) (Berthold et al., 2008a) and with RhoA, as well as BACURD1, 
RhoBTB1 could be competing with BACURD1 for RhoA binding in the cullin3 ubiquitin 
ligase complex.  
To study the hypothesis that RhoBTB1 and BACURD1 could compete for GDP-RhoA 
binding, BACURD1 was subcloned into a GFP-vector (section 2.2.13). To test if RhoA-
N19 was able to interact with BACURD1, Cos7 cells were co-transfected with vectors 
encoding FLAG-RhoA-N19, myc-RhoBTB1 and GFP-BACURD1. Both RhoBTB1 and 
BACURD1 interacted with RhoA-N19 (Figure 5.6).  
 
 
Figure 5.6 - Interaction of BACURD1 with RhoA-N19 
Cos7 cells were co-transfected with vector encoding FLAG-RhoA-N19 and myc-
RhoBTB1 or GFP-BACURD1. After 24 hours, cells were lysed and incubated with anti-
FLAG-agarose beads. Total lysates (input) and immunoprecipitates (FLAG-IP) were 
probed to show expression of FLAG-RhoA-N19, myc-RhoBTB1 and GFP-BACURD1. 
The interactions between FLAG-RhoA-N19 and myc-RhoBTB1, and FLAG-RhoA-N19 
and GFP-BACURD1 are shown in the immunoprecipitates (FLAG-IP). Blots are from 
one experiment.  




A competition assay was performed transfecting constant amounts of vectors encoding 
FLAG-RhoA-N19 and GFP-BACURD1, and different amounts of the vector encoding 
GFP-RhoBTB1. It was observed a decrease in the expression of GFP-BACURD1 and 
FLAG-RhoA-N19 in the presence of GFP-RhoBTB1. One possible explanation is a 
competition between the plasmids which is commonly observed when two or more 
plasmids are transfected at the same time in the cell. Even with this difference in 
expression, a decrease in the amount of BACURD1 which interacted with RhoA-N19 
was observed when RhoBTB1 was co-transfected (Figure 5.7). More repeats are 
necessary to confim that, since the results are not statistically significant. In addition, 
an unspecific binding between FLAG-beads and GFP-BACURD1 was observed. 










Figure 5.7 - Competition between RhoBTB1 and BACURD1 to interact with RhoA-
N19 
A) Cos7 cells were co-transfected with empty pFLAG-CMV-2 or vector encoding FLAG-
RhoA-N19 and GFP-BACURD1. Vector encoding GFP-RhoBTB1 is co-transfected with 
increasing amounts of DNA. After 24 hours, cells were lysed and incubated with anti-
FLAG-agarose beads. Total lysates (input) and immunoprecipitates (FLAG-IP) were 
probed to show expression of FLAG-RhoA-N19, GFP-RhoBTB1 and GFP-BACURD1. 
The interaction between FLAG-RhoA-N19 and GFP-RhoBTB1, and FLAG-RhoA-N19 
and GFP-BACURD1 are shown in the immunoprecipitates (FLAG-IP). GAPDH is used 
as a loading control. Blots are representative of three independent experiments. B) 
Graphs show the quantification of the band density of three independent experiments. 
All values were normalized by FLAG-RhoA-N19/GFP-BACURD1 condition. Values 
represent mean ± SEM.  
 




5.3 RhoBTB1 depletion alters cancer cell morphology in 3D   
Although depletion of RhoBTB1 do not seem to affect cell morphology in 2D in MDA-
MB-231 breast cancer cells (Figure 5.8, results from Borda D'Agua (2012)), the effect 
of RhoBTB1 depletion has not been tested in a 3D culture system. However, RhoBTB1 
could affect the morphology in 2D in other cell types. It is well known that 2D cultures 
are not the best representation of the environment that surrounds cells in organisms. 
Cells that grow on flat and hard plastic lose tissue-specific architecture, and have 
different mechanical and biochemical signals, and cell-cell communication to 3D 
systems (Pampaloni et al., 2007). 3D cultures have been shown to mimic better the 
situation in vivo, and these cultures are able to decrease the gap between in vitro and 
in vivo cancer models (Pampaloni et al., 2007). One of the most obvious differences 
between cells grown in 2D and 3D cultures is their morphology. Cells in a monolayer 
are able to adhere and spread horizontally. Once in a 3D environment, cells have the 
option to spread vertically which allows them to acquire a different morphology from in 
2D culture. Changes in cell geometry and organization can affect cell function including 











Figure 5.8 - RhoBTB1 depletion does not affect the actin cytoskeleton of MDA-
MB-231 cells 
A) siRNA-transfected MDA-MB-231 cells were detached from the transfection plate 24 
hours after transfection, seeded on collagen I-coated coverslips and allowed to adhere 
and spread for 48 hours. Cells were fixed and stained for F-actin. B) Graphs show 
quantification of 100 cells, from three independent experiments using Image J 
software. Box plots show the medians, 25th and 75th percentiles and whiskers show the 
5th and 95th percentiles. Scale bars = 100 µm. ns = not significant, compared to siRNA 
control, determined by one-way ANOVA analysis of variance followed by a Dunnett´s 
multiple comparison. Results were generated by Barbara Borda D’Agua.  
 
 
To study the effects of RhoBTB1 depletion on cancer cell morphology in a 3D 
environment, MDA-MB-231 and PC3 cells were embedded in a Matrigel matrix using a 
method stablished in our laboratory using PC3 cells (Colomba and Ridley, 2014). MDA-




MB-231 and PC3 cells were transfected with siRNA oligos targeting RhoBTB1 and 
after 48 hours, cells were embedded in Matrigel and incubated at 37ºC. Phase-contrast 
images of all the conditions were taken after 24 hours. Depletion of RhoA was used as 
a control because it is known that RhoA-depleted cells become elongated in a 3D 
Matrigel matrix. Both MDA-MB-231 and PC3 cells had a more rounded morphology 
when embedded in Matrigel, compared to 2D culture (Figure 5.9). However, when 
RhoBTB1 was depleted, the cells had a more elongated phenotype, similar to the 
phenotype observed for RhoA depletion (Figure 5.10 and 5.11). The effects on cell 
elongation are higher in PC3 cells, since these cells have a more rounded phenotype 
when compared to MDA-MB-231 cells (Figure 5.10 and 5.11). Because RhoBTB1 
depletion had similar results as RhoA depletion, this suggests that the effects observed 
following RhoBTB1 depletion could be caused by reduced RhoA signalling.  
 
Figure 5.9 - Morphology of MDA-MB-231 and PC3 cells in 2D and 3D cultures 
MDA-MB-231 and PC3 cells were grown on plastic or embedded in 3.5 mg/ml of 
Matrigel. Scale bar = 100 µm.  
 





Figure 5.10 - Morphology of MDA-MB-231 cells in Matrigel  
MDA-MB-231 cells transfected with siRNA oligos targeting RhoBTB1 or RhoA, or 
siRNA control. After 48 hours, cells were embedded in 3.5 mg/ml of Matrigel in a 96-
well plate coated with 7 mg/ml of Matrigel. Phase-contrast images were taken after 24 
hours. Images are representative of two independent experiments. Cells were scored 
based on their elongation: 0 = rounded morphology and 3 = elongated morphology. 
Graph shows quantification of cell elongation scores from two independent 
experiments. Ten different fields of each condition were analysed per experiment. 
Values represent mean ± SD. Scale bar = 100 μm. 





Figure 5.11 - Morphology of PC3 cells in Matrigel 
PC3 cells transfected with siRNA oligos targeting RhoBTB1 or RhoA, or siRNA control. 
After 48 hours, cells were embedded in 3.5 mg/ml of Matrigel in a 96-well plate coated 
with 7 mg/ml of Matrigel. Phase-contrast images were taken after 24 hours. Images are 
representative of three independent experiments. Cells were scored based on their 
elongation: 0 = rounded morphology and 3 = elongated morphology. Graph shows 
quantification of cell elongation scores from three independent experiments. Ten 
different fields of each condition were analysed per experiment. Values represent mean 
± SEM. *p<0.05, ****p<0.0001, compared to siRNA control, determined by one-way 
ANOVA analysis of variance followed by a Dunnett´s multiple comparison. Scale bar = 
100 μm. 





In order to investigate at a molecular level the effects of RhoBTB1 depletion, Borda 
D'Agua (2012) analysed whether RhoBTB1 depletion altered the expression or activity 
of the Rho GTPases RhoA, Rac1 and Cdc42. Only RhoA was affected by RhoBTB1 
depletion in MDA-MB-231 cells. siRNA-transfected cells showed a decrease in 
expression and activity of RhoA, without changes in the mRNA levels. This suggests 
that RhoBTB1 could be involved somehow in inhibiting RhoA degradation. It is known 
that RhoA is targeted for degradation after ubiquitination by at least three different 
complexes (Chen et al., 2009; Wang et al., 2003; Wei et al., 2013). As RhoBTB1 
consists of 2 BTB domains and it is able to bind cullin3, it is most likely that it affects 
ubiquitination of RhoA by the BACURD/cullin3 complex (Chen et al., 2009). The 
hypothesis is that RhoBTB1 is a cullin3-interacting BTB adaptor protein. RhoBTB1 
could compete with BACURD, a BTB adaptor protein, for the binding to GDP-RhoA, 
and thereby, inhibit RhoA degradation mediated by BACURD/cullin3 complex. It is 
known that Rho GTPases can regulate each other at different levels. The classic 
example is the crosstalk between RhoA and Rac as mentioned in Chapter 1 (section 
1.1.4).  
First, to confirm the effects of RhoBTB1 depletion on RhoA levels, MDA-MB-231 cells 
were transfected with siRNA oligos targeting cullin3 and RhoBTB1. Depletion of cullin3 
led to increase in RhoA protein levels as expected (Chen et al., 2009). However, after 6 
hours of treatment with cycloheximide, RhoA levels returned to basal levels (control). 
One possible explanation is that the remaining cullin3 (only 50% of knockdown) is able 
to degrade RhoA under these conditions. A decrease in RhoA levels was observed in 
RhoBTB1-depleted cells after 6 hours of cycloheximide treatment, but not without 
cycloheximide. In contrast, Borda D'Agua (2012) observed that RhoA levels were 
reduced by RhoBTB1 depletion even without cycloheximide treatment. One possible 
reason for this difference could be the efficiency of transfection. If the efficiency in 




RhoBTB1 depletion in Borda D’Agua’s experiments was higher than in this study, less 
RhoBTB1 protein would be available in cells, leading to stronger effects on RhoA 
degradation. Because there is no antibody available which detects endogenous 
RhoBTB1 in these cells, this can not be tested directly.  
After showing that RhoBTB1 had an effect on RhoA levels, a possible interaction 
between these two proteins was explored. Based on the hypothesis that RhoBTB1 is a 
BTB adaptor protein for cullin3 and protects RhoA from proteasomal degradation, the 
interaction of RhoBTB1 and RhoA was analysed, using vectors encoding GFP-RhoA, 
GFP-RhoA-V14 (constitutively active) and GFP-RhoA-N19 (dominant negative). It is 
known that the BACURD/cullin3 ubiquitin ligase complex binds preferentially to GDP-
RhoA (Chen et al., 2009). It was observed that BACURD1/2 interacted with 
recombinant GDP-bound RhoA but not with recombinat GTP-RhoA. BACURD1/2 could 
also interact more with RhoA-N19 when compared to wild-type RhoA (Chen et al., 
2009). Interestingly, RhoBTB1 interacted with RhoA-N19 and not with RhoA-V14. The 
RhoA-N19 mutant is to be either the GDP-bound or free-nucleotide (Coso et al., 1995). 
Because RhoBTB1 interacted only with this mutant, and not RhoA-V14 which is mostly 
GTP-bound in cells, it is likely to assume that RhoBTB1 does not interact with the GTP-
bound form of RhoA. If RhoBTB1 interacts with GDP-RhoA, similar to BACURD (Chen 
et al., 2009), then it should also associate with wild-type RhoA. However, this was not 
observed in the immunoprecipitation. One possible explanation is that wild-type RhoA 
was predominantly GTP-bound in cells. The interaction of RhoBTB1 with GTP-RhoA 
versus GDP-RhoA could be tested using recombinant RhoA protein. Using RhoBTB1 
deletion mutants, it was observed that RhoA-N19 interacts with the Rho domain of 
RhoBTB1. Therefore, the model for RhoBTB1 interactions is that it associates with 
RhoA through its Rho domain and cullin3 through its BTB domains (Figure 5.12). 
Another interesting result from this experiment is the fact that the levels of FLAG-RhoA-




N19 were higher in the total lysate in the presence of RhoBTB1. This supports a model 
where RhoBTB1 protect RhoA-N19 from degradation.  
 
 
Figure 5.12 - Model of interaction between RhoBTB1, RhoA and cullin3 
RhoBTB1 interacts with RhoA through its Rho domain and with cullin3 through its BTB 
domains.  
 
Since BACURD1 and RhoBTB1 can both interact with RhoA and cullin3, it was 
hypothesised that these proteins could compete for RhoA binding. The presence of 
exogenous RhoBTB1 decreased the interaction between BACURD1 and RhoA-N19. 
This suggests that RhoA degradation could be regulated by the level of RhoBTB1 
expression. When levels of RhoBTB1 are high, this protein binds preferentially to RhoA 
and cullin3, inhibiting RhoA ubiquitination or allowing a different type of ubiquitination 
that is not targeted for degradation. Therefore, when levels of RhoBTB1 are low, 
BACURD1 can bind to the complex, leading to increased RhoA degradation (Figure 
5.13). However, more experiments are necessary to confirm this hypothesis. For 




example, an ubiquitination assay to analyse the levels of RhoA ubiquitination after 




Figure 5.13 - Model of competition between RhoBTB1 and BACURD1 
High levels of RhoBTB1 lead to preferential binding to RhoA and cullin3, inhibiting 
RhoA degradation. When levels of RhoBTB1 are low, BACURD1 is the BTB adaptor 
protein in the complex, leading to RhoA degradation. 
 
 
Depletion of RhoBTB1 does not affect cell morphology of MDA-MB-231 cells in 2D 
culture (Borda D'Agua, 2012). However, in a 3D environment, RhoBTB1 depletion 
caused changes in the morphology of MDA-MB-231 and PC3 cells. These cells had a 
rounded morphology when embedded in a 3D Matrigel matrix. Depletion of RhoBTB1 
led to elongation of cancer cells, similar to the phenotype observed for RhoA depletion 
(Vega et al., 2011). As mentioned above (section 5.3), cells in a 3D environment are 
often able to interchange between two modes of migration: amoeboid and 
mesenchymal. During amoeboid movement, cells have a rounded morphology and 
require activation of Rho/ROCK signalling to increase levels of actomyosin contractility. 
On the other hand, during mesenchymal movement, cells have an elongated 




morphology and are dependent on Rac1-mediated cell migration. Therefore, the cross-
talk between Rho and Rac is important to control these different cell shapes (Parri and 
Chiarugi, 2010; Sailem et al., 2014). Because RhoBTB1 depletion causes elongation of 
cells and a decrease in RhoA levels, it is possible that RhoBTB1 regulates the actin 
cytoskeleton through RhoA signalling. One hypothesis is that RhoBTB1 protects RhoA 
from degradation which allows this protein to activate effectors that increase cell 
contractility, making the cells round up. It would be interesting to test the effects of 
RhoBTB1 depletion on the close relatives of RhoA, RhoB and RhoC (Wheeler and 
Ridley, 2004). Another possibility is that RhoBTB1 could reduce Rac1 signalling and 
lamellipodial extension, but there is no evidence so far that supports this hypothesis.  
RhoBTB1/RhoA-N19 interaction and changes in cell morphology in 3D culture after 
RhoBTB1 deletion are good indicators that RhoBTB1 might have an indirect role in 
controlling the actin cytoskeleton. Our model suggests that this could be through 
inhibiting RhoA degradation mediated by the BACURD/cullin3 complex. More 
experiments are necessary to elucidate the exact mechanism. It is necessary to 
confirm that RhoA and cullin3 interact with RhoBTB1 in the same complex and that 
RhoA binds directly to RhoBTB1. It would be important to study these interactions 
using recombinant proteins. An ubiquitination assay in vitro would be really interesting 
to analyse the real effects of RhoBTB1 in RhoA ubiquitination (Choo and Zhang, 2009). 
This approach could be also used to study more directly a potential competition 
between RhoBTB1 and BACURD in the cullin3 ubiquitin ligase complex.  
 




6 Interaction of RhoBTB1 and ROCK1 
6.1 Introduction 
Based on the interaction of RhoBTB1 with RhoA observed in Chapter 5, the effects of 
RhoBTB1 depletion on RhoA effectors was analysed. It was predicted that RhoBTB1 
would affect the activity of the RhoA effectors ROCK1 or ROCK2 indirectley through its 
interaction with RhoA. Surprisingly, an interaction between RhoBTB1 and ROCK1 was 
observed and explored in this chapter. As mentioned in Chapter 1, there is a complex 
crosstalk between Rho GTPases that can involve not only their regulators but also their 
effectors. The interaction between RhoBTB1 and ROCK1 could be part of one of these 
crosstalks.  
Rho-associated kinases (ROCKs) are serine/threonine kinases that are part of the 
AGC family of protein kinases (Amano et al., 2010). These proteins have a kinase 
domain at their N-terminus, a long amphipathic α-helix that forms a coiled-coil structure 
in the middle, and a cysteine-rich zinc finger-like motif and a pleckstrin-homology (PH) 
region in their C-terminus (Ishizaki et al., 1997). Both N- and C-terminal regions are 
important for ROCK protein activity (Amano et al., 2010). In mammals, there are two 
ROCKs, ROCK1 and ROCK2, that were first identified as RhoA-binding proteins 
(Ishizaki et al., 1996; Leung et al., 1995; Matsui et al., 1996). The amino-acid 
sequences of ROCK1 and ROCK2 show 65% of overall identity with 92% identity of 
their kinase domain in humans (Figure 6.1A) (Amano et al., 2010; Riento and Ridley, 
2003). The consensus phosphorylation sequence for ROCKs is R/KXS/T or R/KXXS/T 
(where R is arginine, K is lysine, X is any amino acid, S is serine and T is threonine) 
(Kawano et al., 1999; Sumi et al., 2001). However, some substrates are 
phosphorylated on sites that do not conform to the consensus phosphorylation 
sequence. One example is Rnd3/RhoE which is phosphorylated on serine 222 
(HMPSR) by ROCK1 (Riento et al., 2005). Crystal structure and biochemical studies 




have shown that ROCKs dimerise through two different regions: the N-terminal region 
and the coiled-coil region (Figure 6.1B) (Jacobs et al., 2006; Shimizu et al., 2003; 
Yamaguchi et al., 2006).  
 
 
Figure 6.1 - ROCK1 and ROCK2 
A) Domain organization of ROCK1 and ROCK2 in humans. DETD1113/G: conserved 
sequence in ROCK1 cleaved by caspase 3. IGLD1131: conserved sequence in 
ROCK2 cleaved by granzyme B. B) Diagram of the dimer structure of ROCKs. ROCKs 
form parallel dimers through the N-terminal and central coiled-coil regions.  
 
6.1.1 ROCK effectors 
ROCKs induce the formation of stress fibres and focal adhesions in a variety of cell 
lines (Amano et al., 1997; Ishizaki et al., 1997; Leung et al., 1996). They phosphorylate 
the myosin-binding subunit (MBS, also known as myosin phosphatase-targeting 
subunit, MYPT) of myosin phosphatase which inhibits its activity, leading to an increase 
in phosphorylated myosin light chain 2 (MLC2) (Kawano et al., 1999; Kimura et al., 
1996). ROCKs can also directly phosphorylate MLC2 (Amano et al., 1996a). 
Phosphorylated MLC2 promotes the assembly of myosin II filaments and then their 
interaction with F-actin to form stress fibres (Ridley, 1999). It is believed that ROCK1 




and ROCK2 have the same role in regulating MLC2 phosphorylation. Knock out of both 
ROCK1 and ROCK2 is necessary to affect pMLC (Kumper et al., 2016). ROCK1 and 
ROCK2 knockout mice have indicated the two kinases have redundant roles in cell 
proliferation and tumorigenesis (Kumper et al., 2016). However, in some models, 
ROCK1 and ROCK2 have distinct roles. For example, in rat embryo fibroblasts only 
depletion of ROCK1 affects assembly of stress fibres and focal adhesions while 
ROCK2 seems to be involved in phagocytosis (Yoneda et al., 2005). ROCKs can also 
control the actin cytoskeleton through LIM kinase (LIMK)/cofilin pathway. LIMK is 
phosphorylated by ROCK which leads to phosphorylation of cofilin-induced and 
inhibition of actin depolymerisation. This stabilizes F-actin and contributes to increased 
actomyosin contractility (Maekawa et al., 1999). 
Adducin, a membrane-associated actin-interacting protein, is another ROCK substrate. 
ROCK2 phosphorylates adducin which increases its interaction with F-actin (Kimura et 
al., 1998). As well as affecting the actin cytoskeleton, ROCKs phosphorylate many 
other substrates involved in a range of cellular processes (Amano et al., 2010; Morgan-
Fisher et al., 2013). For example, vimentin and glial fibrillary acidic protein (GFAP) are 
intermediate filaments that are phosphorylated during cytokinesis by ROCK1 and 
ROCK2, respectively, which prevents filament formation (Goto et al., 1998; Kosako et 
al., 1997).  
6.1.2 Regulation of ROCKs 
ROCKs can be regulated by protein interactions, phosphorylation and proteolysis. The 
C-terminal region containing the Rho-binding domain and the PH region interacts with 
the kinase domain, inhibiting ROCK activity (Amano et al., 1999). Interaction of GTP-
bound RhoA with Rho-binding domain (RBD) in the coiled-coil region, is believed to 
release the kinase domain from this inhibition (Amano et al., 1999; Fujisawa et al., 
1996; Riento and Ridley, 2003). However, recent data suggest that ROCK2 is present 




in cells in an extended conformation which would be incompatible with intramolecular 
autoinhibition. The authors propose that ROCK2 is constitutively active, based on an in 
vitro activity assay (Truebestein et al., 2015). The activity to ROCK2 is instead 
suggested to be regulated by the length of its coiled-coil region and not by binding to 
membranes, RhoA or phosphorylation (Truebestein et al., 2015).  
Another way of activating ROCKs is through proteolytic cleavage of the C-terminal 
region. During apoptosis, caspase-3 cleaves ROCK1 at a conserved DETD1113/G 
sequence (Figure 6.1), leading to constitutive kinase activity and cell blebbing 
(Coleman et al., 2001; Sebbagh et al., 2001). ROCK2 is also activated during 
apoptosis, but in a caspase-independent manner. Granzyme B, a potent proapoptotic 
protease contained in cytotoxic granules released by natural killer cells or cytotoxic T 
lymphocytes (Lord et al., 2003), cleaves ROCK2 at the IGLD1131 sequence (Figure 
6.1), which is not found in ROCK1 (Sebbagh et al., 2005).  
ROCK can be negatively regulated by small GTP binding proteins. Gem and Rad have 
been shown to bind to ROCK and inhibit MLC phosphorylation. This leads to a 
reduction in stress fibre and focal adhesion formation, neurite retraction and Rho-
dependent transformation (Ward et al., 2002).  
ROCKs can be autophosphorylated (Ishizaki et al., 1996; Leung et al., 1995) and 
phosphorylated by other kinases. Phosphorylation does not seem necessary for kinase 
activity of ROCK, but it could regulate ROCK signalling through the phosphorylation of 
other regions (Julian and Olson, 2014). Autophosphorylation of ROCK1 on Ser1333 
and of ROCK2 on Ser1336 are markers of kinase activation but these modifications do 
not regulate the catalytic activity (Chuang et al., 2013; Chuang et al., 2012; Julian and 
Olson, 2014). Phosphorylation might affect binding of ROCK to RhoA. For example, 
phosphorylation of ROCK2 on Tyr722 decreases binding to RhoA while 
dephosphorylation of ROCK2 by Shp-2 on the same site increases RhoA/ROCK2 




signalling (Lee and Chang, 2008; Lee et al., 2010). However, the mechanistic basis of 
these observations is unclear. ROCK2 is also a substrate of polo-like kinase-1 (Plk1) 
and these proteins co-localise during cytokinesis. In vitro, Plk1 and RhoA cooperate to 
increase the kinase activity of ROCK2 (Lowery et al., 2007).  
ROCKs have been shown to be regulated by microRNAs in some cancers. For 
example, transfection of microRNA-584 into clear renal cell adenocarcinoma cell lines 
leads to a decrease in cell motility and expression of ROCK1 (Ueno et al., 2011). In 
hepatocellular carcinoma cells, ectopic expression of microRNA-124 reduces ROCK2 
expression and decreases formation of stress fibres, filopodia and lamellipodia (Zheng 
et al., 2012).  
6.1.3 ROCKs in cancer 
ROCKs have been shown to be involved in several steps of cancer progression 
(Narumiya et al., 2009; Schofield and Bernard, 2013). Somatic mutations that encode 
constitutively active forms of both ROCK proteins are found in some human cancers 
(Kale et al., 2015; Morgan-Fisher et al., 2013). In addition, high expression of ROCK1 
and ROCK2 has been associated with a more aggressive behaviour of cancer cells 









6.2 Effects on RhoA downstream effectors after RhoBTB1 depletion in 
MDA-MB-231 cells  
As shown in Chapter 5 and by Borda D'Agua (2012), depletion of RhoBTB1 in MDA-
MB-231 cells can decrease RhoA expression. To determine whether RhoBTB1 
affected signalling downstream of RhoA, levels of phosphorylated MLC2, 
phosphorylated cofilin, phosphorylated LIMK1/2, ROCK1 and ROCK2 were evaluated 
by western blotting (Figure 6.2 and Figure 6.3). Unexpectedly, only expression of 
ROCK1 and ROCK2 was reduced following RhoBTB1 depletion (Figure 6.3).  
RhoBTB1 depletion did not appear to affect phosphorylation or expression of known 
RhoA/ROCK effectors (e.g. MLC, cofilin and LIMK). These results could indicate that 
the decrease in ROCK levels is not sufficient to cause detectable effect on these 
effectors, and indeed other kinases (e.g. PAK) are able to phosphorylate the same 
substrates (Edwards et al., 1999). However, this experiment was performed only once 





Figure 6.2 - RhoBTB1 depletion does not affect levels of p-LIMK1/2, p-cofilin and 
p-MLC2 in MDA-MB-231 cells 
MDA-MB-231 cells were transfected with siRNA control or siRNA oligos #1 and #2 
targeting RhoBTB1. After 72 hours, cells were lysed and protein expression was 












Figure 6.3 - RhoBTB1 depletion reduces levels of ROCK1 and ROCK2 proteins in 
MDA-MB-231 cells 
MDA-MB-231 cells were transfected with siRNA control or siRNA oligos #1 and #2 
targeting RhoBTB1. After 72 hours, cells were lysed and protein expression was 
analysed by western blotting. GAPDH is used as a loading control. Graphs show the 
quantification of the band density of five independent experiments, normalised to 
GAPDH and relative to siRNA control.  
 
 
To determine whether RhoBTB1 regulates ROCK1 and ROCK2 expression at the 
transcriptional level, the mRNA levels of ROCK1 and ROCK2 were quantified by qPCR 
after RhoBTB1 knockdown. No significant difference in the mRNA levels of ROCK1 or 
ROCK2 were observed (Figure 6.4).  
 







Figure 6.4 - mRNA levels of ROCK1 and ROCK2 after RhoBTB1 depletion in MDA-
MB-231 cells 
MDA-MB-231 cells were transfected with siRNA control or siRNA oligos #1 and #2 
targeting RhoBTB1. After 72 hours, mRNA was isolated and the amount of RhoBTB1, 
ROCK1 and ROCK2 cDNA was determined by quantitative PCR. Graphs show data of 
three independent experiments. All values were normalized to siRNA control.  
 
6.3 Effects of ROCK1 and ROCK2 depletion in MDA-MB-231 cells on 
endothelial interaction 
 
In an attempt to correlate the effects of RhoBTB1 knockdown on cancer cell 
extravasation and ROCK1/2 expression, MDA-MB-231 cells were transfected with 
siRNAs targeting ROCK1, ROCK2 or both ROCK1 and ROCK2 together (Figure 6.5A). 
Adhesion and intercalation of these cells into endothelial cells were analysed. 
Depletion of ROCK1/2 together or separately increased adhesion (Figure 6.5B) which 
is the opposite of what is reported for RhoBTB1 depletion (Borda D'Agua, 2012). In 
contrast, intercalation was not significantly affected (Figure 6.5C), indicating that the 




reduction in MDA-MB-231 cell intercalation following RhoBTB1 depletion is unlikely to 
be related to lower ROCK1/2 levels.  
 
 
Figure 6.5 - Effects of ROCK1/2 knockdown on adhesion and intercalation of 
MDA-MB-231 cells into endothelial cells 
A) Blots show the expression of ROCK1 and ROCK2 after siRNA transfection with 
oligos targeting ROCK1, ROCK2 and ROCK1/2 together, or control siRNA. B) HUVECs 
were grown to confluence on collagen I-coated plates. CFSE-labelled cancer cells were 
added and allowed to adhere 15 minutes. Not-adherent or loosely adherent cells were 
washed of and the levels of fluorescence were measured. Graphs show data from at 
least three independent experiments, each carried out in quintuplicate. All values were 
normalized to siRNA control. Values represent mean ± SEM. *p<0.05, compared to 
siRNA control, determined by unpaired one-way ANOVA, followed by Dunnett´s test. 
C) MDA-MB-231 cells were monitored by timelapse microscopy acquiring an image 
every 3-5 min over 6 hours. The graph shows the percentage of intercalated cells at 
the indicated time points from two independent experiments. Nine different fields from 
each condition were analysed per experiment (~ 30 cells per field). Values represent 
mean ± SD. MOCK is the condition where the cells are not transfected. 
 
6.4 RhoBTB1 interacts with ROCK1  
 
To investigate how RhoBTB1 regulates the expression of ROCK proteins, the 
possibility that RhoBTB1 interact with ROCK1 was tested. GFP-RhoBTB1 was co-




expressed with myc-ROCK1 and the interaction of the proteins was evaluated after 
immunoprecipitation. RhoBTB1 co-immunoprecipitated with ROCK1 1-727 (Figure 6.6).  
 
 
Figure 6.6 - RhoBTB1 interacts with ROCK1 
Cos7 cells were transfected with empty pEGFP or vectors encoding myc-ROCK1 1-727 
and GFP-RhoBTB1. After 24 hours, cells were lysed and incubated with GFP-binding 
protein coupled to agarose (GFP-trap®). Total lysates (input) and immunoprecipitates 
(GFP-IP) were probed to show levels of myc-ROCK1 1-727 and GFP-RhoBTB1. The 
interaction between myc-ROCK1 1-727 and GFP-RhoBTB1 is shown in the 
immunoprecipitates (GFP-IP). GAPDH is used as a loading control. Blots are 
representative of two independent experiments. 
 
To determine which region of ROCK1 interacted with RhoBTB1, Cos7 cells we 
transfected with vectors encoding RhoBTB1 and different regions of ROCK1 (Figure 
6.7A). RhoBTB1 interacted with full length ROCK1, ROCK1 1-1080, ROCK1 1-727 and 
ROCK1 1-540 but not with ROCK1 1-420 and ROCK1 1096-1394 (Figure 6.7B). 






Figure 6.7 - RhoBTB1 interaction with ROCK1 deletion mutants 
A) Domain structure of ROCK1 and ROCK1 deletion mutants. B) Cos7 cells were 
transfected with empty myc-pRK5 or vectors encoding GFP-RhoBTB1, myc-ROCK1 
and myc-ROCK1 deletion mutants. After 24 hours, cells were lysed and incubated with 
GFP-binding protein coupled to agarose (GFP-trap®). Total lysates (input) and 
immunoprecipitates (GFP-IP) were probed to show levels of GFP-RhoBTB1, myc-
ROCK1 and myc-ROCK1 deletion mutants. The interaction between GFP-RhoBTB1 
and myc-ROCK1 deletion mutants is shown in the immunoprecipitates (GFP-IP). 
GAPDH is used as a loading control. Blots are representative of two independent 
experiments.  
 
To determine if the Rho domain of RhoBTB1 was involved in ROCK1 interaction, a pull 
down assay using the recombinant GST-RhoBTB1 1-301 (Figure 6.8A) was performed 
with lysates of Cos7 cells transfected with vectors encoding different regions of 




ROCK1. RhoBTB1 1-301 was able to interact with full length ROCK1, ROCK1 1-1080, 
ROCK1 1-727 and ROCK1 1-540 (Figure 6.8B). Weak bands were observed for both 
ROCK1 1-420 and ROCK1 1096-1394 (Figure 6.8B). However, these bands could be 
only background. To confirm this, a condition with only GST should be included. More 















Figure 6.8 - GST-RhoBTB1 1-301 interaction with ROCK1 deletion mutants  
A) Domain structure of RhoBTB1, RhoBTB1 1-301, ROCK1 and ROCK1 deletion 
mutants. B) Cos7 cells were transfected with vectors encoding myc-ROCK1 and myc-
ROCK1 deletion mutations. After 24 hours, cells were lysed and incubated with GST-
RhoBTB1 1-301 beads. Total lysates (input) and pull down were probed to show levels 
of myc-ROCK1 and myc-ROCK1 deletion mutants. The interaction between GST-
RhoBTB1 1-301 and myc-ROCK1 deletion mutants is shown in the pull down. GAPDH 
is used as a loading control. Ponceau staining of the western blot was used to verify 
GST-RhoBTB1 1-301 protein levels. Blots are from one experiment.  




Based on the results obtained with the recombinant RhoBTB1 1-301 and ROCK1 
deletion mutants (Figure 6.8), it appears that the RhoBTB1 1-301 is sufficient for the 
interaction with ROCK1. Interestingly, the two ROCK1 deletion mutants (ROCK1 1-420 
and ROCK1 1096-1394) that did not interact with RhoBTB1 lack a region of ROCK1 
where the REM (Ras exchange motif, also known as HR1 domain) domain is located 





Figure 6.9 - Domain structure of ROCK1 deletion mutants 
The magenta rectangle shows the region of ROCK1 that is missing in both ROCK1 1-
420 and ROCK1 1096-1394.   
 
To confirm that the region between amino acids 420 and 540 is important for ROCK1 
and RhoBTB1 interaction, another co-immunoprecipitation was performed using a 
construct encoding ROCK1 375-727 (Figure 6.10A) (Garg et al., 2008). RhoBTB1 
interacted with ROCK1 375-727 but not with ROCK1 1-420, as shown previously 
(Figure 6.10B). 






Figure 6.10 - RhoBTB1 interacts with ROCK1 375-727 but not with ROCK1 1-420 
A) Domain structure of ROCK1 and ROCK1 deletion mutants. B) Cos7 cells were 
transfected with vectors encoding GFP-RhoBTB1 and myc-ROCK1 deletion mutants. 
After 24 hours, cells were lysed and incubated with GFP-binding protein coupled to 
agarose (GFP-trap®). Total lysates (input) and immunoprecipitates (GFP-IP) were 
probed to show levels of GFP-RhoBTB1 and myc-ROCK1 deletion mutants. The 
interaction between GFP-RhoBTB1 and myc-ROCK1 deletion mutants is shown in the 
immunoprecipitates (GFP-IP). GAPDH is used as a loading control. Blots are from one 
experiment.  
 




Taken together, these results suggest that the interaction of RhoBTB1 and ROCK1 
might be mediated through the Rho domain of RhoBTB1 and the REM domain of 
ROCK1. 
Since RhoBTB1 and ROCK1 interact, one possible pathway that could be involved in 
the regulation of ROCK1 expression is proteasomal degradation after ubiquitination by 
RhoBTB1/cullin3 ubiquitin ligase complex. To test this hypothesis, MDA-MB-231 cells 
were treated with the neddylation inhibitor MLN4924 for 2 hours. Inhibition of cullin3 
activity did not affect total protein levels of ROCK1 (Figure 6.11). This suggests that 
RhoBTB1 affects the expression of ROCK1 through another pathway. However, it 
would be important to repeat the experiment after RhoBTB1 depletion. Because 
RhoBTB1 could be protecting ROCK1 from degradation, depletion of RhoBTB1 could 






Figure 6.11 - Inhibition of cullin3 does not affect ROCK1 total protein levels in 
MDA-MB-231 cells 
MDA-MB-231 cells were treated with 1 μM or 2 μM of MLN4924 or DMSO as solvent 
control for 2 hours. Cells were lysed and protein expression was analysed by western 
blotting. GAPDH is used as a loading control. Graph shows the quantification of the 
band density of five independent experiments, normalised to GAPDH and relative to 
DMSO. All values were normalized to DMSO condition. Values represent mean ± SEM.  
 




6.5 Phosphorylation of RhoBTB1 by ROCK1 
ROCK1 is a serine/threonine kinase that can interact with RhoBTB1 and could 
therefore potentially phosphorylate it. To investigate whether ROCK1 might 
phosphorylate RhoBTB1, cells expressing myc-RhoBTB1 were treated with the ROCK 
inhibitor H1152 (Sasaki et al., 2002). Treatment with ROCK inhibitor decreased levels 
of phosphorylated RhoBTB1 at 4 hours after addition (Figure 6.12). These were 
preliminary results and more repeats are necessary.  
 
 
Figure 6.12 - ROCK inhibitor reduces RhoBTB1 phosphorylation 
Cos7 cells were transfected with myc-pRK5 and myc-RhoBTB1. After 24 hours, cells 
were treated with 5 μM H1152 (ROCK inhibitor) for 4 hours. Cells were then lysed and 
incubated with anti-myc-agarose beads. Immunoprecipitated lysates were resolved in a 
4-12% SDS-polyacrylamide gel and transferred to a low fluorescence PVDF 
membrane. The membrane was incubated with ProQ Diamond stain (phosphorylated 
protein) followed by incubation with SyPRO Ruby (total protein). Blots are from one 
experiment. Graph shows the relative value of phosphorylated protein/total protein, 
normalized to myc-RhoBTB1 without H1152 treatment.  




Since these preliminary data suggest that inhibition of ROCK1/2 activity decreases 
RhoBTB1 phosphorylation, a kinase assay using 32P-ATP was performed to analyse 
phosphorylation of RhoBTB1 by ROCK1. ROCK1 was able to phosphorylate RhoBTB1 
(Figure 6.13A) and the Rho domain of RhoBTB1 (RhoBTB1 1-210) (Figure 6.13B). The 
kinase dead ROCK1 (ROCK1 1-727 (K205A)) was not able to phosphorylate RhoBTB1 
(Figure 6.13A).  
 
Figure 6.13 - Phosphorylation of RhoBTB1 by ROCK1 
A) Cos7 cells were transfected with vectors encoding myc-RhoBTB1, myc-ROCK1 1-
727 or myc-ROCK1 1-727 (K205A). After 24 hours, cells were lysed and incubated with 
anti-myc-agarose beads. Immunoprecipitated lysates were combined as indicated (myc 
RhoBTB1 alone, myc-RhoBTB1 and myc-ROCK1 1-727, myc-RhoBTB1 and myc-
ROCK1 1-727 (K205A) (kinase dead), and myc-RhoBTB1 and recombinant GST-
ROCK1 (17-535)). Samples were incubated in a kinase buffer containing 32P-ATP for 
30 minutes and then resolved in a 4-12% SDS polyacrylamide gel. Bands show the 
phosphorylated proteins. Results are representative of three independent experiments. 
B) Cos7 cells were transfected with vectors encoding GFP, GFP-RhoBTB1, GFP-
RhoBTB1 1-210 and myc-ROCK1 1-727. After 24 hours, cells were lysed and 
incubated with either GFP-binding protein coupled to agarose (GFP-trap®) or anti-myc-
agarose beads. Immunoprecipitated lysates were combined as indicated (GFP and 
myc-ROCK1 1-727, GFP-RhoBTB1 alone, GFP-RhoBTB1 and myc-ROCK1 1-727, and 
GFP-RhoBTB1 1-210 and myc-ROCK1 1-727). Samples were incubated in a kinase 
buffer containing 32P-ATP for 30 minutes and then resolved in a 4-12% SDS 
polyacrylamide gel. Bands (top) show the phosphorylated proteins. Results are 
representative of two independent experiments. 




To determine whether any of the sites on PhosphoSite Plus website 
(www.phosphosite.org) (Hornbeck et al., 2015) is phosphorylated by ROCK1, all 5 
possible phosphorylation sites were mutated to alanine 
(S69A/T398A/S480A/T483A/S485A = RhoBTB1 S3T2A) (section 2.2.10) (Table 6-1). 
The PhosphoSite Plus website contains data from low- and high-throughput (LTP and 
HTP) studies. A kinase assay using 32P-ATP was performed to analyse 
phosphorylation of the RhoBTB1 mutant by ROCK1. ROCK1 was still able to 
phosphorylate RhoBTB1-S3T2A (lane 4) (Figure 6.14). This suggests that there are 
other phosphorylation sites on RhoBTB1 that are not on the PhosphoSite Plus website. 
This mutant seems to be less stable than wild-type RhoBTB1 because there is less of 
this protein in the input. ROCK 1-540 was used in the assays to try to have a better 
separation between RhoBTB1 and ROCK1 bands.  
 
Table 6-1 Possible phosphorylated sites on RhoBTB1 (PhosphoSite Plus 
database) 
Amino acid Sequence Conserved in multiple 
species* 
Mutation 
S69 CQEVLERSRDVVD CQEVLERSRDVVD S69A 
T398 RMGPMTVVRMDA RMGPMTVVRMDA T398A 
S480 KECLSKGTFSDV KECLSKGTFSDV S480A 
T483 KECLSKGTFSDV KECLSKGTFSDV T483A 
S485 KECLSKGTFSDV KECLSKGTFSDV S485A 
 
*bold: conversed residues. Homo sapiens, Pan troglodytes, Macaca mulatta, Lupus familis, Mus musculus, 
Rattus norvegicus, Ornithorhyncus anatinus, Gallus gallus, Xenopus laevis, Brachydanio rerio. 
 
 







Figure 6.14 - Mutation of possible phosphorylation sites does not prevent 
phosphorylation of RhoBTB1 
A) Mutation of 5 possible phosphorylation sites on RhoBTB1 B) Cos7 cells were 
transfected with vectors encoding GFP, GFP-RhoBTB1, GFP-RhoBTB1 S3T2A or 
myc-ROCK1 1-540. After 24 hours, cells were lysed and incubated with either GFP-
binding protein coupled to agarose (GFP-trap®) or anti-myc-agarose beads. 
Immunoprecitated lysates were combined as indicated (GFP and myc-ROCK1 1-540, 
GFP-RhoBTB1 alone, GFP-RhoBTB1 and myc-ROCK1 1-540, and GFP-RhoBTB1 
S3T2A and myc-ROCK1 1-540). Samples were incubated in a kinase buffer containing 
32P-ATP for 30 minutes and then resolved in a 4-12% SDS polyacrylamide gel. Bands 




show the phosphorylated proteins. Results are representative of three independent 
experiments. 
The role of RhoBTB1 phosphorylation is unknown. Phosphorylation can affect different 
aspects of a protein including activity, stability, conformation and localisation which in 
turn could influence protein-protein interactions (Nishi et al., 2011). RhoBTB1 mutants 
were therefore used to study the possible effects of phosphorylation on RhoBTB1 
interaction with other proteins. Several different point mutations were introduced in the 
5 phosphorylation sites on RhoBTB1 (Figure 6.14A).  
Because RhoBTB1 interacts with RhoA through its Rho domain (Chapter 5), the serine 
69 (S69) localised in the Rho domain (Figure 6.14A) was mutated to an alanine and 
this mutant was used in a co-immunoprecipitation assay with myc-RhoBTB1 and GFP-
RhoA-N19. RhoA-N19 interacted with both RhoBTB1 and RhoBTB1 S69A (Figure 
6.15), suggesting that the phosphorylation of this residue is not necessary for this 
interaction. These are only preliminary results and more repeats are necessary. 
 
 







Figure 6.15 - Mutation of serine 69 does not affect RhoBTB1 interaction with 
RhoA-N19 
Cos7 cells were transfected with empty myc-pRK5 and pEGFP or vectors encoding 
myc-RhoBTB1, myc-RhoBTB1 S69A and GFP-RhoA-N19. After 24 hours, cells were 
lysed and incubated with anti-myc-agarose beads. Total lysates (input) and 
immunoprecipitates (myc-IP) were probed to show levels of myc-RhoBTB1, myc-
RhoBTB1 S69A and GFP-RhoA N19. The interaction between myc-RhoBTB1 and 
GFP-RhoA-N19, and myc-RhoBTB1 S69A and GFP-RhoA-N19 is shown in the 








It is known that cullin3 interacts with RhoBTB1 (Chapter 4) (Berthold et al., 2008a) but 
not whether phosphorylation regulates this interaction. To study if phosphorylation is 
involved in the interaction between cullin3 and RhoBTB1, two different approaches 
were used: single point mutations of phosphorylation sites and multiple point mutations 
of the 5 possible phosphorylation sites.  
Serine 480 (S480) and threonine 483 (T483), localised close to the second BTB 
domain, were mutated to alanine and these mutants were used in an 
immunoprecipitation assay. Cullin3 and RhoA-N19 were able to interact with RhoBTB1, 
RhoBTB1 S480A and RhoBTB1 T483A (Figure 6.16). However, mutation of T483 
seemed to increase interaction with cullin3 and mutation of S480 seemed to decrease 












Figure 6.16 - Mutation of serine 480 or threonine 483 affects RhoBTB1 interaction 
with RhoA-N19 and cullin3 
Cos7 cells were transfected with empty myc-pRK5 and pEGFP or vectors encoding 
myc-RhoBTB1, myc-RhoBTB1 S480A, myc-RhoBTB1 T483A and GFP-RhoA-N19. 
After 24 hours, cells were lysed and incubated with anti-myc-agarose beads. Total 
lysates (input) and immunoprecipitates (myc-IP) were probed to show levels of myc-
RhoBTB1, myc-RhoBTB1 S480A, myc-RhoBTB1 T483A, GFP-RhoA-N19 and cullin3. 
The interaction between myc-RhoBTB1 and GFP-RhoA-N19, myc-RhoBTB1 and 
cullin3, myc-RhoBTB1 S480A and GFP-RhoA-N19, myc-RhoBTB1 S480A and cullin3, 
myc-RhoBTB1 T483A and GFP-RhoA-N19, and myc-RhoBTB1 T483A and cullin3 is 
shown in the immunoprecipitates (myc-IP). GAPDH is used as a loading control. 
Graphs show the quantification of the band density from one experiment. Band density 
of cullin3 (myc IP) or GFP-RhoA-N19 was normalized by myc-RhoBTB1 (myc IP). All 









In addition to the single point mutations, interaction of RhoBTB1 and cullin3 was 
analysed using RhoBTB1 containing multiple point mutations. Multiple mutations could 
lead to a stronger effect on RhoBTB1 and cullin3 interaction. Mutation of 4 sites 
together, serine 69 (S69), serine 480 (S480), threonine 483 (T483) and serine 485 
(S485) to alanine (RhoBTB1 S3T1A), seemed to increase binding of RhoBTB1 to 
cullin3 (lane 4) (Figure 6.17). However, when threonine 398 (T398) was also mutated 
to an alanine (RhoBTB1 S3T2A), the interaction was decreased (lane 5) (Figure 6.17). 
The single mutation of serine S69 (S69) to alanine also seemed to decrease interaction 
between RhoBTB1 and cullin3. RhoBTB1 S3T1 and RhoBTB1 S3T2 seems to be less 
stable than wild-type RhoBTB1 due to reduced levels of these mutants in the input.  
 
 
Figure 6.17 - Effect of different RhoBTB1 residues on cullin3 interaction 
Cos7 cells were transfected with empty myc-pRK5 or vectors encoding myc-RhoBTB1, 
myc-RhoBTB1 S69A, myc-RhoBTB1 S3T1A and myc-RhoBTB1 S3T2A. After 24 
hours, cells were lysed and incubated with anti-myc-agarose beads. Total lysates 
(input) and immunoprecipitates (myc-IP) were probed to show levels of myc-RhoBTB1, 
myc-RhoBTB1 S69A, myc-RhoBTB1 S3T1A, myc-RhoBTB1 S3T2A and cullin3. The 
interaction between myc-RhoBTB1 and cullin3, myc-RhoBTB1 S69A and cullin3, myc-
RhoBTB1 S3T1A and cullin3, and myc-RhoBTB1 S3T2A and cullin3 is shown in the 
immunoprecipitates (myc-IP). GAPDH is used as a loading control. Graph shows the 
quantification of the band density from two independent experiments. Band density of 
cullin3 (myc IP) was normalized by myc-RhoBTB1 (myc IP). All values were normalized 
to myc-RhoBTB1 condition. Values represent mean ± SD.  






Depletion of RhoBTB1 reduced protein levels of ROCK1 and ROCK2, without changing 
their mRNA levels. This suggests that RhoBTB1 could protect ROCKs from 
degradation, similar to RhoA (Chapter 5). So far, ROCKs have not been reported to be 
targets for proteasomal degradation. In contrast to RhoA levels (Chapter 5), inhibition 
of cullin3 activity did not affect protein levels of ROCK1. RhoBTB1 could be protecting 
ROCK1 from degradation by other ubiquitin ligases, instead of cullin3-associated 
ubiquitin ligase complexes. Another possible explanation for the apparent decrease in 
ROCK expression is that RhoBTB1 affects localisation of ROCKs between soluble and 
insoluble fractions of cells rather than total levels. It has been shown that serum-
starvation and/or stimulation with thrombin cause translocation of a small percentage of 
ROCKs to the Triton X-100 insoluble fraction (Fujita et al., 1997; Sahai et al., 2001).  
When RhoBTB1 is depleted, there is a decrease in ROCK levels in the blot (Figure 6.3) 
which corresponds only to the soluble fraction. To confirm this hypothesis, a 
fractionation assay should be performed to compare the levels of ROCKs in soluble 
and insoluble fractions with or without RhoBTB1 depletion.  
To investigate if the effect of depleting RhoBTB1 on ROCK1 and ROCK2 levels could 
be involved in its effect in decreasing MDA-MB-231 cell adhesion to and intercalation 
into endothelial cells (Borda D'Agua, 2012), ROCK1 and ROCK2 were depleted in 
MDA-MDA-231 cells. Although double depletion of ROCK1 and ROCK2 led to an 
increase in cancer cell adhesion to endothelial cells, the levels were similar to only 
depletion of ROCK1, suggesting that the phenotype observed is a consequence of a 
decrease in ROCK1 protein levels. This is the opposite of what was observed for 
RhoBTB1 depletion, and therefore it is unlikely that this RhoBTB1 effect is related to 
the decrease in ROCK1 levels. It has been shown that depletion of ROCK1 and 
ROCK2 can affect cell adhesion in different ways. For example, depletion of ROCK1, 
but not ROCK2, decreases adhesion of keratinocytes to fibronectin (Shi et al., 2013). 




The reasons for this difference are still unknown, but the activation of distinct receptors 
by ROCK1 and ROCK2 is a possible explanation. These results suggest that the 
phenotype of RhoBTB1 depletion does not involve the decrease in ROCK1 or ROCK2 
levels. No difference in cancer cell intercalation into endothelial cells was observed 
after ROCK1 and/or ROCK2 depletion.  
The interaction discovered here between RhoBTB1 and ROCK1 is new and 
unexpected. Using different vectors encoding deletion mutants for ROCK1, it was 
possible to map a potential binding region in ROCK1 for RhoBTB1, to a site including 
the REM domain. This domain is found in some Ras and Rho GEFs (Bos et al., 2007) 
and it has been shown to be important for binding of RhoA to PKNs, rhotekin and 
rhophilin (Bishop and Hall, 2000; Blumenstein and Ahmadian, 2004; Flynn et al., 1998). 
It was also observed that the Rho domain of RhoBTB1 was sufficient for the interaction 
with ROCK1. To determine whether there is a direct interaction between RhoBTB1 and 
ROCK1 recombinant protein domains should be used. Since both RhoBTB1 and 
ROCK1 are high molecular weight proteins (79 kDa and 160 kDa, respectively), it 
would be necessary to use isolated domains, for example, the Rho domain of 
RhoBTB1 and ROCK1 375-727 which includes the REM domain and part of the coiled-
coil region. ROCK2 should also be tested in the future, since it has a REM domain 
which is 56% identical to the REM domain of ROCK1. The results in this chapter also 
show that RhoBTB1 is phosphorylated by ROCK1 in vitro. However, the specific sites 
that were phosphorylated were unknown.  
ROCK1 was able to phosphorylate RhoBTB1 1-210. The phosphorylated site in this 
region could be serine 69 (Table 6-1). Furthermore, mutation of all 5 potential 
phosphorylation sites reported in PhophoSite Plus website did not prevent 
phosphorylation of RhoBTB1. Other serine(s) and/or threonine(s) on RhoBTB1 might 
be phosphorylated by ROCK1. At least eight consensus phosphorylation sequences for 
ROCK are present in RhoBTB1 (R/KXS/T or R/KXXS/T, where R is arginine, K is 




lysine, X is any amino acid, S is serine and T is threonine) (Figure 6.18). Only one of 
the 5 sites tested here, threonine 483 (T483), is among them. Because RhoBTB1 have 
many serines and threonines, it would be interesting to use mass spectrometry to map 
the sites phosphorylated by ROCK1 in vitro. In addition to ROCK1, other kinases could 
phosphorylate RhoBTB1.  
 
Figure 6.18 - Potential phosphorylation sites for ROCKS 
ROCK consensus phosphorylation sequences in RhoBTB1 are shown in red.  
 
Even without knowing which sites are phosphorylated on RhoBTB1 in Cos7 cells, 
RhoBTB1 phosphosite-mutants were used to study the effects that these sites might 
have in the interaction of RhoBTB1 with other proteins. I hypothesised that 
phosphorylation could regulate RhoBTB1 interaction with cullin3 or RhoA. As 
suggested in Chapter 5, RhoBTB1 could be a BTB adaptor in cullin3 ubiquitin ligase 
complexes. Adaptor proteins in E3 ubiquitin ligase complexes can undergo post-
translational modifications that affect their activity or affinity for the substrate (Chapter 
1, section 1.2.2). Phosphorylation could play an important role in regulating binding of 
RhoBTB1 to cullin3. Indeed, mutation of some potential phosphorylation sites seemed 
to affect RhoBTB1 and cullin3 interaction. Mutation of serine 69 to alanine led to a 




decrease while mutation of threonine 483 led to an increase in RhoBTB1 association 
with cullin3. Serine 69 is located in the Rho domain of RhoBTB1 and its mutation could 
perhaps stabilise an inactive conformation in which the Rho domain of RhoBTB1 
interacts with the first BTB domain (Figure 6.19) (Berthold et al., 2008a).  
 
Figure 6.19 - Model of RhoBTB1 inactive conformation 
Rho domain of RhoBTB1 interacts with the first BTB domain, keeping RhoBTB1 in an 
inactive conformation (adapted from Berthold et al. (2008a)).  
 
Threonine 483 is located close to the second BTB domain (Figure 6.13A). Mutation of 
this site could affect binding of cullin3 and RhoBTB1 since it seems that the second 
BTB domain is also involved in this interaction (Chapter 4). In addition, mutation of 
serine 69, serine 480, threonine 483 and serine 485 altogether led to an increase in 
RhoBTB1 and cullin3 co-immunoprecipitation. However, when threonine 398 was also 
mutated, the association decreased more than two fold. This suggests that threonine 
398 is important for RhoBTB1 and cullin3 interaction. An additional experiment with 
only threonine 398 mutated in RhoBTB1 is necessary to confirm this hypothesis. 
Although these results are interesting, more repetitions are necessary to confirm them, 




since some experiments were performed only once. RhoA-N19 interaction with 
RhoBTB1 was also affected by mutation of serine 480. Because this site is close to the 
second BTB domain and RhoA-N19 interacts with the Rho domain of RhoBTB1 
(Chapter 5), it is possible that this mutation leads to a change in conformational in 
RhoBTB1, affecting interaction with RhoA. However, more repeats are necessary to 
confirm this.  
These results show that RhoBTB1 can be phosphorylated by ROCK1 and probably by 
other kinases as well. Phosphorylation of RhoBTB1 could be a way of regulating its 
interaction with other proteins. Phosphorylation could also be involved in RhoBTB1 
localisation and degradation which could affect the activity and expression of other 
proteins and thus it would be interesting to investigate the localisation of mutants tested 
in this chapter.  
  




7 Concluding remarks  
7.1 RhoBTB1 and potential functions in cancer 
RhoBTB1 is an atypical Rho GTPase which does not have any known function. Initially, 
RhoBTB1 was considered a candidate tumour suppressor gene because RhoBTB2 
was identified as homozygously deleted in breast cancer (Hamaguchi et al., 2002). 
RhoBTB1 has been shown to be downregulated in some cancers such as head and 
neck, breast and kidney cancers, but it has also been reported to be upregulated in 
some cancer cell lines (Beder et al., 2006; Berthold et al., 2008b; Ramos et al., 2002). 
Since cancer is among the leading causes of morbidity and mortality in the world, 
causing more than 8 million deaths in 2012 (World Health Organization – WHO), it is 
important to investigate how putative tumour suppressors such as RhoBTB1 contribute 
to cancer progression. Metastasis is one of the main reasons for the aggressive course 
of this disease. Two main steps during metastasis are invasion and transendothelial 
migration. During intravasation and extravasation from the blood vessels, cancer cells 
attach to the endothelium and transmigrate (Reymond et al., 2013). Rho GTPases are 
known to be involved in this process (Ridley, 2015). It was found that RhoBTB1 
depletion affected adhesion and intercalation of MDA-MB-231 and PC3 cells to 
endothelial cells in vitro (Borda D'Agua, 2012). This suggested that RhoBTB1 might 
promote cancer cell metastasis, having a role in the extravasation of cancer cells from 
the blood vessels. However, this phenotype in MDA-MB-231 and PC3 cells was not 
observed here in Cal51 cells. This could mean that the effects of RhoBTB1 are cell line 
specific or that it is necessary to inhibit RhoBTB1 above a certain threshold to observe 
effects on cell adhesion and intercalation. More experiments are necessary with a 
larger panel of cell lines to determine if a threshold knockdown of RhoBTB1 is 
important to obtain the depletion phenotype observed by Borda D'Agua (2012). An 
antibody that detects endogenous levels of RhoBTB1 would be very useful for this 




purpose. In addition, generation of stable cell lines that do not express RhoBTB1 using 
CRISPR/Cas9 approaches would be useful to avoid variations in siRNA transfection 
(Ran et al., 2013). 
The changes in cancer cell morphology after RhoBTB1 depletion in a 3D Matrigel 
matrix assay presented here indicate that RhoBTB1 might have a role in cancer 
progression. RhoBTB1 depletion in MDA-MB-231 and PC3 cells leads to cell 
elongation which indicates that RhoBTB1 promotes cell rounding. RhoA depletion in 
MDA-MB-231 cells also led to cell elongation with a consequent increase in cell 
invasion (Vega et al., 2011). If this is true for other types of tumours, the fact that 
RhoBTB1 might be involved in cell rounding could also mean that RhoBTB1 promotes 
a decrease in cancer cell invasion. It would be interesting in the future to test the role of 
RhoBTB1 in invasion assays into different matrices (e.g. collagen I and Matrigel) and 
study the effects of RhoBTB1 depletion in an in vivo model such as experimental 
metastasis in mice or human-mouse xenograft models (Khanna and Hunter, 2005), 
using a panel of cancer cell lines. This would give clues of how much RhoBTB1 is 
involved in this process.  
7.2 RhoBTB1-interacting partners and Rho function 
Identifying RhoBTB1-interacting proteins could provide clues to its function. Cullin3 is 
the only protein known to associate with RhoBTB1 and therefore, it has been 
hypothesized that RhoBTB1 could be involved in targeting proteins for degradation 
(Berthold et al., 2008b). It is still unclear whether RhoBTB1 is an adaptor protein in 
cullin3 ubiquitin ligase complexes that presents its binding proteins for ubiquitination. 
However, results presented here and by Borda D'Agua (2012) suggest that RhoBTB1 
might have a protective role towards RhoA, inhibiting its degradation. There are other 
similar cases where the interaction between two proteins protects one of them from 




degradation. For example, RhoA binding to RhoGDIs protects it from proteasomal 
degradation (Boulter and Garcia-Mata, 2010).  
Initial results show that RhoBTB1 is able to interact preferentially with a dominant 
negative RhoA mutant, possibly through its Rho domain region. In addition, RhoBTB1 
depletion leads to a decrease in total RhoA protein levels after treatment with 
cycloheximide. Preliminary data suggest that RhoBTB1 might compete with BACURD1 
for RhoA-N19 binding. Altogether, these results suggest a potential role for RhoBTB1 
as protector of RhoA degradation (Figure 7.1). This hypothesis needs to be confirmed 
using additional experiments. For example, it would be interesting to confirm 
preferential interaction of RhoBTB1 with GDP-RhoA rather than GTP-RhoA, using 
recombinant RhoA, and to solve the crystal structure of Rho domain of RhoBTB1. An in 
vitro ubiquitination assay would be useful to either test competition between RhoBTB1 
and BACURD or ubiquitination of RhoA in the presence of RhoBTB1 (Choo and Zhang, 
2009). RhoBTB1 could still bring GDP-RhoA to the cullin3 ubiquitin ligase complex, but 
promote other forms of ubiquitination (Figure 1.10) which do not lead to degradation. 
This would be possible to observe by changes in migration of RhoA in western blots or 
by using mass spectrometry (Kaiser and Wohlschlegel, 2005). 





Figure 7.1 - RhoBTB1 and RhoA model of interaction 
In the absence or low levels of RhoBTB1, BACURD binds preferentially to GDP-RhoA 
and brings it to be ubiquitinated by the cullin3 ubiquitin ligase complex. 
Polyubiquitination (K48) of RhoA leads to proteasomal degradation. In the presence or 
high levels of RhoBTB1, GDP-RhoA binds preferentially to RhoBTB1 and it is protected 
from polyubiquination (K48) which targets protein to proteasomal degradation.   
 
RhoBTB1 is reported here for the first time to interact with ROCK1 and to be 
phosphorylated by this kinase. It would be interesting to test if ROCK2 could also 
phosphorylate RhoBTB1, since Rnd3 is only phosphorylated by ROCK1 (Riento et al., 
2005). The relevance of RhoBTB1 phosphorylation is still unclear, but it could affect the 
interaction of RhoBTB1 with other proteins (e.g. cullin3 and RhoA). This could occur 
directly, through changes in RhoBTB1 conformation which would increase or decrease 
its interaction with other proteins; or indirectly, through changes in RhoBTB1 
localisation which would bring the proteins close together. The specific site(s) on 
RhoBTB1 which is phosphorylated by ROCK1 is still unknown. It is possible that 




RhoBTB1 is phosphorylated by other kinases, since there is only one possible 
phosphorylated site from the five obtained from PhosphoSite Plus database that 
matches the consensus for ROCKs. Preliminary data suggest that RhoBTB1 could also 
affect ROCK1/2 degradation. However, it does not seem that this involves cullin3 
ubiquitin ligase complexes. Proteasomal degradation of ROCKs has never been 
described before, and thus it would be interesting to test other ubiquitin ligases in future 
experiments to identify ROCK1/2-specific ligases such as using siRNA screens.  
In summary, the data presented in this thesis show new and unexpected protein-
protein interactions involving RhoBTB1, and suggest a role in cancer cell invasion. To 
confirm these interactions and identify new ones, an unbiased proteomic screen using 
different domains of RhoBTB1 should be performed. The presence of several clearly 
distinct domains in RhoBTB1 is an indicator that this protein could be involved in 
different cellular processes to classic Rho GTPases, as well as have overlapping 
functions through its interactions with RhoA and ROCK1.  
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